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 SUMMARY 
Caprazamycins are potent anti-mycobacterial liponucleoside antibiotics isolated from 
Streptomyces sp. MK730-62F2 and belong to the translocase I inhibitor family. Their 
complex structure is derived from 5’-(β-O-aminoribosyl)-glycyluridine and comprises 
a unique N-methyl-diazepanone ring. The biosynthesis of these unusual compounds 
is unknown and only limited information is available on the formation of other 
translocase I inhibitors.  
The first part of the presented thesis describes the identification, cloning and 
sequencing of the caprazamycin biosynthetic gene cluster, representing the first 
identified gene cluster of a translocase I inhibitor. Sequence analysis revealed the 
presence of 23 open reading frames putatively involved in export, resistance, 
regulation and biosynthesis of the caprazamycins. Heterologous expression of 
cosmid cpzLK09, containing the gene cluster, in Streptomyces coelicolor M512 led to 
the production of non-glycosylated bioactive caprazamycin derivatives. A set of gene 
deletions validated the boundaries of the cluster. In the following part of the thesis 
(carried out in collaboration with Diploma student Liane Lutsch) inactivation of cpz20, 
cpz21 and cpz25 resulted in the accumulation of novel simplified liponucleoside 
antibiotics which lack the 3-methylglutaryl moiety. Cpz21 was therefore assigned to 
act as an acyltransferase, responsible for the attachment of methylglutarate in 
caprazamycin biosynthesis. The co-enzyme A activated substrate would be 
generated from 3-methylglutaconate via dehydrogenation and activation catalyzed by 
Cpz25 and Cpz20, respectively.  
The next part of the thesis is focused on the biosynthetic origin of the deoxysugar 
moiety of caprazamycins. On cosmid cpzLK09 which harbours the caprazamycin 
gene cluster the genes for the formation of dTDP-L-rhamnose could not be identified. 
However, co-expression of cpzLK09 in S. coelicolor M512 with plasmid pRHAM, 
containing all required genes for dTDP-L-rhamnose biosynthesis, led to the 
production of intact caprazamycins. In vitro studies showed that Cpz31 is responsible 
for the attachment of the L-rhamnose to the caprazamycin aglycones, generating a 
rare acylated deoxyhexose. An L-rhamnose gene cluster was identified elsewhere on 
the Streptomyces sp. MK730-62F2 genome and its involvement in caprazamycin 
formation was demonstrated by insertional inactivation of cpzDIII. The L-rhamnose 
subcluster was assembled to cpzLK09 using Red/ET-mediated recombination. 
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Heterologous expression of the resulting cosmid led to the production of 
caprazamycins, demonstrating that both set of genes are required for caprazamycin 
biosynthesis. Knock-outs of cpzDI and cpzDV in the L-rhamnose subcluster 
confirmed that four genes, cpzDII, cpzDIII, cpzDIV and cpzDVI, are sufficient for the 
biosynthesis of the deoxysugar moiety.  
The liposidomycins are potent inhibitors of the bacterial translocase I and differ from 
the caprazamycins only in the absence of the permethylated L-rhamnose and the 
presence of a sulfate group at the aminoribosyl moiety. In the next part of the thesis 
the liposidomycin biosynthetic gene cluster was identified in Streptomyces sp. SN-
1061M using cpz11, a putative N-methyltransferase from the caprazamycin gene 
cluster, as a probe. Heterologous expression of the identified cosmid in 
Streptomyces coelicolor M512 led to the production of liposidomycins. A comparison 
of the liposidomycin gene cluster and the caprazamycin gene cluster revealed strong 
similarities in both clusters though other parts reflect the structural differences of the 
two compounds. A set of genes were assigned to be involved in the characteristic 
sulfation reaction of the liposidomycins, including a putative sulfotransferase gene. 
Surprisingly, similar genes were found adjacent to the caprazamycin gene cluster in 
Streptomyces sp. MK630-62F2. Reinvestigation of extracts from both, Streptomyces 
sp. MK630-62F2 and the heterologous caprazamycin producer S. coelicolor 
M512/cpzLK09 led to the identification of novel sulfated caprazamycin derivatives. 
The last part of the thesis (carried out in collaboration with Diploma student Kornelia 
Eitel) demonstrates that Cpz4 from Streptomyces sp. MK730-62F2 is an arylsulfate 
sulfotransferase (ASST) responsible for the formation of sulfated liponucleoside 
antibiotics. Gene deletion mutants showed that cpz4 is required for the production of 
sulfated caprazamycin derivatives. Cloning, overproduction and purification of Cpz4 
resulted in a 58 kDa soluble protein. The enzyme catalyzed the transfer of a sulfate 
group from p-nitrophenol sulfate (pNS; Km 48.1 µM, kcat 0.14 s-1) and 
methylumbelliferone sulfate (MUS; Km 34.5 µM, kcat 0.15 s-1) onto phenol (Km 25.9 
mM and 29.7 mM, respectively). The Cpz4 reaction proceeds by a ping pong bi-bi 
mechanism. Several synthetic structural analogs of intermediates of the 
caprazamycin biosynthetic pathway were tested as substrates of Cpz4. Des-N-
methyl-acyl-caprazol was converted with highest efficiency 100 times faster than 
phenol. The fatty acyl side chain and the uridyl moiety seem to be important for 
substrate recognition by Cpz4. Liponucleosides, partially purified from various mutant 
 SUMMARY 
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strains, were readily sulfated by Cpz4 using pNS. No product formation could be 
observed with PAPS as the donor substrate. Sequence homology of Cpz4 to the 
previously examined ASSTs is low. However, numerous orthologs are encoded in 
microbial genomes and represent interesting subjects for future investigations. 
 
In vivo, in vitro and in silico analysis of the caprazamycin and the liposidomycins 
biosynthetic gene clusters conducted in this thesis allowed a first proposal of the 
biosynthetic pathway to the liponucleosides and provides insights into the formation 
of related uridyl-antibiotics. 
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 ZUSAMMENFASSUNG 
Caprazamycine sind Liponukleosid-Antibiotika die aus Streptomyces sp. MK730-
62F2 isoliert wurden und den Translokase I-Inhibitoren zugerechnet werden. Sie 
weisen eine sehr gute Wirksamkeit gegen Mykobakterien und anderen Gram-
positiven Mikroorganismen auf. Die Caprazamycine besitzen eine hochkomplexe 
chemische Struktur, bestehend aus einem 5’-(β-O-Aminoribosyl)-Glycyluridin und 
einem N-Methyl-Diazepanonring. Über die Biosynthese dieser ungewöhnlichen 
Naturstoffe ist bislang nichts bekannt und auch über die Biosynthese anderer 
Translokase I-Inhibitoren weiß man nur wenig. 
Im ersten Teil dieser Arbeit wird die Identifizierung, Klonierung und Sequenzierung 
des Caprazamycin-Genclusters beschrieben; des ersten identifizierten Biosynthese-
Genclusters eines Translokase I-Inhibitors. Die Sequenzanalyse ergab, dass 23 
mögliche Gene auf dem Cluster am Export, der Resistenz, der Regulation und an der 
Biosynthese der Caprazamycine beteiligt sind. Die heterologe Expression des 
Clusters, auf dem Cosmid cpzLK09, in Streptomyces coelicolor M512 führte zur 
Produktion nicht-glykosylierter Caprazamycin-Derivate. Durch verschiedene 
Deletions-Experimenten konnten die Grenzen des Clusters bestimmt werden. Im 
nächsten Teil der Arbeit, durchgeführt in Zusammenarbeit mit der Diplomandin Liane 
Lutsch, wird gezeigt, dass durch die Inaktivierung der Gene cpz20, cpz21 und cpz25 
nur noch die Hydroxyacyl-Caprazole produziert werden. Diesen neuen Substanzen 
fehlt die Methylglutaryl-Einheit der Caprazamycine. Dennoch weisen sie Bioaktivität 
gegen Mykobakterien auf und stellen damit strukturell vereinfachte Liponukleosid-
Antibiotika dar. Aufgrund dieser Ergebnisse kann angenommen werden, dass die 
Methylglutarat-Gruppe der Caprazamycine aus Methylglutaconat entsteht, durch 
Hydrogenierung katalysiert von Cpz25, CoA-Aktivierung katalysiert von Cpz20 und 
dem abschliessenden Transfer der Einheit an die Hydroxyacyl-Caprazole katalysiert 
durch Cpz21. 
Der nächste Teil der Arbeit beschäftigt sich mit der Herkunft der Desoxyzucker-
Gruppe der Caprazamycine. Auf dem Cosmid cpzLK09, welches das Caprazamycin-
Gencluster trägt, konnten keine Gene identifiziert werden die für die Biosynthese der  
benötigten dTDP-L-Rhamnose zuständig sein könnten. Durch die Co-Expression von 
cpzLK09 mit dem Plasmid pRHAM, das die ensprechenden Gene zur Herstellung 
von dTDP-L-Rhamnose trägt, wurden die glykosilierten Caprazamycine im 
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heterologen Stamm S. coelicolor M512 akkumuliert. In vitro-Experimente zeigten, 
dass Cpz31 für den Transfer der Desoxyzucker-Einheit zuständig ist. Im 
Caprazamycin-Produzenten Streptomyces sp. MK730-62F2 konnten daraufhin die 
fehlenden Gene cpzDII, cpzDIII, cpzDIV und cpzDVI, für die Biosynthese der dTDP-
L-Rhamnose auf einem separaten Gencluster identifiziert werden. Die Vereinigung 
und Expression des neu gefundenen Clusters mit dem Caprazamycin-Gencluster 
führte zur heterologen Produktion der glykosilierten Caprazamycine. 
Die Liposidomycine sind mit den Caprazamycinen strukturell verwandte Translokase 
I-Inhibitoren. Sie unterscheiden sich von Caprazamycinen durch die sulfatierte 
Aminoribose-Gruppe und durch die Abwesenheit der Desoxyzucker-Einheit. In 
diesem Teil der Arbeit wird die Identifizierung des Liposidomycin-Genclusters aus 
Streptomyces sp. SN-1061M beschrieben. Heterologe Expression des Genclusters in 
S. coelicolor M512 erlaubte die Produktion der Liposidomycine. Ein Vergleich mit 
dem Caprazamycin-Gencluster zeigte starke Ähnlichkeiten, aber auch Unterschiede, 
entsprechend der strukturellen Besonderheiten beider Liponukleosid-Antibiotika. Eine 
Reihe von Genen wurde der Sulfatierungsreaktion in der Liposidomycin-Biosynthese 
zugeordnet. Interessanterweise, wurden ähnliche Gene auch nahe des 
Caprazamycin-Genclusters gefunden. Die daraufhin durchgeführte Untersuchung der 
Caprazamycin-Produzenten Streptomyces sp. MK730-62F2 und S. coelicolor 
M512/cpzLK09 zeigte dass in den Extrakten beider Stämme sulfatierte 
Caprazamycin-Derivate zu finden waren. 
Im letzten Teil der Arbeit, durchgeführt in Zusammenarbeit mit der Diplomandin 
Kornelia Eitel, wird gezeigt, dass es sich bei dem Enzym Cpz4 aus Streptomyces sp. 
MK730-62F2 um eine neuartige Arylsulfatsulfotransferase (ASST) handelt, welches 
die Sulfatierung von Liponukleosid-Antibiotika katalysiert. Die Untersuchung von 
Deletionsmutanten zeigte, dass cpz4 für die Produktion sulfatierter Caprazamycin-
Derivate essentiell ist. Cpz4 wurde kloniert, heterolog überproduziert und als 58-kDa 
großes lösliches Protein aufgereinigt. Das Enzym katalysiert den Transfer einer 
Sulfatgruppe von p-Nitrophenol (pNS; Km 48.1 µM, kcat 0.14 s-1) bzw. 
Methylumbelliferonsulfat (MUS; Km 34.5 µM, kcat 0.15 s-1) auf Phenol (Km 25.9 mM 
bzw. 29.7 mM) mittels eines Ping-Pong Reaktionsmechanismus. Die Untersuchung 
verschiedener synthetisch hergestellter Strukturanaloga von Intermediaten der 
Caprazamycin-Biosynthese ergab, dass Des-N-Methyl-Acyl-Caprazol von Cpz4 
100fach besser umgesetzt wird als Phenol. Der Fettsäure-Rest und die Uridyl-Einheit 
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der Caprazamycin-Derivate scheinen wichtig zu sein für die Substraterkennung 
durch Cpz4. Die von bakteriellen Mutantenstämmen akkumulierten und partiell 
aufgereinigten Liponukleosid-Antibiotika wurden in Anwesenheit von pNS als 
Substratgruppen-Donor ebenfalls von Cpz4 sulfatiert. Kein Umsatz wurde hingegen 
mit PAPS als Sulfatgruppen-Donor beobachtet. Während die bisher bekannten 
Arylsulfatsulfotransferasen nur geringe Sequenzhomologie zu Cpz4 aufweisen, 
scheinen etliche Cpz4-orthologe Proteine in Genomen verschiedenster 
Mikroorganismen kodiert zu sein.  
Die in dieser Arbeit vorgestellte in vivo-, in vitro- und in silico-Analyse der 
Caprazamycin- und Liposidomycin-Gencluster ermöglichte es ein erstes Model zur 
Biosynthese der Liponukleosid-Antibiotika vorzuschlagen.  
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I. INTRODUCTION 
1. The search for new antibiotics 
Natural products have been the fundamental source of new bioactive compounds. In 
the last 25 years, more than 60% of the small-molecule chemicals which were 
introduced as drugs are derived from natural products (Newman, 2008). In the 1990s 
the focus of the pharmaceutical industries switched to combinatorial chemistry, high-
throughput screening of synthetic chemical libraries and computer assisted drug 
design (Christoffersen, 2006). However, natural products still represent 
unprecedented structural diversity and are regarded as privileged scaffolds for drug 
lead development (Kumar & Waldmann, 2009). Substantial progress in the areas of 
DNA sequencing, genetic engineering, analytical chemistry and the accessibility of so 
far unexplored microbial habitats has now renewed the interest in natural product-
based drug discovery (Harvey, 2007; Lam, 2007; Li & Vederas, 2009; Newman, 
2008). Historically, the actinomycetes have been a prolific source of 
chemotherapeutic agents for the treatment of infectious diseases (Pelaez, 2006). 
Numerous compounds were isolated over the last decades, which showed 
antimicrobial properties (Saleem et al., 2010). However, only a small fraction of these 
are in clinical use. With the emergence of multi-drug resistance pathogens in recent 
years there is now an urgent need for new antibiotics (Arias & Murray, 2009). In order 
to avoid cross-resistance with the antimicrobial agents on the market, attention is 
especially drawn to compounds which consist of novel structural scaffolds and act 
against new targets (Clardy et al., 2006; Falconer & Brown, 2009; Fischbach & 
Walsh, 2009). 
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2. Translocase I inhibitors 
Fosfomycin
Liposidomycin Enduracidin
VancomycinMoenomycin
Penicillin
Figure I.2.1 Overview of the biosynthesis of the bacterial cell wall and antibiotics targeting the same. 
Figure modified from (Al-Dabbagh et al., 2008). 
 
The biosynthesis of the bacterial cell wall (Figure I.2.1) is a well precedent target for 
antibacterial action. Peptidoglycan, the main chemical component of the cell wall 
consists of alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc) units which are β-1,4-glycosidically linked to form a polysaccharide. A 
pentapeptide side chain is attached to the lactyl group of the MurNAc unit via an 
amide bond. The pentapeptide generally consists of an L-alanine, a γ-D-glutamate, 
two D-alanines and either an L-lysine (in the case of Gram-positive bacteria) or 
diaminopimelic acid (DAP; in the case of Gram-negative bacteria). Cross-linking 
confers stability to the peptidoglycan scaffold and occurs between the lysine/DAP 
residue and the D-alanine residue of another polysaccharide chain by 
transpeptidation. Formation of the peptidoglycan takes place in different 
compartments of the bacterial cell. The MurNAc-pentapeptide and the GlcNAc are 
synthesized in the cytoplasm. Two lipid-linked glycosylation steps, the first at the 
inner cytoplasmic membrane and the second at the outer membrane, generate the 
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glycan polysaccharide. The transpeptidation occurs in the periplasm. The 
biosynthetic steps at the outer membrane and in the periplasm are extensively 
exploited as targets for the treatment infectious disease e.g. by the application of the 
β-lactam antibiotics, the penicillin or the cephalosporines, and the glycopeptide 
antibiotic vancomycin. However, inhibitors of other reactions in the formation of the 
microbial cell wall are comparably unexplored for their use as leads in drug 
development.  
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Figure I.2.2 Selected nucleoside antibiotics which target the translocase I, an essential enzyme in 
peptidoglycan biosynthesis. 
 
A growing group of structurally diverse nucleoside antibiotics have been found to 
interfere in peptidoglycan biosynthesis by targeting the translocase I. This enzyme 
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(also referred to as MraY) is an integral membrane protein and responsible for the 
transfer of the MurNAc-pentapeptide on the lipid carried undecaprenyl phosphate to 
generate lipid I (Struve et al., 1966) (Figure I.2.1). The translocase I inhibitors have 
been classified into three different groups (Winn et al.). The peptidyl nucleoside 
antibiotics include the mureidomycins (Isono et al., 1989a), the pacidamycins (Chen 
et al., 1989), the napsamycins (Chatterjee et al., 1994) (Figure I.2.2) and the 
sansanmycins (Xie et al., 2008). These compounds share a 3’-deoxyuridine and a 
non-ribosomal derived peptide backbone which are linked via a 4’,5’-enamide bond. 
Peptidyl nucleoside antibiotics show specific inhibitory activity against 
Pseudomonades e.g. MICs 0.1-6.5 µg/mL against different Pseudomonas 
aeruginosa strains in the case of mureidomycin C (Isono et al., 1989b). A second 
class of translocase I inhibitors comprise the liponucleoside antibiotics of the 
tunicamycin-type, the tunicamycins (Takatsuki et al., 1971) (Figure I.2.2), the 
streptoviridins (Eckardt et al., 1975) and the corynetoxins (Vogel et al., 1981). 
Structurally, they contain a unique 11-carbon dialdose sugar, the tunicamine, an N-
acetylglucosamine and a fatty acid side chain. Unlike other nucleoside translocase I 
inhibitors these compounds are not only antimicrobials but also exhibit high 
mammalian toxicity, as they effect N-linked protein glycosylation in eucaryotic cells 
(Heifetz et al., 1979). The liponucleoside antibiotics of the liposidomycins-type 
constitute the third class and include the liposidomycins (Figure I.2.2) and the 
caprazamycins. A detailed description of these structurally complex nucleosides is 
given in the next sections. Recently, the isolation of two other liposidomycins 
analogs, the muraminocins (Muramatsu et al., 2004) and the A-97065 (Fujita et al., 
2006) were reported.  
Other nucleoside antibiotics of the translocase I inhibitor family can not be classified 
to these three groups, which are e.g. the antimycobacterial capuramycin (Yamaguchi 
et al., 1986), the muraymycins (McDonald et al., 2002) and FR-900493 (Ochi et al., 
1989), a compound isolated from Bacillus cereus (Figure I.2.2). 
2.1. The liposidomycins 
The liposidomycins (LPMs, Figure I.2.3, 1) were identified in a culture broth of 
Streptomyces griseosporeus in 1985 through screening for inhibitors of peptidoglycan 
synthesis (Isono et al., 1985). They show strong and selective activity against the 
Escherichia coli translocase I MraY with IC50 from 30 ng mL-1 (LPM C) but inhibit 
eucaryotic glycoconjugate formation, e.g. glycoprotein, glycosaminoglycan and 
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teichoic acid biosynthesis only at high dosage (Kimura et al., 1989; Muroi et al., 
1997). Structurally, the liposidomycins are liponucleoside antibiotics of unusual 
complexity (Ubukata et al., 1988). They comprise a 5’-substituted uridine, a 5-amino-
5-deoxyribose-2-sulfate and an N-methylated perhydro-1,4-diazepine. A fatty acid 
side chain of variable length and conformation distinguishes the different known 
liposidomycins and is linked to a rare 3-methylglutaryl moiety. The 5’-(β-O-
aminoribosyl)-glycyluridyl core moiety is also known from the translocase I inhibitors 
FR-900493 (Ochi et al., 1989) and the muraymycins (McDonald et al., 2002). 
However, the overall structure resembles only the caprazamycins (2, Figure I.2.3) 
(Igarashi et al., 2005), which lack the sulfate group at the 2’’-position of the 
aminoribose. Generally, the introduction of a sulfate group in a molecule alters its 
characteristics significantly e.g. size, charge and water solubility. This is used by 
mammals for detoxification of xenobiotics. In bacterial secondary metabolism, 
however, sulfation is uncommon and not many of the compounds have been 
investigated in detail. In one of the few examples, incorporation of the sulfate group 
into the glycopeptide A47934 from Streptomyces toyocaensis has been linked to the 
PAPS-dependent enzyme StaL (Lamb et al., 2006). Though, the liposidomycins are 
potent inhibitors of the translocase I in vitro, they exhibited only weak antimicrobial 
activity. However, change of medium components and UV-radiation of the original 
producer strain led to the production of liposidomycin derivatives with strong activity 
against mycobacteria (Kimura et al., 1998c). Interestingly, the change of capacity 
was mainly due to the compounds which lost the sulfate moiety. It seems that the 
hydrophilic sulfate attached to the 2’’-position of the aminoribose confers deficient 
membrane permeability to the liposidomycins. On the other hand, a comparison of 
the sulfated liposidomycin A-(I) (Figure I.2.3, 1) and non-sulfated liposidomycin A-(III) 
(Figure I.2.3, 3) showed liposidomycin A-(I) to be more selective in vitro against 
peptidoglycan biosynthesis versus glycoprotein biosynthesis by one order of 
magnitude (Kimura et al., 1998a). Thus, the role of the sulfate group remains an 
intriguing subject to investigate. 
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Figure I.2.3. Liponucleoside antibiotics and derivatives. 
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2.2. The caprazamycins  
Caprazamycins (CPZs, Figure I.2.3, 2) are liponucleoside antibiotics isolated from a 
fermentation broth of Streptomyces sp. MK730-62F2 (Igarashi et al., 2003; Igarashi 
et al., 2005). They show excellent activity in vitro against gram-positive bacteria, in 
particular against the genus Mycobacterium including M. intracellulare (MIC = 0.78 – 
1.56 µg/mL), M. avium (MIC = 0.025 – 0.1 µg/mL) and M. tuberculosis (MIC = 0.78 – 
1.56 µg/mL) (Takeuchi et al., 2004). In a pulmonary mouse model with M. 
tuberculosis H37Rv, nasal administration of caprazamycin B exhibited a therapeutic 
effect at 1.5 mg kg-1 day-1 but no significant toxicity (Igarashi et al., 2002). Structural 
elucidation (Igarashi et al., 2005) revealed a complex and unique composition of 
elements the caprazamycins share only with the closely related liposidomycins 
(Isono et al., 1985). They differ from the liposidomycins in the absence of a sulfate 
group at the 2’’-position of the aminoribose and the presence of a permethylated L-
rhamnose ß-glycosidically linked to the 3-methylglutaryl (3-MG) moiety. Similar to the 
liposidomycins the 3-MG motif is attached to ß-hydroxy-fatty acids of different chain 
length resulting in caprazamycins A-G (Figure I.2.3, 2). 
The liposidomycins have been shown to inhibit the biosynthesis of the bacterial cell 
wall by targeting the formation of lipid I (Brandish et al., 1996). The caprazamycins 
are expected to act in the same way and are assigned to the growing number of 
translocase I inhibitors (Kimura & Bugg, 2003).  
Recent investigations indicate that the 3’’-OH group (Dini et al., 2001b), the amino 
group of the aminoribosyl-glycyluridine and an intact uracil moiety (Dini et al., 2001a) 
are essential for the inhibition of the Escherichia coli translocase I MraY. The 
chemical synthesis of the (+)-caprazol (Figure I.2.3, 5) was recently accomplished 
(Hirano et al., 2005), however, this compound only shows weak antibacterial activity. 
In contrast, the acylated compounds (Figure I.2.3, 3 and 4) exhibit strong growth 
inhibition of mycobacteria, suggesting a potential role of the fatty acid side chain in 
penetration of the bacterial cell (Hirano et al., 2008; Kimura et al., 1998a). 
Apparently, the acyl-caprazols (Figure I.2.3, 4) represent the most simplified 
antibiotically active liponucleosides and a good starting point for further optimization 
of this class of potential therapeutics. 
 
Although chemical synthesis and biological activity of caprazamycins and 
liposidomycins has been studied in some detail, their biosynthesis remains 
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speculative and only few data existed about the formation of other translocase I 
inhibitors (Ohnuki et al., 2003; Price & Tsvetanova, 2007) upon the start of my 
studies. Nevertheless, we assumed that the caprazamycin biosynthetic pathway is 
partially similar to that of liposidomycins, FR-90043 and muraymycins and presents a 
model for the comprehension and manipulation of liponucleoside formation. 
Considering the unique structural features of the caprazamycins we also expected 
some unusual biotransformations to be involved in the formation of e.g. the (+)-
caprazol.  
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3. Aims of this study 
My general objective was to investigate the biosynthesis of the liposidomycin-type of 
liponucleoside translocase I inhibitors using molecular methods. Therefore I had to 
identify the biosynthetic gene clusters of these antibiotics. However, no gene cluster 
of a structurally related compound or another translocase I inhibitor had been 
reported so far. From the different structural motifs which compose the scaffold of the 
liponucleosides only the permethylated L-rhamnose moiety of the caprazamycin has 
been investigated in the biosynthesis of other secondary metabolites. Thus, probe 
development for screening of a genomic library was most promising for the 
caprazamycin gene cluster.  
Consequently, the identification of the caprazamycin gene cluster was my first 
objective. In order to clone and sequence the biosynthetic gene cluster of the 
caprazamycins, the following experiments were necessary: 
 
 Optimization of culture conditions for caprazamycin production and 
development of extraction methods for the isolation of secondary metabolites. 
Establishment of a reliable method for the analysis of caprazamycin 
derivatives by liquid chromatography (LC) and mass spectrometry (MS). 
 Development of a specific probe for the identification of the caprazamycin 
gene cluster. Generation and screening of cosmid library from genomic DNA 
of Streptomyces sp. MK730-62F2. 
 Sequencing and analysis of cosmids containing the caprazamycin gene 
cluster. 
 Functional proof of the identity of the caprazamycin gene cluster by gene 
deletion experiments and heterologous expression in S. coelicolor M512. 
 Determination of the borders of the caprazamycin gene cluster by gene 
deletion experiments. 
 Establishment of a model for caprazamycin biosynthesis. 
 
The analysis of liponucleosides from bacterial culture extracts by LC-ESI-MS was 
conducted in cooperation with Stefanie Siebenberg and Bernd Kammerer (Clinical 
Pharmacology, University Hospital Tübingen, Germany).  
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My second objective was to elucidate the role of the putative methyltransferases 
Cpz11 and Cpz26 in caprazamycin biosynthesis. I also aimed to investigate the 
putative acyltransferases Cpz21 and Cpz23, the putative acyl-CoA synthase Cpz20 
and the hypothetical dehydrogenase Cpz25. Thereby I hoped to provide evidence of 
the biosynthetic origin and attachment of the methylglutaryl moiety and to produce 
structurally simplified liponucleoside antibiotics. This involved the following 
experiments: 
 
 Generation of mutant cosmids by single in-frame gene deletions and 
heterologous expression in S. coelicolor M512. 
 Cultivation of the mutant strains and analysis of extracts for the identification 
of caprazamycin derivatives by LC-MS. 
 
The generation and investigation of mutant strains was carried out in cooperation 
with Liane Lutsch as diploma student.  
 
In the caprazamycin gene cluster, potential genes responsible for the biosynthesis of 
dTDP-L-rhamnose could not be found. And only the caprazamycin aglycones were 
accumulated in a heterologous host containing the caprazamycin gene cluster. 
Consequently, my third objective was the identification of the dTDP-L-rhamnose 
gene cluster and investigations in the formation and attachment of the deoxysugar 
moiety in caprazamycin biosynthesis. The following experiments were required for 
this task: 
 
 Heterologous co-expression of the caprazamycin gene cluster and plasmid 
pRHAM, which contains genes directing the formation of dTDP-L-rhamnose. 
Analysis of mutant extracts for the accumulation of intact caprazamycins. 
 Expression and purification of the putative glycosyltransferase Cpz31. In vitro 
studies for its role in the attachment of the rhamnosyl moiety in caprazamycin 
biosynthesis. 
 Introduction of the caprazamycin gene cluster in different Streptomyces strains 
for the production of caprazamycin derivatives with altered deoxysugar moiety. 
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 Screening of the cosmid library of Streptomyces sp. MK730-62F2 for the 
dTDP-L-rhamnose biosynthetic gene cluster using primers for the amplification 
of a dTDP-glucose 4,6-dehydratase. 
 Sequencing and analysis of a cosmid containing the dTDP-L-rhamnose gene 
cluster. 
 Functional proof of the involvement of the dTDP-L-rhamnose gene cluster in 
caprazamycin biosynthesis by inactivation of the dTDP-glucose 4,6-
dehydratase gene in Streptomyces sp. MK730-62F2 and complementation 
with pRHAM. 
 Assembling of the caprazamycin and the dTDP-L-rhamnose gene clusters 
onto one cosmid. Heterologous expression of the mutant cosmid in S. 
coelicolor M512 and analysis of extracts for the accumulation of intact 
caprazamycins by LC-MS. 
 Confirmation of cpzDI and cpzDV as non-essential in caprazamycin 
biosynthesis by gene deletion experiments performed on the assembled 
cluster. 
 
With the caprazamycin biosynthetic gene cluster at hand I had all necessary 
information to proceed with my fourth objective: the identification of the liposidomycin 
gene cluster. The following experiments had to be conducted:  
 
 Generation and screening of a cosmid library from genomic DNA of 
Streptomyces sp. SN-1061M for the liposidomycin biosynthetic gene cluster 
using cpz11 as probe. 
 Sequencing and analysis of a cosmid containing the liposidomycin gene 
cluster. And comparison of the sequence with the caprazamycin gene cluster. 
 Functional proof of the identity of the liposidomycin gene cluster by 
heterologous expression in S. coelicolor M512. 
 Establishment of a model for liposidomycin biosynthesis. 
 Analysis of extracts from Streptomyces strains producing caprazamycin 
derivatives for the presence of sulfated liponucleosides. 
 
From the comparison of the caprazamycin and the liposidomycins gene cluster we 
could identify a set of genes which are responsible for the sulfation of the 
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aminoribose moiety in liposidomycin biosynthesis. Interestingly, similar genes were 
found adjacent to the caprazamycin gene cluster and the expected sulfated 
caprazamycin derivatives were readily detected in extracts of caprazamycin producer 
strains. One of these genes, Cpz4, was annotated as potential arylsulfate 
sulfotransferase. My fifth aim was therefore to elucidate the role of Cpz4 in the 
sulfation reaction of liponucleoside antibiotics. In order investigate the function of 
Cpz4, the following experiments were necessary: 
 
 Verification of Cpz4 to be involved in the sulfation of caprazamycin derivatives 
by gene deletion experiments. 
 Expression and purification of the Cpz4. Biochemical characterization of Cpz4 
and investigations in the reaction mechanism. 
 In vitro studies of Cpz4 for the sulfation of caprazamycin derivatives and 
synthetic precursor analogs of the biosynthetic pathway. 
 
The biochemical investigations on Cpz4 were carried out in cooperation with Kornelia 
Eitel as diploma student. 
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II. MATERIALS AND METHODS 
1. Chemicals 
Table II.1.1 Chemicals and media components 
Supplier Chemical / Media component 
Amersham Biosciences, Freiburg, 
Germany 
Agarose 
Bacto-Difco, Heidelberg, Germany Agar 
Casaminoacids 
Malt extract 
Peptone  
Tryptic soy broth 
Tryptone  
Yeast extract 
Calbiochem-Novabiochem, Bad 
Soden, Germany 
L-proline 
Thiostrepton 
Fluka, Ulm, Germany Apramycin 
Tetramethyl ethylendiamine (TEMED) 
Potassium sulfate (K2SO4) 
Genaxxon Bioscience, Ulm, 
Germany 
Hygromycin 
Merck, Darmstadt, Germany L-asparagine 
Chloramphenicol 
Coomassie brilliant blue R250 
Copper chloride (CuCl2) 
Dipotassium phosphate (K2HPO4) 
Disodium phosphate (Na2HPO4) 
Ethylene-diamine tetraacetic acid (EDTA)  
Ethanol 
Glucose 
D-maltose 
Iron(II) sulfate (FeSO4) 
Manganese(II) chloride (MnCl2) 
Methanol  
Monopotassium phosphate (KH2PO4) 
Monosodium phosphate (NaH2PO4) 
Potassium acetate (KAc) 
Sodium borate (Na2B4O6) 
Roth, Karlsruhe, Germany 1,4-dithiothreitol (DTT) 
5-bromo-4-chlor-3-indolyl-β-D-
galactopyranoside (X-Gal) 
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Carbenicillin 
Glacial acetic acid 
Glycerol [86%] 
Glycine 
Isopropanol 
Isopropyl-β-thiogalactoside (IPTG) 
Mannitol 
MES 
Nickel(II) chloride (NiCl2) 
Phenol/Chloroform/Isoamylalcohol(25:24:1) 
Polyethylene glycol (PEG) 1000 
Rotiphorese® Gel 30 
Sodium dodecyl sulphate (SDS) 
Tris-(hydroxymethyl)-aminomethane-maleate 
(Tris-maleate) 
N-tris-(Hydroxymethyl)-methyl-2-aminoethane 
sulfonic acid (TES) 
Serva, Heidelberg, Germany N-lauroylsarcosine (Na-Salt, 35%) 
Sigma-Aldrich, Deisenhofen, 
Germany 
4-methylumbelliferone  
4-nitrophenol (pN) 
4-nitrophenolsulfate (pNS) 
Ammonium persulfate (APS) 
Bromophenol blue  
Calcium chloride (CaCl2) 
n-butanol 
Diethyl pyrocarbonate (DEPC) 
Dimethyl formamide (DMF) 
Dimethyl sulfoxide (DMSO) 
Imidazole 
Iron(III) chloride (FeCl3) 
Kanamycin  
Magnesium chloride (MgCl2) 
Magnesium sulfate (MgSO4) 
Methylumbelliferone sulfate (MUS) 
Nalidixic acid 
Phenol, crystalline 
Phenylmethylsulfonyl fluoride (PMSF) 
3’-phosphoadenosine 5’-phosphosulfate 
(PAPS) 
Polyoxyethylenesorbitan monolaurate (Tween 
20) 
Sodium chloride (NaCl) 
Sodium hydroxide (NaOH) 
Spectinomycin 
Streptomycin 
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Tetracycline 
Tris base 
SOBO Naturkost, Köln, Germany Soy flour 
Südzucker, Mannheim, Germany Sucrose  
VWR Intern. Prolabo, Leuben, 
Belgium 
Acetonitrile 
β-mercaptoethanol 
 
2. Materials for chromatography 
The liquid chromatography media were obtained as dry beads, suspensions or 
commercial columns. The storage of the media or columns was carried out according 
to the manufacturers’ instructions. 
 
Table II.1.2 Materials for chromatography 
Supplier Medium 
Amersham Biosciences, Freiburg, 
Germany 
Sephadex® LH-20 (dry beads) 
Sephadex®  G-25 NAP-10 (commercial column) 
C+S Chromatographie Service, 
Düren, Germany 
Multosphere® RP 18-5 (commercial colum, 5 
µm, 250×4 mm) 
Multosphere® 100 RP 18-5 (commercial column, 
5 µm, 250×20 mm) 
Qiagen, Hilden, Germany Ni-NTA Agarose (Suspension) 
 
3. Enzymes and kits 
Table II.1.2  Enzymes and kits 
Supplier Enzymes and kits 
Amersham Biosciences, Freiburg, 
Germany 
Restriction endonucleases 
T4 DNA Ligase 
Fermentas Deoxyribonuclease I (1 U/µL) 
10 x buffer with MgCl2 (100 mM Tris-HCl 
(pH 7.5 at 25 °C), 25 mM MgCl2, 1mM CaCl2) 
Revert-Aid™M-MuLV Reverse Transcriptase 
(200 U/µL) 
5 x reaction buffer (250 mM Tris-HCl (pH: 8.3 
at 25 °C), 250 mM KCl, 20 mM MgCl2, 50 mM 
DTT) 
10 mM dNTP-mix (10 mM each) 
1 kb DNA Ladder 
Fluka, Ulm, Germany Lysozyme (47 000 U/mg) 
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Lysozyme (85 400 U/mg) 
Macherey-Nagel, Düren, Germany Nucleobond® AX100 
NucleoSpin® Extract 2 in 1 
Nucleo-spin® RNA Clean-up 
New England Biolabs, Schwalbach, 
Germany 
Restriction endonucleases 
T4 DNA Ligase 
Plant Bioscience Limited, Norwich, 
UK 
REDIRECT© technology: PCR-targeting 
system in Streptomyces coelicolor 
Promega, Madison, WI, USA pGEM-T Easy® Vector System 1 
Taq DNA polymerase 
Pfu DNA polymerase 
Qiagen, Hilden, Germany RNase A (100g/mL) 
Roche, Mannheim, Germany DNA Molecular Weight Marker VII, DIG-
Labelled 
Expand High Fidelity PCR System  
Strategene, Taufkirchen, Germany Restriction endonucleases 
SuperCos1 cosmid vector kit 
Gigapack® III Gold Packaging Extract 
 
4. Media, buffers and solutions 
4.1. Media for bacterial cultivation 
The media used in this study were as follows. Unless otherwise stated, the media 
were prepared with distilled water and autoclaved for 20 min at 121 °C (15 psi). To 
obtain solid media, 2% (w/v) agar was added before autoclaving. If necessary, sterile 
supplementary components like antibiotics and other heat-labile substances were 
added in the sterile media at time of use. The media were stored at room 
temperature or at 4 °C. 
Cultivation of E. coli 
LB (Luria-Bertani) Medium (Sambrook & Russell, 2001)  
NaCl                                10.0 g 
Tryptone                          10.0 g 
Yeast extract                     5.0 g 
Dissolve the ingredients in about 900 mL water, adjust the pH to 7.0, and 
adjust the volume to 1 litre with water. Sterilize by autoclaving. 
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SOB Medium 
Tryptone                          20.0 g 
Yeast extract                     5.0 g 
NaCl                                  0.5 g 
Dissolve the ingredients in about 900 mL water, adjust the pH to 7.0, and 
adjust the volume to 1 litre with water. Sterilize by autoclaving. Add 10 mL 
of a sterile solution of 1 M MgCl2. 
 
TB Medium 
Tryptone                          12.0 g 
Yeast extract                   24.0 g 
Glycerol (87%)                4.6 mL             
Dissolve the ingredients in 900 mL water. Sterilize by autoclaving.  
 
KH2PO4                            2.31 g 
K2HPO4                          12.54 g 
are dissolved in 100 mL water, sterilized by autoclaving and added to the 
medium. 
Cultivation of Streptomyces 
2YT Medium (Kieser et al., 2000) 
Tryptone                           16.0 g 
Yeast extract                    10.0 g 
NaCl                                      5 g 
Dissolve the ingredients in 100 mL water. Sterilize by autoclaving. 
 
TSB (Tryptone Soya Broth) Medium (Kieser et al., 2000) 
Tryptone Soya Broth  30.0 g 
Dissolve the ingredient in up to 1 litre water, and sterilize by autoclaving. 
 
YEME (Yeast Extract – Malt Extract) Medium (Kieser et al., 2000)  
Yeast extract   3.0 g 
Peptone    5.0 g 
Malt extract   3.0 g 
Glucose            10.0 g 
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Sucrose             340 g 
Dissolve the ingredients in 1 litre water. Sterilize by autoclaving. Add 5 mL 
of a sterile solution of 1 M MgCl2. 
 
MS (Mannitol Soya flour) Agar (Kieser et al., 2000) 
Mannitol    20.0 g 
Soya flour   20.0 g 
Agar    20.0 g 
Dissolve the mannitol in 1 litre tap water and pour 100 mL into 300 mL 
Erlenmeyer flasks each containing 2 g agar and 2 g soy flour. Sterilize by 
autoclaving twice (115 ºC, 15 min) with gentle shaking between the two 
runs.  
 
MM Medium (Kieser et al., 2000) 
L-asparagine      0.5 g 
K2HPO4      0.5 g 
MgSO4  7H2O      0.2 g 
FeSO4  7H2O   0.01 g 
Mannitol         5 g 
Agar        10 g 
Distilled water      ad 1000ml 
Dissolve the ingredients, except agar, in the distilled water, adjust to pH 
7.0-7.2 and dispense 200 mL into 300 mL Erlenmeyer flasks each 
containing 2 g agar. Close the flasks and sterilize by autoclaving.  
 
Caprazamycin and liposidomycin production medium (P-medium) 
Soytone         10 g  
Soluble starch        10 g  
D-maltose        20 g  
Trace elements solution      5 mL (see protoplast transformation) 
Dissolve the ingredients in water, adjust to pH 6.7. Add water to 1000 mL 
Sterilize by autoclaving.  
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Protoplast transformation of Streptomyces 
Trace elements solution 
ZnCl2    40 mg 
FeCl3  6H2O           200 mg 
CuCl2  2H2O   10 mg 
MnCl2  4H2O   10 mg 
Na2B4O6  10H2O  10 mg 
(NH4)6Mo7O24  4H2O  10 mg 
Dissolve in 1 litre distilled water and autoclave. 
R5 Medium (Kieser et al., 2000) 
Sucrose            103.0 g 
K2SO4    0.25 g 
MgCl2  6H2O           10.12 g 
Glucose    10.0 g 
Difco Casaminoacids    0.1 g 
Trace elements solution 2.0 mL 
DifcoYeast extract    5.0 g 
TES buffer   5.73 g 
Agar (plates)   23.0 g 
Dissolve in water to a final volume of 1 litre and sterilize by autoclaving. To 
prepare soft agar, 6 g Agar instead of 23 g, were added.  
After autoclaving, add the following sterile solutions: 
 
KH2PO4 (0.5%)   10 mL 
CaCl2  2H2O (5 M)    4 mL 
L-Proline (20% (w/v))  15 mL 
NaOH (1M)     7 mL 
 
4.2. Antibiotic solutions 
Antibiotics were dissolved in appropriate solvents as stock solutions and kept at         
-20 °C. The aqueous solutions were sterilized by passing through a 0.22 µm filter. 
The solutions in ethanol and DMSO were autosterile. For antibiotic selection, the 
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required antibiotics were added to the cooled media (room temperature to 60 °C) in 
appropriate concentration. 
Table II.3.1 Solutions of antibiotics 
Concentration in 
Antibiotic 
stock solution (mg/mL)
media 
(µg/mL) 
Solvent 
Apramycin 50 15-50a H2O 
Carbenicillin 50-100 50-100 H2O 
Chloramphenicol 25-50 25-50 ethanol 
Kanamycin 50 15-50a H2O 
Tetracycline 12 12 ethanol 
Thiostrepton 50 15-50a DMSO 
Nalidixic acid 25 25 0.3 M NaOH
Spectinomycin 200 200 H2O 
Streptomycin 10 10 H2O 
Hygromycin 40 40 H2O 
a15 µg/mL in liquid and 50 µg/mL in solid media for selection of Streptomyces strains; otherwise, 50 µg/mL. 
 
4.3. Buffers and solutions 
Unless otherwise stated, the buffers and solutions were prepared with distilled water, 
autoclaved and stored at room temperature. 
Buffers and Solutions for DNA isolation 
Table II.3.2 Buffers and solutions for plasmid and cosmid isolation from E.coli 
Buffer Components Final concentration Preparation 
Solution 
MP1 
Tris-HCl 
EDTA 
RNase A 
50 mM 
10 mM 
100 µg/mL 
Adjust the pH to 8.0. Add 
RNase A just before use. 
Solution 
MP2 
NaOH 
SDS 
0.2 M 
1% (w/v) 
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Solution 
MP3 
KAc  3H2O 3 M Adjust the pH to 4.8. Store at 4 
°C.  
Table II.3.3 Buffers for isolation of genomic DNA from Streptomyces 
Buffer Components Final 
concentration 
Preparation 
Lysozyme 
solution 
Sucrose 
Tris-HCl 
EDTA 
RNase A 
Lysozyme 
10.3% 
25 mM 
25 mM 
100 µg/mL 
3 mg/mL 
Adjust the pH to 8.0. Add 
RNase A and lysozyme just 
before use. 
SDS 
solution 
SDS 
2 M Tris-HCl 
pH 8 
2 g 
12 g 
 
Dissolve the SDS in up to 89 
mL distilled water; add the 
Tris-HCl buffer. Do not 
autoclave.  
KAc 
solution 
KAc  3H2O 3 M Adjust the pH to 4.8.  
Tris-Buffer Tris-HCl 10 mM Adjust the pH to 7.5.  
 
Buffers for DNA gel electrophoresis 
Table II.3.4 Buffers for DNA gel electrophoresis 
Buffer/solution Components 
Final 
concentration
Preparation 
50×TAE Tris base 
EDTA 
Glacial acetic acid  
2 M 
0.05 M 
57.1 mL/l 
Adjust the pH to 8.0 
with glacial acetic 
acid. 
Loading buffer Glycerol  
Bromophenol blue 
30% (w/v) 
0.25% (w/v) 
Store at 4 °C 
Ethidium bromide 
solution for staining 
the agarose gel 
Ethidium bromide 1 µg/mL  
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Solutions for blue/white selection of E. coli 
The storage was carried out at -20°C. 
 
Table II.3.5 Stock solutions for blue/white selection. 
Solution Composition Per plate 
IPTG 80 mg/mL in distilled water, sterilize by filtering  15 µL 
X-Gal 20 mg/mL in DMF, autosterile 60 µL 
 
Buffers for preparation of protoplasts and transformation of Streptomyces 
The following sterile solutions were prepared separately. To obtain P-buffer and T-
buffer, they were mixed according to the description and stored at -20°C. 
 
Table II.3.6 Buffers for preparation of protoplasts and transformation of Streptomyces 
Buffer Components Amount (mL) 
P(protoplast)-buffer 
(100 mL) 
(Kieser et al., 2000) 
Sucrose (12% (w/v) in H2O) 
MgCl2  6H2O (1M) 
K2SO4   (140 mM) 
Trace elements solution  
KH2PO4 (40 mM) 
CaCl2  2H2O (250 mM) 
TES (0.25M, pH 7.2) 
85.5 
1.0 
1.0 
0.2 
1.0 
1.0 
10.0 
T(transformation)-
buffer (10 mL) 
(Kieser et al., 2000) 
Sucrose (25% (w/v) in H2O) 
Trace elements solution 
K2SO4 (140 mM) 
KH2PO4 (40 mM) 
MgCl2  6H2O (1 M) 
CaCl2  2H2O (5 M) 
Tris-maleate (0.5 M, pH 8.0) 
PEG 1000 (50% (w/v) in H2O); 
1.0 
0.03 
0.1 
0.1 
0.1 
1.0 
1.0 
                 5.0 
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Buffers for protein purification by nickel affinity chromatography 
The buffers for protein purification were prepared with distilled water, autoclaved and 
stored at 4 °C. If required, lysozyme, imidazole, DTT and PMSF were added just 
before use. 
 
Table II.3.7 Buffers for protein purification 
Buffer Components Amount 
Buffer A Tris-HCl 
NaCl 
Glycerol 
Imidazole 
β-mercaptoethanol 
50 mM (pH 8.0) 
500 mM 
10% 
20 mM 
10 mM 
 
Buffers and solutions for protein gel electrophoresis (SDS-PAGE) and for 
Coomassie staining 
All the buffers and solutions were prepared according to the user manual for protein 
gel electrophoresis of Bio-Rad (Bio-Rad, München, Germany).  
 
Table II.3.8 Buffers and solutions for SDS-PAGE and Coomassie staining 
Buffer/solution Components Amount Preparation 
Stacking gel 
(4%) 
Distilled water 
0.5 M Tris-HCl (pH 6.8) 
10% (w/v) SDS 
Rotiphorese® Gel 30 
10% (w/v) APS 
TEMED 
6.1 mL 
2.5 mL 
0.1 mL 
1.3 mL 
0.05 mL 
0.01 mL 
Combine all the 
components, except 
APS and TEMED; degas 
under vacuum for about 
15 min. Add APS and 
TEMED just before 
pouring the gel. 
Resolving gel 
(12%) 
Distilled water 
1.5 M Tris-HCl (pH 8.8) 
10% (w/v) SDS 
Rotiphorese® Gel 30 
10% (w/v) APS 
3.35 mL 
2.5 mL 
0.1 mL 
4.0 mL 
0.05 mL 
(See above). 
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TEMED 0.005 mL 
Sample buffer Distilled water 
0.5 M Tris-HCl (pH 6.8) 
Glycerol 
SDS (10% (w/v) in H2O) 
Bromophenol blue (0.5% 
(w/v) in H2O) 
3.55 mL 
1.25 mL 
2.5 mL 
2.0 mL 
0.2 mL 
Add 5 µL β-mercapto-
ethanol to 95 µL sample 
buffer prior to each use. 
Store at 4 °C. 
10×running 
buffer 
Tris base 
Glycine 
SDS 
30.0 g 
144.0 g 
10.0 g 
Dissolve in distilled 
water to a final volume 
of 1 litre. Store at 4 °C. 
Fixing buffer Distilled water 
Acetic acid 
Methanol 
70% (w/v) 
10% (w/v) 
20% (w/v) 
Store at RT. 
Coomassie 
Brilliant Blue G-
250 solution 
Coomassie Brilliant Blue 
G-250 
Distilled water 
Acetic acid 
Methanol 
0.25% (w/v) 
 
45% (w/v) 
10% (w/v) 
45% (w/v) 
Store at RT. 
Bleaching 
solution for 
SDS-PAGE 
Distilled water 
Acetic acid 
Methanol 
45% (w/v) 
10% (w/v) 
45% (w/v) 
Store at RT. 
 
5. Plasmids, bacterial strains, primers and probes 
5.1. Vectors, cosmids and plasmids 
Table II.4.1 Vectors, cosmids and plasmids 
Name Description Source or reference 
Vector 
pGEM-T Linearized vector with T-overhang for direct 
cloning of PCR fragments with A-overhang, 
lacZ, ori, f1-origin, AmpR 
Promega 
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pUWL201 E. coli - Streptomyces shuttle vector, ermE* 
promoter, colE1, rep; AmpR, ThioR 
(Doumith et al., 
2000) 
pHis8 General expression vector for protein 
overproduction; pET-28a(+) (Merck, Darmstadt, 
Germany) derivative providing an His8-tag; KanR 
(Jez et al., 
2000) 
SuperCos1 Cloning vector for the construction of genomic 
libraries; cos pSV40 oripUC; AmpR, KanR 
Stratagene 
Plasmid 
pIJ787 SuperCos1-derivative, bla gene replaced by a 
cassette containing oriT, tet, attP, int ΦC31, 
KanR 
(Eustáquio et 
al., 2004) 
pIJ773 aac(3)IV (ApraR), oriT, FRT (Gust et al., 2003) 
pIJ774 aac(3)IV (ApraR), oriT, loxP (Gust et al., 2003) 
pIJ778 aadA (SpcR, StrR), oriT, FRT (Gust et al., 2003) 
pIJ10700 hyg (HygR), oriT, FRT 
John Innes 
Centre, 
Norwich, UK 
pIJ790  RED (gam bet exo), araC, rep101ts; CmlR (Gust et al., 2003) 
pUZ8002 tra, RP4 ; KanR (Paget et al., 1999) 
pUB307 „Driver“-Plasmid for triparental conjugation; tra oriT ; KanR, CmlR 
(Flett et al., 
1997) 
pRHAM Derivative of pUK21 (Vieira & Messing, 1991) 
containing the genes oleL, oleS, oleE and oleU 
from S. antibioticus ATCC 1891 for dTDP-L-
rhamnose biosynthesis, permE, ThioR 
(Rodriguez et 
al., 2000) 
 
Table II.4.2 Plasmids and cosmids produced in this study 
Name Description 
Plasmid 
pLK01 1.2 kb PCR product comprising cpz31 flanked by EcoRI/HindIII 
restriction sites in pGEM®-T; CarbR 
pLK02 EcoRI/HindIII restriction fragment from pLK01 comprising cpz31 into 
the same sites of pHis8; KanR 
pLK03 1.6 kb PCR product comprising cpz4 flanked by SacI/XhoI restriction 
sites in pGEM®-T; CarbR 
pLK04 SacI/XhoI restriction fragment from pLK03 comprising cpz4 cloned 
into the same sites of pHis8; KanR 
pLL05 EcoRI/HindIII restriction fragment from a 0.6 kb PCR product 
comprising cpz11 cloned into the same sites of pUWL201; ThioR 
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pLL06 EcoRI/HindIII restriction fragment from a 1.5 kb PCR product 
comprising cpz21 cloned into the same sites of pUWL201; ThioR 
pLL07 EcoRI/HindIII restriction fragment from a 1.0 kb PCR product 
comprising cpz23 cloned into the same sites of pUWL201; ThioR 
Cosmid 
4H11 SuperCos1-based cosmid containing the dTDP-L-rhamnose 
biosynthetic genes from Streptomyces sp. MK730-62F2, AmpR, KanR 
31C2 SuperCos1-based cosmid containing the caprazamycin biosynthetic 
gene cluster from Streptomyces sp. MK730-62F2, AmpR, KanR 
3G5 SuperCos1-based cosmid containing the liposidomycin biosynthetic 
gene cluster from Streptomyces sp. SN-1061M, AmpR, KanR 
cpzLK01 from 4H11; cpzDIII is replaced by an apramycin resistance cassette 
from pIJ773; ApraR, KanR 
cpzLK02 from 31C2; cpz28-30 are replaced by an apramycin resistance 
cassette from pIJ773; AmpR, ApraR, KanR 
cpzLK04 from cpzLK02; Δcpz28-30 (apramycin resistance cassette removed 
by SpeI restriction); AmpR, ApraR, KanR 
cpzLK09 from 31C2; bla gene replaced by cassette from pIJ787 (oriT, tet, attP, 
int C31); TetR, KanR. 
cpzEW01 from 4H11; orf1-9 are replaced by an apramycin resistance cassette 
from pIJ774; ApraR, AmpR, KanR 
cpzEW02 from cpzEW01; orf10-25 are replaced by an hygromycin resistance 
cassette from pIJ10700; ; HygR, ApraR, AmpR, KanR 
cpzEW03 from cpzLK09; orf32-33 are replaced by an apramycin resistance 
cassette from pIJ774; ApraR, TetR, KanR 
cpzEW05 from cpzEW03; orf34 is replaced by an spectinomycin/streptomycin 
resistance cassette from pIJ778; SpcR, StrR, ApraR, TetR, KanR 
cpzEW07 from cpzEW05; a 4116 bp region upstream of cpz32 is replaced by a 
9950 bp NheI/PmeI restriction fragment from cpzEW02 containing the 
genes cpzDI-cpzDVII; TetR, HygR, ApraR, KanR 
cpzEW08 from cpzEW07; apramycin resistance cassette removed by SpeI 
restriction; TetR, HygR, KanR 
cpzEW09 from cpzEW08; cpzDI is replaced by an apramycin resistance 
cassette from pIJ774; TetR, HygR, ApraR, KanR 
cpzEW10 from cpzEW09; ΔcpzDI (apramycin resistance cassette removed by 
Cre-recombinase mediated recombination); TetR, HygR, KanR 
cpzEW11 from cpzEW08; cpzDV is replaced by an apramycin resistance 
cassette from pIJ774; TetR, HygR, ApraR, KanR 
cpzEW12 from cpzEW11; ΔcpzDV (apramycin resistance cassette removed by 
Cre-recombinase mediated recombination); TetR, HygR, KanR 
cpzLL05 from cpzLK09; cpz11 is deleted (81 bp scar); TetR, KanR 
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cpzLL06 from cpzLK09; cpz21 is deleted (81 bp scar); TetR, KanR 
cpzLL07 from cpzLK09; cpz23 is deleted (81 bp scar); TetR, KanR 
cpzLL08 from cpzLK09; cpz26 is deleted (81 bp scar); TetR, KanR 
cpzWP01 from cpzLK09; cpz33-34 are deleted (81 bp scar); TetR, KanR 
cpzWP02 from cpzLK09; cpz32-34 are deleted (81 bp scar); TetR, KanR 
cpzWP04 from cpzLK09; cpz1-3 are deleted (81 bp scar); TetR, KanR 
cpzWP05 from cpzLK09; cpz1-4 are deleted (81 bp scar); TetR, KanR 
cpzWP06 from cpzLK09; cpz1-5 are deleted (81 bp scar); TetR, KanR 
cpzWP07 from cpzLK09; cpz1-6 are deleted (81 bp scar); TetR, KanR 
cpzWP22 from cpzLK09; cpz20 is deleted (81 bp scar); TetR, KanR 
cpzWP25 from cpzLK09; cpz25 is deleted (81 bp scar); TetR, KanR 
lipLK01 from 3G5; bla gene replaced by cassette from pIJ787 (oriT, tet, attP, 
int C31), TetR, KanR. 
 
5.2. Bacterial strains 
Table II.4.3 Bacterial strains 
Strain Relevant characteristics Source or reference 
E. coli XL1Blue MRF’ General cloning host (recA1 endA1 gyrA96 
thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
laclqZDM15 Tn10 (TetR)]), TetR 
Stratagene 
E. coli ET12567 Strain triply defective in DNA methylation 
(dam- dcm- hsdM-), TetR, CmR 
 (MacNeil et al., 
1992) 
E. coli BW25113 
(araD-araB)567 lacZ4787::rrnB-4;lacIP-
4000(lacQ) - rpoS369(Am) rph-1 (rhaD-
rhaB)568 hsdR514 
(Datsenko & 
Wanner, 2000) 
E. coli BT340 DH5α/pCP20 
(Cherepanov & 
Wackernagel, 
1995) 
E. coli SURE® Host strain for cosmid cloning (endA1 
glnV44 thi-1 gyrA96 relA1 lac recB recJ 
sbcC umuC::Tn5 uvrC e14- Δ(mcrCB-
hsdSMR-mrr)171 F'[ proAB+ lacIq 
lacZΔM15 Tn10]); TetR, KanR 
Stratagene 
E. coli Rosetta(DE3) 
pLysS 
Host for the heterologous expression of 
His8 tagged proteins (F- ompT hsdSB(rB-mB-
) gal dcm λ(DE3 [lacI lacUV5-T7 gene 1 
ind1 sam7 nin5]) pLysSRARE); CmR 
Invitrogen 
 
S. coelicolor M512 ΔredD ΔactII-ORF4 SCP1- SCP2- (no 
production of actinorhodin, 
 (Floriano and 
Bibb, 1996) 
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undecylprodigiosin, and methylenomycin) 
Streptomyces sp. 
MK730-62F2 
caprazamycin producer; wildtype strain. acc. no. FERM-
BP7218 (National 
Institute of 
Bioscience and 
Human 
Technology, 
Tsukuba, Japan) 
Streptomyces sp. SN-
1061M 
liposidomycin producer; obtained from UV-
mutagenesis of the wildtype strain. 
acc. no. FERM-
BP5800 (National 
Institute of 
Bioscience and 
Human 
Technology, 
Tsukuba, Japan) 
Streptomyces sp. 
MK730-62F2 Δcpz28-30-
(1),-(2) and -(3) 
Three independent cpz28-30.– mutants of 
Streptomyces sp. MK730-62F2 
this study 
Streptomyces sp. 
MK730-62F2 ΔcpzDIII-
(1),-(2) and -(3) 
Three independent cpzDIII.– mutants of 
Streptomyces sp. MK730-62F2; ApraR 
this study 
Streptomyces sp. 
MK730-62F2 ΔcpzDIII-
(1)/pRHAM 
cpzDIII.– mutant of Streptomyces sp. 
MK730-62F2 complemented with pRHAM; 
ThioR, ApraR 
this study 
S. coelicolor M512/ 
cpzLK09-(1),-(2) and -(3) 
S. coelicolor M512 containing the 
caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzLK09-(1)/pRHAM 
S. coelicolor M512 mutant co-expressing 
the caprazamycin gene cluster and 
pRHAM; ThioR, KanR  
this study 
S. coelicolor M512/ 
lipLK01-(1),-(2) and  -(3) 
S. coelicolor M512 containing the 
liposidomycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzEW07-(1),-(2) and -
(3) 
S. coelicolor M512 containing the 
assembled caprazamycin gene cluster and 
the genes cpzDI-cpzDVII for dTDP-L-
rhamnose biosynthesis, three independent 
mutants; HygR, ApraR, KanR 
this study 
S. coelicolor M512/ 
cpzEW10-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpzDI 
deficient assembled caprazamycin gene 
cluster, three independent mutants; HygR, 
KanR 
this study 
S. coelicolor M512/ 
cpzEW12-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpzDV 
deficient assembled caprazamycin gene 
cluster, three independent mutants; HygR, 
KanR 
this study 
 MATERIALS AND METHODS 
  29 
S. coelicolor M512/ 
cpzLL05-(1),-(2) and -(3) 
S. coelicolor M512 containing a cpz11 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzLL05-(1)/pLL05 
A heterologous cpz11.– mutant 
complemented with pLL05; ThioR, KanR 
this study 
S. coelicolor M512/ 
cpzLL06-(1),-(2) and -(3) 
S. coelicolor M512 containing a cpz21 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzLL06-(1)/pLL06 
A heterologous cpz21.– mutant 
complemented with pLL06; ThioR, KanR 
this study 
S. coelicolor M512/ 
cpzLL07-(1),-(2) and -(3) 
S. coelicolor M512 containing a cpz23 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzLL07-(1)/pLL07 
A heterologous cpz23.– mutant 
complemented with pLL07; ThioR, KanR 
this study 
S. coelicolor M512/ 
cpzLL08-(1),-(2) and -(3) 
S. coelicolor M512 containing a cpz26 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzWP01-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpz33-34 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzWP02-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpz32-34 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzWP04-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpz1-3 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzWP05-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpz1-4 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzWP06-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpz1-5 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzWP07-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpz1-6 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzWP22-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpz20 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
S. coelicolor M512/ 
cpzWP25-(1),-(2) and -
(3) 
S. coelicolor M512 containing a cpz25 
deficient caprazamycin gene cluster, three 
independent mutants; KanR  
this study 
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S. fradiae A0  urdGT1a –, urdGT1b –, urdGT1c – mutant 
of the urdamycin producer S. fradiae 
TÜ2171  
(Trefzer et al., 
2000) 
S. fradiae A0/cpzLK09-
(1), -(2) and -(3) 
S. fradiae A0 containing the caprazamycin 
gene cluster, three independent mutants; 
KanR  
this study 
Streptomyces sp. 
TÜ6071ΔplaA6 
plaA6 – mutant of the phenalinolactone 
producer Streptomyces sp. TÜ607 
A. Luzhetskyy, 
Pharmaceutical 
Biotechnology, 
University of 
Freiburg 
Streptomyces sp. 
TÜ6071ΔplaA6/cpzLK09-
(1), -(2) and -(3) 
Streptomyces sp. TÜ6071ΔplaA6 
containing the caprazamycin gene cluster, 
three independent mutants; KanR 
this study 
 
Mycobacterium phlei Indicator strain for caprazamycins and 
derivatives 
acc. no. DSM750 
(German 
Collection of 
Microorganisms 
and Cell Cultures, 
Braunschweig, 
Germany)  
 
6. Culture conditions 
6.1. Cultivation of E. coli 
For cloning experiments, E. coli strains were grown overnight (16-18 h) in liquid or 
solid LB medium with appropriate antibiotic at 37 °C (Sambrook and Russell, 2001).  
For protein overproduction, the incubation temperature was 20 ºC. 
Permanent cultures of E. coli were prepared by mixing 600 µL of overnight culture 
with 400 µL of glycerol solution (50% (w/v) in distilled water) and stored at -70°C. 
6.2. Cultivation of Streptomyces 
General cultivation 
Streptomyces strains were routinely cultured in liquid or solid TSB medium. Liquid 
cultures were carried out in baffled Erlenmeyer flasks containing a stainless steel 
spring at 180-200 rpm and 28-30 °C for 2 to 3 days. For preparation of protoplasts, 
Streptomyces were cultured in YEME medium containing 0.5% glycine; For isolation 
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of genomic DNA, Streptomyces were cultured in YEME medium. An appropriate 
concentration of antibiotic was added, if required. 
Production of secondary metabolites 
For the production of caprazamycins, liposidomycins and derivatives thereof, 1 mL of 
a two-day-old TSB culture of the respective Streptomyces strain was inoculated into 
50 mL P-medium and grown at 30 °C and 210 rpm for 7 days.  
Preparation of spore suspensions of Streptomyces 
To prepare spore suspensions, Streptomyces strains were spread on MS agar and 
incubated at 30 °C for about a week.  
 The plates were grown till they were well sporulated. 4 mL of sterile ddH2O were 
added to each plate and the spores scraped off of the top of the plates and into 
suspension. The resulting spore suspension was poured into a falcon tube and 
vortexed vigorously (about 1 min). The spores were separated from the mycelium by 
passing the suspension through sterile cotton plugged in a disposable syringe. 
Spores were collected by centrifugation (2,100×g, 10 min, 4 °C), and resuspended in 
1-3 mL of 20% glycerol. The spore suspensions were stored at -70°C. 
7. Methods of molecular biology 
7.1. Purification, concentration and quantification of DNA 
Standard methods for DNA isolation and manipulation were performed as described 
elsewhere (Kieser et al., 2000; Sambrook & Russell, 2001).  
Phenol/chloroform extraction and ion exchange column chromatography were used 
for purification of DNA. Ethanol or isopropanol precipitation was used for 
concentration.  
Quantification of DNA was carried out by using a GeneQuant photometer 
(Pharmacia, Freiburg, Germany) at 260 nm as well as by comparing the fluorescent 
intensity with DNA markers on agarose gels. 
7.2. Agarose gel electrophoresis of DNA 
Gel electrophoresis with 0.8-1.5% (w/v) agarose was used to separate DNA 
fragments between 0.5 and 50 kb. The buffer system employed was 1×TAE buffer. 
After running the gels, they were stained with the fluorescent dye ethidium bromide, 
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detected under the UV light at 312 nm and photographed by using Eagle Eye II 
System (Strategene, Heidelberg, Germany) (Sambrook & Russell, 2001). 
DNA fragments were isolated from agarose gels using a NucleoSpin® 2 in 1 
extraction kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s 
protocol. 
7.3. DNA manipulation with enzymes 
Restriction of DNA with endonucleases was carried out according to the 
manufacturer's instructions.  
DNA ligation was achieved by using T4-DNA ligase. The ligation preparation, 
containing 1U T4 DNA ligase, 1×ligation buffer and a 1:1 (mole ratio) mixture of insert 
and linearized vector (about 100 ng) in a final volume of 10 µL, was incubated at 
room temperature for 2 h or at 16 °C or 4 °C overnight. 
7.4. DNA isolation 
 Isolation of plasmids from E. coli 
Mini-preps employing alkaline lysis were used to isolate recombinant plasmids from 
E. coli for routine screening. 5 mL LB-medium was inoculated with a single colony 
and grown overnight at 37 °C, 170 rpm. 4 mL of this culture were harvested by 
centrifugation (10000×g, 4 °C, 1 min) and resuspended in 200 µL solution MP1 by 
vortexing. The suspension was mixed with 400 µL solution MP2 by inversion and 
incubated at room temperature for 1-5 min. 300 µL solution MP3 was added and the 
mixture was incubated on ice for 5 min. After centrifugation (20,000×g, 4 °C, 15 min), 
the supernatant was poured into a fresh microfuge tube. The DNA was precipitated 
by addition of 0.7-fold isopropanol and centrifugation (20,000×g, 4 °C, 30 min). The 
DNA pellet was washed with 500 µL 70% ethanol, air dried and resuspended in 50 
µL distilled water or Tris-HCl pH 8 buffer. The mentioned solutions are listed in Table 
II.5. 
Preparative isolation of plasmids from E. coli was carried out from 50 mL overnight 
culture. 2 mL MP1, 4 mL MP2 and 3 mL MP1 were applied as described above. The 
DNA was precipitated with 2.5 vol. ethanol instead of Isopropanol. 
For the isolation of cosmids a similar protocol was used. In this case, after addition of 
solution MP2, the suspension was inverted and immediately treated with solution 
MP3. 
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Isolation of genomic DNA from Streptomyces coelicolor 
Genomic DNA was isolated by the following procedure (Kieser et al., 2000). 2 mL of 
a 2-day-old culture in TSB medium were harvested by centrifugation (17,000×g, 4 °C,   
1 min). The cells were washed with 0.5 mL 0.3 M sucrose and resuspended in 500 
µL Lysozyme solution by vortexing. The suspension was incubated for 30 min at 37 
°C. 250 µL of SDS solution were added and the mixture was vortexed vigorously for 
1 min. 250 µL phenol/chloroform/isoamyl alcohol (25:24:1) were added and the 
mixture was vortexed vigorously for 15 s and centrifuged at 17,000×g and 4 °C for 10 
min. The supernatant was poured into a fresh microfuge tube and extracted a second 
time with 250 µL phenol/chloroform/isoamyl alcohol (25:24:1) (1 min vigorous 
vortexing). The aqueous phase was separated and genomic DNA was precipitated 
by addition of 0.1 volume of KAc solution and 0.8 volume of isopropanol and 
centrifugation (20,000×g, 4 °C, 30 min). The DNA pellet was washed with 500 µL 
70% ethanol, air dried and resuspended in 50 to 100 µL Tris-HCl pH 8 buffer. 
A similar procedure was used for the isolation of high-molecular genomic DNA. In 
order to avoid mechanical forces on the DNA, mixing was done by gentle inverting 
instead of vortexing in all steps. Cells were harvested from a 50 mL culture and 
treated with 10 mL Lysozyme solution and 8ml SDS solution. Extraction was done at 
least 5 times with 1 volume of phenol/chloroform/isoamyl alcohol (25:24:1) until the 
aqueous phase appeared clear.  
7.5. PCR amplification 
General conditions  
PCR amplifications were carried out with the GeneAmp® PCR System 2400 or 
GeneAmp® PCR-System 9700 (Perkin-Eimer, Weiterstadt, Germany).  
Table II.6.1 PCR reaction and amplification conditions using the Expand High Fidelity PCR 
system 
Substance Final 
concentration 
 Cyclus Temperatur
e 
Time Cycles 
Reaction buffer 
(10) 
1  Hot start 94 °C 2 min 1 
DMSO  5% (v/v)  Denaturing 94 °C 45 s 
Template DNA about 100 ng  Annealing 50-60 °C 45 s 
30 
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dNTPs 0.2 mM each  Elongation 72 °C 90 s  
Primer  50 pmol each  Final 
elongation 
72 °C 5 min 1 
DNA-Polymerase 2.5 U  End 4 °C  1 
Add distilled water to make up to 50 l      
 
For PCR amplification with Taq or Pfu polymerase, the PCR mixture (50-100 µL) 
contained 50 pmol each primer, 100-300 ng template DNA, 0.2 mM each dNTP, 1× 
reaction buffer, 5% (v/v) DMSO and 2-3 U polymerase. Amplification conditions were 
according to the supplier’s instructions. 
In general, 5 to 10 µL of the PCR reaction were analysed by gel electrophoresis. 
Conditions for the amplification of resistance cassettes from pIJ773, pIJ774, 
pIJ778 and pIJ10700 
The conditions for amplification of a resistance cassette from pIJ773, pIJ774, pIJ778 
and pIJ10700 (REDIRECT© technology kit for PCR targeting (Gust et al., 2003)) 
using the Expand High Fidelity PCR system (Roche) are given in Table II.21. 
Template DNA was prepared by digesting about 10 µg of the respective plasmid with 
KpnI and SacII, and by isolating the respective cassette fragment from an agarose 
gel (Gust et al., 2003). 
Table II.6.2 Conditions for amplification of resistance cassettes  
Substance Final 
concentration 
 Cyclus Temperatur
e 
Time Cycles 
Reaction buffer 
(10) 
1  Hot start 94 °C 2 min 1 
DMSO  5% (v/v)  Denaturing 94 °C 45 s 
Template DNA about 100 ng  Annealing 50 °C 45 s 
dNTPs 0.2 mM each  Elongation 72 °C 90 s 
10 
Primer  50 pmol each  Denaturing 94 °C 45 s 
DNA-Polymerase 2.5 U  Annealing 55 °C 45 s 
Add distilled water to make up to 50 l  Elongation 72 °C 90 s 
15 
   Final 
elongation 
72 °C 5 min 1 
   End 4 °C  1 
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7.6. Introduction of DNA in E. coli  
The methods described in this section were modified from (Sambrook & Russell, 
2001). 
Preparation of electro-competent cells  
50 mL LB-medium was inoculated with 1 mL of an overnight culture of E. coli and 
cultivated at 30 to 37 °C (see note below), 170 rpm till the OD600 reached 0.6 (2.5-4 
h). The cells were harvested by centrifugation (3,000×g, 4°C, 5 min), and washed 
twice with 50 and 25 mL ice-cold 10% (w/v) glycerol solution, respectively. The cell 
pellet was suspended in the remaining drops after discarding the supernatant. 
Competent cells could be used immediately or dispensed in 50-µL aliquots in 1.5-mL 
microfuge tubes, and stored at -70 °C.  
Electroporation  
DNA (about 100 ng in 1-2 µL distilled water) was added to 50 µL competent cells in 
1.5-mL microfuge tube and incubated on ice for about 1 min. The mixture was then 
carefully transferred to an ice-cold electroporation cuvette (0.2 cm), avoiding 
formation of air bubbles, and electroporation was carried out using a BioRad 
electroporator set to 2.5 kV. The optimal time constant is 4.5 – 5.0 ms. 1 mL LB 
medium was immediately pipetted into the cuvette, and the suspension was 
transferred to a microfuge tube and incubated on a water bath or on a shaker (170 
rpm) for 1 h at 30 to 37 °C. The mixture was spread on LB agar plates containing the 
appropriate antibiotic(s) (no more than 200 µL per plate) and the plates were 
incubated at 30 to 37 °C. 
Note: To maintain plasmid pIJ790 in E. coli BW25113 (REDIRECT© technology kit for 
PCR targeting (Gust et al., 2003)), cells must be cultured at 30 °C, since pIJ790 
contains a temperature sensitive origin of replication. Otherwise, the cultivation 
temperature was 37 °C. 
Blue/white selection 
If a lacZ-containing cloning vector was used to prepare the recombinant plasmid, 
blue/white selection can facilitate the identification of the expected clones. For this 
purpose, first 15 µL of IPTG solution (80 mg/mL) in up to 100 µL H2O (sterile) were 
pipetted on the top of the plates and spread evenly, and then 60 µL of X-Gal solution 
(20 mg/mL in DMF) was plated in the same way. The plates were air dried under the 
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laminar flow for 30-45 min in order to evaporate the toxic DMF. Colonies containing 
the recombinant plasmid lack -galactosidase activity and remain white. 
7.7. Site-directed mutagenesis 
Cpz4 variants were generated by site-directed mutagenesis using plasmid pLK03 as 
template and primer His180Leu_fw GCGGGAGCCGATCTCCTTGACA 
TGCAGATCACT and His180Leu_rv AGTGATCTGCATGTCAAGGAGATCGGCT 
CCCGC, His253Leu_fw CCGTATGACTACGTCCTCATCAACTCCATGTCC and 
His253Leu_rv GGACATGGAGTTGATGAGGACGTAGTCATACGG, His308Leu_fw 
TCCTTCGCCTGGCAGCTCGACGTGAGCCGGGAA and His308Leu_rv TTCCCGG 
CTCACGTCGAGCTGCCAGGCGAAGGA. PCR and subsequent DpnI restriction was 
performed according to the QuickChange™ manual (Stratagene, Heidelberg, 
Germany). cpz4 variants were verified by sequencing and cloned into vector pHis8 
(Jez et al., 2000). 
7.8. PEG-mediated protoplast transformation for introduction of DNA 
in Streptomyces 
Preparation of protoplasts from Streptomyces 
Slightly modified from (Kieser et al., 2000). Mycelium from a 40 h old culture (50 mL 
TSB medium containing 0.4 % glycine) was washed twice with 15 mL of a 10.3% 
sucrose solution, resuspended in 10 mL of lysozyme solution (2 mg/mL in P buffer) 
and incubated at 30 ºC for 15-60 min with gentle agitation. Protoplast formation was 
monitored using the microscope. After most cells became protoplasts, the reaction 
was stopped by incubation on ice. The following steps were carried out on ice. 10 mL 
of ice-cold P buffer were added and the suspension was drawn in and out of a 10 mL 
pipette three times and filtered through glass wool. Protoplasts were sedimented 
gently by centrifugation (e.g. 1,000xg, 7 min). The supernatant was discarded, the 
pellet was first carefully resuspended in the remaining drop of liquid by tapping the 
tube, and then in 1 mL P buffer. The protoplast suspension can be immediately used 
for transformation or 100 µL aliquots can be stored at -70 ºC. To freeze protoplasts 
for storage, tubes were placed in ice contained in a plastic beaker, and the beaker 
was placed at -70 ºC overnight. To assess the protoplast regeneration, dilution series 
of the protoplast suspension in P buffer were prepared and plated on R5 agar plates. 
The plates were incubated at 30 °C for 3-7 days. The regenerable protoplasts per mL 
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suspension were calculated. To assess the proportion of non-protoplasted units in 
the suspension, samples were also diluted in distilled water and plated on 
regeneration plates (R5 agar).  
Transformation  
The transformation of Streptomyces strains was carried out by a modification of the 
method described by Kieser et al. (2000).  
Before transformation of Streptomyces strains the plasmids were propagated in E. 
coli ET 12567 to bypass methyl-sensing restriction.  
1-20 µg DNA (in maximal 10-20 µL Tris buffer) were added to 100-200 µL of a 
protoplast suspension, containing at least 108 protoplasts per mL; 400-500 µL T-
buffer containing PEG 1000 (25% (w/v) were immediately added, mixed by pipetting 
carefully three times and incubated at room temperature for 1 min. Increasing 
volumes of the resulting suspension (e.g. 10 µL, 100 µL, 200 µL, rest) were mixed 
with warm R5 soft agar (about 50 °C, 4×3 mL) and plated on four R5 plates. After 16-
24 h incubation at 30 °C, the plates were overlaid with 1 mL of dH2O including the 
required antibiotics for selection of mutants, and incubation was continued for further 
3-7 days.  
7.9. Intergeneric conjugation for introduction of DNA in Streptomyces 
Intergeneric conjugation was performed for the transfer of modified cosmid DNA into 
Streptomyces. Therefore, the cosmid (containing an oriT) was introduced into the 
non-methylating strain E. coli ET12567/pUZ8002 harbouring the tra-genes required 
for mobilization and transfer of circular DNA. A culture of E. coli ET12567/pUZ8002 
containing the cosmid was grown in LB supplemented with the appropriate antibiotics 
on 37°C until OD600 0.6. The cells were harvested by centrifugation (3,000×g, 4°C, 5 
min), and washed twice with 25 mL ice-cold LB medium without antibiotics. The cell 
pellet was suspended in LB to give a final OD600 of 0.5. In parallel 50 µL of spores of 
the target Streptomyces strain were incubated in 500 µL 2YT medium for 10 min at 
50°C and incubated on ice for 5 min. 500 µL of the E. coli ET12567/pUZ8002 
suspension was added and centrifuged (3,000×g, 4°C, 2 min). The supernatant was 
discarded and the pellet resuspended in 200 µL LB. The suspension was spread on 
four MS agar plates supplemented with 10 mM MgCl2. After 16-24 h incubation at 30 
°C, the plates were overlaid with 1 mL of dH2O including the required antibiotics for 
selection of mutants, and incubation was continued for further 3-7 days. 
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For triparental conjugation cosmid DNA was introduced into E. coli ET12567. Two 
parallel cultures, one with E. coli ET12567 containing the cosmid and one with E. coli 
ET12567/pUB307 were set up as described above. After washing and resuspension 
of the cells, 250 µL of each E. coli culture was added to 500 µL 2YT medium 
containing the Streptomyces spores. 
7.10. Generation and screening of a cosmid library  
Genomic cosmid libraries were constructed from the caprazamycin producer strain 
Streptomyces sp. MK730-62F2 and from the liposidomycins producer strain 
Streptomyces sp. SN-1061M. In both cases chromosomal DNA was prepared and 
ligated into the SuperCos1 vector according to the manufacturer’s instructions 
(SuperCos1 cosmid vector kit, Stratagene, Heidelberg).  
Preparation of SuperCos1 vector DNA 
20 µg of the cosmid vector DNA was linearized by XbaI digestion to dissect the cos-
sites. After phenol/chloroform extraction and precipitation the vector DNA solution (1 
µg/µL) was treated with 2 µL Calf Intestinal Alkaline Phosphatase (CIAP). Again the 
DNA was extracted with phenol/chloroform and precipitated. The vector DNA was 
than resuspended to a 1 µg/µL solution and digested with BamHI to dissect the 
cloning sites. After another round of phenol/chloroform extraction and precipitation 
the vector was ready to use. 
Preparation of chromosomal DNA 
Preparation of the chromosomal DNA started with partial digestion by Bsp1431. The 
digestion was checked by agarose gel electrophoresis to result in DNA fragments of 
~40 kb. The partially digested chromosomal DNA was extracted with 
phenol/chloroform, precipitated and treated with CIAP. Again the DNA was extracted 
with phenol/chloroform, precipitated and resuspended to a 1 µg/µL solution. 
Subsequently, the partially digested chromosomal DNA was ligated with the BamHI 
sites of the digested SuperCos1 DNA. The ligation was checked by agarose gel 
electrophoresis. 
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Packaging 
The packaging was performed using Gigapack III XL Packaging Extract 
(Stratagene, Heidelberg, Germany). This kit packages preferentially large inserts 
(i.e., 40- to 51-Kb recombinants). E. coli SURE® was used as host strain. After 
transfection, the cells were plated on LB with carbenicillin (50 µg/mL) plates and 
incubated overnight at 37°C. 3000 carbenicillin resistant E. coli clones were obtained 
from genomic DNA of Streptomyces sp. MK730-62F2 and 1100 clones from 
Streptomyces sp. SN-1061M. 
Screening for the caprazamycin gene cluster 
A 0.45 kb fragment of cpz28 was amplified from genomic DNA of Streptomyces sp. 
MK730-62F2 using primer omt1CH_fw CCGTCCGCTACGGCTCNSMNAARTGG 
and omt1CH_rv GCGGTCCACAGGTCCTCNAYNACRTA. Perfect matching primers 
were deduced from the sequence of the obtained fragment. Oligonucleotides 
omt7218_fw GGCTGCACTGGTTCACGGG and omt7218_rv 
CCAGAGGTCCTCGATCACG amplifying a 0.39 kb fragment of cpz28 were applied 
in a PCR screening of the cosmid library. Clones were pooled in order to facilitate the 
screening procedure. In the first round, pools of 48 clones were screened, followed 
by a screening of subpools of 8 clones and eventually the testing of single colonies.  
Screening for the genes for dTDP-L-rhamnose biosynthesis 
A 0.5 kb fragment of cpzDIII was amplified from genomic DNA using degenerated 
primer as described by Decker et al. (Decker et al., 1996). Perfect matching primers 
GDHspf_fw CGTAGTTGTTGGAGCAGCGCG and GDHspf_rv 
GGTTCATCGGCTCCCGCTACG amplifying a 0.5 kb fragment of cpzDIII were 
applied in a PCR screening of the cosmid library as described above. 
Screening for the liposidomycin gene cluster 
LipI was amplified from genomic DNA of Streptomyces sp. SN-1061M using primer 
MT2_fw GTGACGAACTTGGTGGCGC and MT2_rv TCACCGGCTCACCCGGAAC. 
Perfect matching primers MTLip_fw ACCTACTCGCTGCTGTTC and MTLip_rv 
TTGGAGATGCTCGACCAC amplifying a 0.42 kb fragment of lipI were applied in a 
PCR screening of the cosmid library as described above.  
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7.11. DNA sequencing and computer-assisted sequence analysis 
Double-stranded sequencing of recombinant plasmids was done by the 
dideoxynucleotide chain termination method on a LI-COR automatic sequencer 
(MWG-Biotech AG, Ebersberg, Germany). 
Double-stranded sequencing of entire cosmid clones (~40 000 bp insert) was 
performed by GenoTech (Baejeon, Korea) by using a shotgun library with DNA 
fragments of approximately 0.5–1.0 kb in length. 
The DNASIS software package (Hitachi Software Engineering, Tokyo, Japan) and 
Artemis (Wellcome Trust Genome Campus, Cambridge, UK) were used for sequence 
analysis and annotation. Database comparisons were carried out in the GenBank 
database by using the BLAST program (Altschul et al., 1997). Alignment and 
comparison of sequences were performed using ClustalX algorithm (Jeanmougin et 
al., 1998) and GeneDoc alignment editor (http://www.psc.edu/biomed/genedoc). 
8. Methods of biochemistry and biology 
8.1. Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The discontinuous SDS-PAGE was carried out according to the method of Laemmli  
(1970). Probes were mixed with sample buffer in ration 1:1 to 1:4 and incubated for 1 
min in boiling water. 4% and 12% Polyacrylamide gel were used as stocking and 
resolving gel, respectively. Gel electrophoresis was carried out with working voltage 
of 200 V using the Mini-PROTEAN® II Electrophoresis Cell (Bio-Rad, München, 
Germany). Protein bands were stained with Coomassie Brilliant Blue G-250.:1-5 min 
in Fixing buffer, 15 min in Coomassie Brilliant Blue G-250 solution, and 90 min in 
Bleaching solution. To determine protein sizes, the Low Molecular Weight Calibration 
Kit for SDS gel electrophoresis (Amersham Biosciences, Freiburg, Germany) was 
used. 
8.2. Heterologous overproduction and purification of recombinant 
protein from E. coli 
Heterologous overproduction and purification of 8×His-tagged proteins from E. coli 
were carried out using expression vector pHis8 and E. coli Rosetta2pLys (Novagen, 
Darmstadt, Germany) as the recombinant host strain. Different conditions for 
cultivation and purification were tested (e.g. different cultivation temperatures, 
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amount of IPTG used for induction). The preparative method described bellow 
yielded the best results.  
Cloning and purification of Cpz31 
cpz31 was amplified from cosmid DNA using the primers cpzGTEco_fw 
GAATTCATGCGCGTGCTCTTCACG and cpzGTHind_rv AAGCTTCTAGGCCCTCC 
TCGCCAG (restriction sites for EcoRI and HindIII are underlined). A 1.2 kb PCR 
product was cloned into the pGEM®-T cloning vector (Promega, Mannheim, 
Germany). The resulting plasmid pLK01 was verified by sequencing. cpz31 was 
subsequently cloned into the expression vector pHis8 (Jez et al., 2000) taking 
advantage of the EcoRI and HindIII restriction sites and confirmed by sequencing. 
The resulting plasmid was named pLK02.  
E. coli Rosetta2™ (DE3)pLys containing plasmid pLK02 were cultivated in 1 l TB 
broth supplemented with 50 µg mL-1 kanamycin and 50 µg mL-1 chloramphenicol at 
37°C. At OD600 0.7 the temperature was adjusted to 20°C and isopropyl 
thiogalactoside (IPTG) was added to 0.5 mM final concentration. After additional 10 h 
cultivation at 20°C the culture was harvested and 10 mL Buffer A supplemented with 
0.5 mg mL-1 lysozyme and 0.5 mM PMSF was added to the pellet (12 g). Cells were 
disrupted by sonication (Branson, Danbury, CT) at 4°C. The lysate was centrifuged 
(55000×g, 45 min) and the supernatant was applied to affinity chromatography using 
Ni-nitrilotriacetic acid (Ni-NTA) agarose resin (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. 4 mL of the resin was loaded onto a column and 
equilibrated with 20 mL Buffer A. Subsequently the column was loaded with the 
lysate and washed using 25 mL of Buffer A. His8-Cpz31 was eluted from the column 
with 6 mL 250 mM imidazole in Buffer A. Buffer exchange was carried out with PD10 
columns (Amersham Bioscience, Freiburg, Germany) and Buffer A without β-
mercaptoethanol and imidazole. The protein was concentrated by centrifugation 
using the Centriprep YM-10 columns (Millipore, Billerica, US). Low solubility of His8-
Cpz31 resulted in a yield of 0.46 mg of partially purified protein per litre culture. The 
protein was stored at -80°C in aliquots of 50 µL. 
Heterologous overproduction and purification of the Cpz4 derivatives obtained from 
site-directed mutagenesis were performed similarly. 
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Cloning and purification of Cpz4 
cpz4 was amplified from cosmid 31C2 containing the caprazamycin gene cluster 
(Kaysser et al., 2009). Primers cpz4Sac_fw 5’-
GAGCTCATGACTGTGTTGGTCCGCAG-3’ and cpz4Xho_rv 5’-
CTCGAGTCAGCGCACCCGGGAGGCCT-3’ (restriction sites for SacI and XhoI are 
underlined) were used. The PCR product with 1.6 kb was cloned into the pGEM®-T 
cloning vector (Promega, Mannheim, Germany). The resulting plasmid pLK03 was 
verified by sequencing. The gene was subsequently cloned into the expression 
vector pHis8 (Jez et al., 2000), taking advantage of the SacI and XhoI restriction 
sites, and confirmed by sequencing. The resulting plasmid was named pLK04. E. coli 
Rosetta2™ (DE3)pLys containing pLK04 was cultivated in 2 L TB broth as described 
for Cpz31. Induction of the Cpz4-expression with IPTG, and harvesting and 
disruption of the cells were performed analogous to Cpz31. The supernatants of the 
lysates were applied to affinity chromatography using an Äktapurifier™ platform (GE 
Healthcare, Freiburg, Germany) equipped with a HisTrap™ (34 µm, 1.6 x 2.5 cm) HP 
column (GE Healthcare, Freiburg, Germany). The His-tagged proteins were eluted 
from the column using a linear gradient from 0-100% imidazole (250 mM) in Buffer A 
over 60 min and collected by a Frac-920TM system (GE Healthcare, Freiburg, 
Germany). Fractions were checked for the presence of the desired proteins by SDS-
PAGE and further purified by gel filtration, using a Superdex 200 (CV 120 mL) 
column (GE Healthcare, Freiburg, Germany), on the platform described above. A 
yield of 12.5 mg of purified His8-Cpz4 was obtained per litre culture. Cpz4 was stored 
at -80°C in aliquots. 
8.3. In vitro studies on Cpz31 
Caprazamycin aglycones were obtained from cultures of S. coelicolor M512/cpzLK09 
by butanolic extraction, evaporation of the organic solvent and resuspension in 
methanol (as described in sections II.5.2 and II.9.1). 5 µL of this methanolic solution 
containing partially purified caprazamycin aglycones were applied to a reaction tube, 
air dried and dissolved in 50 µL reaction mixture containing 50 mM Tris-HCl pH 7.5, 5 
mM MgCl2, 5 mM dTDP-L-rhamnose and 9 µM protein. dTDP-L-rhamnose was kindly 
provided to us by Prof. Jae Kyung Sohng (Asansi, Korea) The assay was performed 
at 30°C for 2 h and stopped by the addition of 150 µL methanol. The activity of His8-
Cpz31 was measured by LC-ESI-MS. 
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8.4. In vitro studies on Cpz4 using aromatic substrates 
Assays for the sulfotransferase activity of Cpz4 and mutants were performed at 30°C 
using phenol as sulfate acceptor substrate. Conversion of pNS as sulfate donor 
substrate was measured on a UV/VIS Spectrometer Lambda™ 25 (Perkin Elmer, 
Waltham, United States) at 405 nm. For this purpose, assays were adjusted to pH 8 
after incubation by the addition of 500 µL 1 M Tris-HCl pH 8. Conversion of MUS as 
sulfate donor was monitored on a Synergy™ HT Multi-Detection Microplate Reader 
(BioTek, Bad Friedrichshall, Germany) at 460 nm (excitation 360 nm). Both systems 
were calibrated with at least 5 different concentrations of p-nitrophenol or 
methylumbelliferone for each single experiment. Sulfatase activity of Cpz4 was 
checked in parallel control reactions without phenol for each single assay. All 
experiments were run as duplicates and included a duplicate control assay lacking 
the protein. The reactions were started by the addition of Cpz4. 
Analysis of Cpz4 as arylsulfate sulfotransferase 
For the analysis of the Cpz4 products by LC-ESI-MS, 500 µL containing 50 mM Tris-
HCl pH 7.4, 50 mM MES pH 7.4, 140 mM NaCl, 0,1 mM EDTA, 10 mM Phenol, 750 
nM Cpz4 and 100 µM pNS or MUS were incubated overnight. The reactions were 
stopped by the addition of 1 volume of methanol and analysed by LC-ESI-MS. 
Dependency of the reaction on Mg2+, Ni2+ and EDTA 
800 µL of 20 mM Tris-HCl pH 8, 140 mM NaCl, 10 mM Phenol and 25 µM pNS with 
750 nM Cpz4 contained either 1-50 mM MgCl2 or 2 mM NiCl2 or 0.1 mM, 1 mM or 10 
mM EDTA. Incubation time was 60 min. 
Dependency of the reaction on pH 
Assays of 500 µL contained 1 M NaCl, 0.1 mM EDTA, 10 mM Phenol, 25 µM pNS 
and 250 nM Cpz4. The reactions were buffered either with 100 mM MES for pH 4, 5, 
6, 7 or 80 mM Tris-HCl and 20 mM glycine for pH 8 or 60 mM Tris-HCl and 40 mM 
glycine for pH 9 or 100 mM glycine for pH 10, 11. The reaction solutions were 
adjusted to the respective pH values (pH 4-11) prior to the addition of protein. 
Incubation time was 60 min. 
 
 
 
 MATERIALS AND METHODS 
  44 
Dependency of the reaction on protein concentration and time 
For the reaction with pNS as sulfate donor substrate an assay of 500 µL contained 
100 mM MES pH 6.7, 1 M NaCl, 0,1 mM EDTA, 75 mM Phenol, 300 µM pNS and 50-
3000 nM Cpz4. Incubation time was 60 min. For the reaction with MUS as sulfate 
donor substrate an assay of 200 µL contained 100 mM MES pH 6.7, 1 M NaCl, 0.1 
mM EDTA, 60 mM Phenol, 450 µM MUS and 25-450 nM Cpz4. Incubation time was 
15 min.  
Dependency of the reaction on time 
For the reaction with pNS as sulfate donor substrate an assay of 500 µL contained 
100 mM MES pH 6.7, 1 M NaCl, 0,1 mM EDTA, 75 mM Phenol, 300 µM pNS and 
125 nM Cpz4. Conversion of pNS was measured every 15 min over 7 hours of 
incubation. For the reaction with MUS as sulfate donor substrate an assay of 200 µL 
contained 100 mM MES pH 6.7, 1 M NaCl, 0,1 mM EDTA, 60 mM Phenol, 450 µM 
MUS and 100 nM Cpz4. Conversion of MUS was measured every 15 min over 5 
hours of incubation. 
Influence of inhibitors on Cpz4 activity 
An assay containing 100 mM MES pH 6.7, 1 M NaCl, 0,1 mM EDTA, 75 mM Phenol, 
300 µM pNS and 125 nM Cpz4 was supplemented either with 0%, 0.05%, 0.1% or 
0.3% DEPC or 1 mM PMSF. Reaction volume was 500 µL and incubation time 60 
min. 
Analysis of Cpz4 mutants 
Cpz4 mutants Cpz4_His180Leu, Cpz4_His253Leu and Cpz4_His308Leu, derived 
from site-directed mutagenesis, were analysed for the conversion of pNS in 500 µL 
reaction buffer containing 100 mM MES pH 6.7, 1 M NaCl, 0.1 mM EDTA, 75 mM 
Phenol, 300 µM pNS. ~90 nM of protein was added and incubated for 60 min. 
Kinetic analysis of Cpz4 
Reaction velocities of Cpz4 with pNS as donor substrate (27 – 270 µM) and phenol 
as acceptor substrate (6.5 – 160 mM) were measured in 500 µL reaction buffer (100 
mM MES pH 6.7, 1 M NaCl, 0,1 mM EDTA) containing 125 nM protein. Incubation 
time was 25 min. Reaction velocities of Cpz4 with MUS as donor substrate (25 – 550 
µM) and phenol as acceptor substrate (12.5 – 160 mM) were monitored over 15 min 
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in 200 µL reaction buffer (100 mM MES pH 6.7, 1 M NaCl, 0,1 mM EDTA) containing 
100 nM protein. Initial rates were globally fitted with GraFit 6 (Erithacus Software, 
Surrey, United Kingdom) to the equation  
 
v = V[A][B]/(Ka[B](1+[B]/Kib)+Kb[A]+[A][B] 
 
describing ping pong kinetics with substrate inhibition (Malojcic et al., 2008). [A] and 
[B] are the initial concentrations of pNS or MUS and phenol, respectively. Ka and Kb 
are the respective Michealis constants for pNS or MUS and phenol. The inhibition 
constant of phenol is Kib. V is the maximum and v the measured initial velocity. 
8.5. In vitro studies on Cpz4 using nucleosidic substrates 
Sulfation of caprazamycin derivatives 
Partially purified caprazamycin derivatives were obtained from culture extracts of S. 
coelicolor M512/cpzWP05 (CPZ aglycones), S. coelicolor M512/cpzEW07 (CPZs) 
and S. coelicolor M512/cpzLL06 (hydroxyacyl-caprazols) as described in section 
II.5.2 and II.9.1. Caprazamycins, caprazamycins aglycones or hydroxyacyl-caprazols 
were dissolved in 500 µL reaction buffer (100 mM MES pH 6.7, 1 M NaCl, 0,1 mM 
EDTA) containing 500 µM pNS and 1.5 - 2 µM Cpz4. Conversion of pNS was 
measured at 405 nm. The reactions were stopped by the addition of 1 volume of 
methanol. Product formation was analyzed by LC-ESI-MS.  
Investigations on PAPS as sulfate donor 
Assays with 3’-phosphoadenosine 5’-phosphosulfate (PAPS) (500 µM) as sulfate 
donor substrate (instead of pNS) were performed under the same conditions as 
described above but included 0.1 mM sodium ascorbate to avoid oxidation. A control 
experiment showed that 0.1 mM sodium ascorbate in the assay had no effect on the 
activity of Cpz4. 
Sulfation of synthetic nucleoside analogs 
Different analogs of potential precursors for liponucleoside biosynthesis were 
synthesized by Satoshi Ichikawa and colleagues from the Faculty of Pharmaceutical 
Science, Hokkaido University, Japan as described in (Kaysser et al., 2010). The 
compounds were kindly provided to us for the testing as substrates of Cpz4. 
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Table II.7.1 Synthetic nucleoside analogs kindly provided by Satoshi Ichikawa from the 
Hokkaido University, Japan  
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Compound 1: des-N-Me-palmitoylcaprazol 
Exact Mass: 799,4215 
Compound 2: des-uridyl-palmitoylcaprazol 
Exact Mass: 615,4095 
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Compound 3: des-N-Me-caprazol 
Exact Mass: 561,1918 
Compound 4: (+)-caprazol 
Exact Mass: 575,2075 
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Compound 5: N-aminopropyl-O-
aminoribosyl-glycyluridine 
Exact Mass: 505,2020 
Compound 6: N-carboxy-aminopropyl-O-
aminoribosyl-glycyluridine 
Exact Mass: 549,1918 
 
In order to assay the sulfation of the synthetic caprazamycin precursor, compounds 1 
- 6 were added to a final concentration of 200 µM to the reaction buffer (100 mM 
MES pH 6.7, 1 M NaCl, 0,1 mM EDTA) containing 300 µM pNS and 125 nM protein. 
The reaction was measured at 405 nm after 60 min. The assays were stopped by the 
addition of 1 volume of methanol prior to LC-ESI-MS analysis of product formation. 
8.6. Bioassay with Mycobacterium phlei 
Antibacterial activity was determined by a disc diffusion assay using Mycobacterium 
phlei as the indicator strain. 10 µL methanolic culture extracts were applied to filter 
paper disks (Ø 6 mm; MN 440 B blotting paper, Macherey-Nagel), air dried under the 
clean bench and placed on the top of nutrient agar plates, which were spread with 
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Mycobacterium phlei for confluent growth. Plates were cultured overnight at 37 °C, 
and the diameters of growth inhibition zones measured.  
9. Construction of Streptomyces mutant strains  
Generally, manipulation of Streptomyces DNA was performed in E. coli using the 
PCR targeting system according to the instructions of the REDIRECT© technology kit 
(Gust et al., 2003; Gust et al., 2004). This strategy is to replace a chromosomal 
sequence within a genomic library clone (e.g. cosmid) by a selectable marker that 
has been generated by PCR using primers with homologous extensions. 
Amplification was performed using the Expand High Fidelity PCR system. The PCR 
product was introduced into the cells by electroporation. The recombination event in 
E. coli between the cosmid and the PCR-product is mediated by the λ-Red system 
(Red/ET-recombineering). Cosmids which had integrated the cassette were isolated 
and analyzed by restriction enzyme digestion. The inclusion of oriT in the disruption 
cassette allows the conjugation of the modified cosmid DNA from E. coli into the 
actinomycete. The PCR-targeting cassettes are flanked by FLP recognition target 
(FRT) sites which can be used to remove the resistance marker by the co-expression 
of the mutant cosmid and the FLP-recombinase in E. coli. The residual scar 
sequence (81 bp) represents a nonpolar in-frame gene deletion and allows the 
repeated use of the same cassette for making multiple knock-outs. Alternatively, 
restriction sites can be introduced into the PCR primers and later used to excise the 
resistance marker by restriction and relegation. 
9.1. Deletion of cpz28-30 in Streptomyces sp. MK730-62F2 
An apramycin resistance (aac(3)IV) cassette was amplified from plasmid pIJ773 
using primers KOomtbox_fw TTCTCGAAGACGAACCTCACCAGGGAGTTGCT 
GAAGATGACTAGTATTCCGGGGATCCGTCGACC and KOomtbox_rv CAGCCCG 
GGCGACGTCGTGAAGAGCACGCGCATGGCTCAACTAGTTGTAGGCTGGAGCTG
CTTC with flanking regions homologous to the target sequence. Priming sequence 
for pIJ773 is shown in bold, SpeI restriction sites are underlined. The genes were 
replaced in E. coli BW25113/pIJ790/31C2 by using the PCR-targeting system (Gust 
et al., 2003). Resulting cosmid cpzLK02 was confirmed by restriction analysis. SpeI 
digestion and religation led to the excision of the cassette resulting in cosmid 
cpzLK04 which was further verified by restriction analysis and PCR using 
 MATERIALS AND METHODS 
  48 
omtboxtest_fw CCTCACCAGGGAGTTGCTG and omtboxtest_rv 
CGACGTCGTGAAGAGCACG as primers. Cosmid cpzLK04 was introduced into S. 
sp. MK730-62F2 by PEG-mediated protoplast transformation with non-methylated 
DNA isolated from E. coli ET12567. Double-crossover mutants were confirmed by 
their kanamycin sensitivity, checked by PCR and designated as Streptomyces sp. 
MK730-62F2 Δcpz28-30 (1-3). 
9.2. Inactivation of cpzDIII in Streptomyces sp. MK730-62F2 
An apramycin resistance cassette (aac(3)IV) was amplified from plasmid pIJ773 
(Gust et al., 2003) using primer pair gdhKO_fw GTGCTGGACAAGCTCACCTACGC 
CGGCACCCTCGACGACATTCCGGGGATCCGTCGACC and gdhKO_rv GAGCTG 
GCACGGGCCGTAGTTGTTGGAGCAGCGCGTGACTGTAGGCTGGAGCTGCTTC. 
Priming sequence for pIJ773 is shown in bold. The gene was replaced in E. coli 
BW25113/pIJ790/4H11 by using Red/ET-mediated recombination (Gust et al., 2003) 
and the resulting cosmid cpzLK01 was confirmed by restriction analysis. cpzLK01 
was transferred into the non-methylating strain E. coli ET12567/pUZ8002 (Paget et 
al., 1999) and introduced into Streptomyces sp. MK730-62F2 by conjugation. 
Exconjugants, resistant to apramycin, were isolated and tested for the loss of their 
kanamycin resistance indicating a successful double-crossover. The mutants were 
further analysed by PCR with chromosomal DNA as template. Mutant strains were 
designated as Streptomyces sp. MK730-62F2ΔcpzDIII-(1-3).  
9.3. Heterologous expression of the caprazamycin and the 
liposidomycin gene cluster 
Plasmid is a SuperCos1 derivative, in which the ampicillin resistance gene (bla) was 
replaced by a cassette containing the integrase gene (int) and attachment site (attP) 
of phage C31 as well as a resistance marker (tet, tetracycline resistance gene) 
(Eustaquio et al., 2005). 
The DraI-BsaI-fragment of pIJ787, containing the integrase cassette and flanked by 
about 100 bp bla sequence on one site and about 300 bp bla sequence on the other 
side was isolated. This fragment was used to replace the respective bla gene in the 
SuperCos1 backbone of cosmids 31C2 carrying the caprazamycin gene cluster and 
3G5 carrying the liposidomycin gene cluster in E. coli BW25113/pIJ790, via -Red-
mediated recombination (Datsenko and Wanner, 2000; Gust et al., 2003). The 
generated cosmids were termed cpzLK09 and lipLK01 respectively. 
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The modified cosmid cpzLK09, still carrying the kanamycin resistance gene neo, was 
then introduced into S. coelicolor M512 via PEG-mediated protoplast transformation. 
Kanamycin resistant clones were selected, checked by PCR and designated as S. 
coelicolor M512/cpzLK09 (1-3). Cosmid lipLK01 was introduced into S. coelicolor 
M512 by triparental intergeneric conjugation with the help of E. coli ET12567/pUB307 
(Flett et al., 1997). Kanamycin resistance clones were selected, confirmed by PCR 
and designated as S. coelicolor M512/lipLK01 (1-3). 
9.4. Introduction of pRHAM into Streptomyces mutant strains 
Plasmid pRHAM (Rodriguez et al., 2000), containing all required genes for the 
biosynthesis of dTDP-L-rhamnose oleL, oleS, oleE and oleU from S. antibioticus 
ATCC 1891, was kindly provided to us by Prof. Jose A. Salas (Oviedo, Spain). 
pRHAM was introduced into the non-methylating strain E. coli ET12567 (MacNeil, 
1988) and re-isolated. The isolated plasmid DNA was used for PEG-mediated 
protoplast transformation with either Streptomyces sp. MK730-62F2ΔcpzDIII for 
complementation of the cpzDIII knock-out or with S. coelicolor/cpzLK09 for the 
production of intact caprazamycins. Thiostrepton resistance mutants were selected 
and termed as either Streptomyces sp. MK730-62F2/pRHAM-(1-3) or S. 
coelicolor/cpzLK09/pRHAM-(1-3). 
9.5. Deletion of genes for the determination of the boundaries of the 
caprazamycin gene cluster  
An apramycin resistance (aac(3)IV) cassette was amplified from plasmid pIJ773 
(Gust et al., 2003) using primer pairs B4_rv (CACCCTCCACACCCGCACCACCCG 
ACTGGCCCACGCCCTACTAGTTGTAGGCTGGAGCTGCTTC)/B5_fw (CGGCAAC 
CGCCGGTTCCTGACCGTCCACGTCCGAGGGAGACTAGTATTCCGGGGATCCGT
CGACC) (Δcpz1-4), B4_rv/B6_fw (AACCGGGACAACGAGACAGCAAAGGTCG 
GTGTTTGGGACACTAGTATTCCGGGGATCCGTCGACC) (Δcpz1-5), B4_rv/B7_fw 
(TGCCGGCCATCACAGTGACCGGCTTCGCAACGTGTACGGACTAGTATTCCGGG
GATCCGTCGACC) (Δcpz1-6), B1_rv (TCGCCGCGGTGGCGCACCACGACGAA 
CTGGTGCCGCGGGACTAGTTGTAGGCTGGAGCTGCTTC)/B1_fw (AACCCGGGC 
CATCCGGCCGACGCTCCGTCGAGGCCGCACACTAGTATTCCGGGGATCCGTC
GACC) (Δcpz33-34) and B1_rv/B2_fw (TGCGCGCCGGGTGGCTGCCCTGCCCC 
CCAGGGCCATCGGACTAGTATTCCGGGGATCCGTCGACC) (Δcpz32-34). 
Priming sequence for pIJ773 is shown in bold, SpeI restriction sites are underlined. 
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The genes were replaced in E. coli BW25113/pIJ790/cpzLK09. Resulting cosmids 
were confirmed by restriction analysis. Excision of the cassette was performed in E. 
coli BT340 taking advantage of the FLP/FRT recognition sites adjacent to the 
resistance cassette (Cherepanov & Wackernagel, 1995). Positive cosmids were 
screened for their apramycin sensitivity and verified by restriction analysis and PCR 
using primers B1_test_rv (CGGGACTAGTTGTAGGCTG), B1_test_fw 
(GCACTTCGACGGTGCG GTG), B2_test_fw (GTCCTGGCCGACTGGTTGC), 
B4_test_fw (CACCGAATACGGC ACCCTC), B5_test_rv 
(CTTCGCCGGGACTCTCGTC), B6_test_rv (CGGCAGCGTC CAGGAGGTG), 
B7_test_rv (CGAGGACGGCGGGCAGTAC). Cosmids cpzWP01 (Δcpz33-34), 
cpzWP02 (Δcpz32-34), cpzWP05 (Δcpz1-4), czWP06 (Δcpz1-5) and cpzWP07 
(Δcpz1-6) were transferred into E. coli ET12567 (MacNeil, 1988) and introduced into 
S. coelicolor M512 by triparental intergeneric conjugation. Kanamycin resistance 
clones were selected, confirmed by PCR and designated as S. coelicolor 
M512/cpzWP01 (1-3), S. coelicolor M512/cpzWP02 (1-3), S. coelicolor 
M512/cpzWP05 (1-3), S. coelicolor M512/cpzWP06 (1-3) and S. coelicolor 
M512/cpzWP07 (1-3). 
9.6. Generation of single gene deletions on cpzLK09 
Deletion mutants for the genes cpz11, cpz20, cpz21, cpz23, cpz25 and cpz26 were 
generated in accordance to the generation of the mutants for the detection of the 
cluster boundaries. Primer pairs cpz11_rv (TCGGCAGCGCCCAGGGGCCCGTGAC 
GACGATGATCACCGACTAGTTGTAGGCTGGAGCTGCTTC)/cpz11_fw (GCGAGT 
CGAAGTAGCGGCCGGAGGAGTCGGGGCGTGACGACTAGTATTCCGGGGATCC
GTCGACC), cpz20_F (TCCGCACCGACGAAACGGGGACCGTTCATGTCTGACG 
GGACTAGTATTCCGGGGATCCGTCGACC)/cpz20_R (GGACCTTCTGCCCGTCTC 
GGCCGTTCGCCATCAGTAGATACTAGTTGTAGGCTGGAGCTGCTTC), cpz21_fw 
(GTTCGAAGGCAGTCGGGTAGTCGAGGGGATCTACTGATGACTAGTATTCCGGG
GATCCGTCGACC)/cpz21_rv (CCATCCATGACGGCGACACCCGCACTTCCGTG 
CTCACCAACTAGTTGTAGGCTGGAGCTGCTTC), cpz23_fw (AGCAACGAGCAAC 
CCAGGACAAGGAGACGAAGCGTGAAGACTAGTATTCCGGGGATCCGTCGACC)/
cpz23_rv (CATGTGTGGCTGTTCGTCACGGGGCCGAGCGGTTCATCCACTAGTT 
GTAGGCTGGAGCTGCTTC), cpz25_F (TGGGAACGCCATCCGGCAGCCCGAGG 
ACGACGACTCATGACTAGTATTCCGGGGATCCGTCGACC)/cpz25_R (TGGTCT 
GCATGTGCGCTCCGCGCGGGTCCTGGGCCGTCAACTAGTTGTAGGCTGGAGC
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TGCTTC) and cpz26_rv (TGATCCACACCAGCAAGGGCTTCTCCGTCCTGGT 
CACGTACTAGTTGTAGGCTGGAGCTGCTTC)/cpz26_fw (CGGAGCGCACATGCA 
GACCATGTTCCAGAAAGGGTGATGACTAGTATTCCGGGGATCCGTCGACC) 
were used to amplify the apramycin resistance cassette from pIJ773. The resulting 
mutants were designated S. coelicolor M512/cpzLL05 (1-3) (Δcpz11), S. coelicolor 
M512/cpzLL06 (1-3) (Δcpz21), S. coelicolor M512/cpzLL07 (1-3) (Δcpz23) and S. 
coelicolor M512/cpzLL08 (1-3) (Δcpz26). 
9.7. Complementation of single gene deletions 
To generate the expression plasmids for mutant complementation cpz11, cpz21 and 
cpz23 were amplified from cosmid cpzLK09 using primer pairs (restriction sites are 
underlined) cpz11Hind_fw (AAGCTTGTGACGAACTTGGTGGCGC)/cpz11Eco_rv 
(GAATTCTCACCGGCTCACCCGGAAC), cpz21Eco_fw (GAATTCATGGCGAACGG 
CCGAGACG)/cpz21Hind_rv (AAGCTTTCACCACCGGTGGTCCTCG) and 
cpz23Eco_fw (GAATTCGTGAAGTCGTTGACGCACG)/cpz23Hind_rv (AAGCTTTCA 
TCCGAGGCACTTCCGG) and cloned into the vector pGEM®-T (Promega, 
Mannheim, Germany). The genes were subcloned into the EcoRI/SpeI sites of the 
expression vector pUWL201 (Doumith et al., 2000) under the control of the ermE* 
promoter. This resulted in plasmids pLL05 (cpz11), pLL06 (cpz21) and pLL07 
(cpz23) respectively. DNA sequencing of these plasmids confirmed the correct 
sequence of all constructs. Transformation of the S. coelicolor mutant strains by 
polyethylene glycol-mediated protoplast transformation finally generated the strains 
S. coelicolor M512/cpzLL05/pLL05 S. coelicolor M512/cpzLL06/pLL06 and S. 
coelicolor M512/cpzLL07/pLL07. 
9.8. Assembly of the caprazamycin gene cluster and the genes cpzDI-
cpzDVII onto one cosmid 
An apramycin resistance cassette (aac(3)IV) was amplified by PCR from plasmid 
pIJ774 (Gust et al., 2004) with primers 4H11_774_fw GCCCGAGCACCCGCAGCC 
GGTTCGCCCGCGAGCCCAGCAGCTAGCTTATGAGCAGCCAATCGAC, including 
a NheI restriction site (underlined) and 4H11_774_rv CAGAGGGTGCGCTCGGAAG 
ACGGGCGCGGAAGCCGCCCGACTAGTATTCCGGGGATCCGTCGACC, including 
a SpeI restriction site (underlined). Italic letters represent 39 nt homologous 
extensions to an internal region of orf1 and to a region downstream of orf9 
respectively. The resulting 1310 bp PCR product contained the aac(3)IV gene and a 
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single loxP site. The PCR-product was inserted into cosmid 4H11 by Red/ET-
mediated recombination (Gust et al., 2003) thereby replacing a 13531 bp region (orf1 
- orf9) upstream of cpzDI resulting in the apramycin and kanamycin resistant cosmid 
cpzEW01. A hygromycin resistance cassette (hyg) was amplified from pIJ10700 by 
PCR with primers 4H11_10700_fw TGACGGGCGGGCGGGGCTCGC 
AGCCCCTAGGCTGAGGAGATTTAAATTGTAGGCTGGAGCTGCTTC including a 
SwaI restriction site (underlined) and 4H11_10700_rv GGGGGCCGTCGCCGA 
AGTGCGGGCCGCCGGGCGGCACGGGTTTAAACATTCCGGGGATCCGTCGACC, 
including a PmeI restriction site (underlined). Italic letters represent 39 nt 
homologous extensions to sequences upstream of orf10 and to an internal region of 
orf25 respectively. The resulting 1678 bp PCR product contained the hygromycin 
resistance gene hyg, an origin of transfer oriT and was flanked by two FLP-
recombinase recognition sites (FRT). The PCR-product was inserted into cosmid 
cpzEW01 by Red/ET-mediated recombination thereby replacing a 16144 bp region 
(orf10 – orf25) upstream of cpzDVII resulting in the hygromycin, apramycin and 
kanamycin resistant cosmid cpzEW02. Restriction of cpzEW02 with NheI and PmeI 
generated the 9950 bp L-rhamnose subcluster fragment (cpzD1 – cpzDVII) flanked 
by the apramycin and the hygromycin resistance cassettes. 
Cosmid cpzLK09 which already contained the ΦC31 integration cassette from pIJ787 
(Eustaquio et al., 2005) was prepared as the L-rhamnose subcluster acceptor 
cosmid. An apramycin resistance cassette (aac(3)IV) was amplified from pIJ774 
(Gust et al., 2003) by PCR with primers 31C2_774_fw2 TGCCGTACCCGCGGTCA 
CCGGTTCCGCCTCGGCGGGTGCACTAGTTGTAGGCTGGAGCTGCTTC including 
a SpeI restriction site (underlined) and 31C2_774_rv CGTGCTGGTGCT 
CGCCAACCACCCCATGCGGCTGGGCATGCTAGCAAATGCCGGCCTTTGAATGG 
including a NheI restriction site (underlined). Italic letters represent 39 nt homologous 
extensions to sequences downstream of cpz31 and to an internal region of cpz33 
respectively. The resulting 1079 bp PCR product contained the aac(3)IV gene and a 
single loxP site. The PCR-product was inserted into cosmid cpzLK09 by Red/ET-
mediated recombination thereby replacing a 1000 bp region downstream of cpz31 
and resulted in the apramycin and kanamycin resistant cosmid cpzEW03. A 
spectinomycin/streptomycin resistance cassette (aadA) was amplified from pIJ778 
(Gust et al., 2003) by PCR with primers 31C2_778_fw 
TCGTCAGATGCAGATGGACGTCGTGCCCGGCCGCGTTCTATTTAAATTTATTTG
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CCGACTACCTTGG including a SwaI restriction site (underlined) and 31C2_778_rv 
CCGCGGTGGCGCACCACGACGAACTGGTGCCGCGGGCCGGTTTAAACATTCC
GGGGATCCGTCGACC including a PmeI restriction site (underlined). Italic letters 
represent 39 nt homologous extensions to an internal sequence of cpz34 and to a 
region 351 bp upstream of cpz34 respectively. The resulting 1406 bp PCR product 
contained the aadA gene, an oriT and a single FRT site. The PCR-product was 
inserted into cosmid cpzEW03 thereby replacing the  613 bp region between 
aac(3)IV and the beginning of the SuperCos1 backbone resulting in the 
spectinomycin/streptomycin, apramycin and kanamycin resistant cosmid cpzEW05.  
For the generation of cpzEW07, the cosmid containing the caprazamycin gene 
cluster and the L-rhamnose subcluster, Red/ET-mediated recombination was used. A 
Red/ET-proficient E. coli BW25113/pIJ790 harbouring cpzEW05 was transformed of 
with the 9950 bp NheI/PmeI fragment from cpzEW02. Homologous recombination 
took place between a 924 bp region, represented by the apramycin resistance gene 
aac(3)IV, and a 523 bp region of identical sequences between the hygromycin- and 
the spectinomycin/streptomycin-resistance cassettes. A positive selection with 
hygromycin was possible for this recombination event due to the exchange of the 
resistance gene aadA by hyg. Note that after Red/ET-mediated recombination, the 
apramycin resistance cassette is now flanked by loxP sites and the hygromycin 
resistance cassette by FRT sites, allowing removal of the resistance cassettes by the 
use of Cre-recombinase or FLP-recombinase respectively. The isolated cosmid DNA 
of cpzEW07 was verified by restriction analysis. cpzEW07 was introduced into S. 
coelicolor M512 by triparental intergeneric conjugation. Apramycin, hygromycin and 
kanamycin resistant clones were selected and termed as S. coelicolor 
M512/cpzEW07-(1-3). 
9.9. Generation of single gene deletions on the assembled 
caprazamycin gene cluster 
The apramycin resistance cassette in cosmid cpzEW07 was eliminated by SpeI 
restriction and religation. The resulting cosmid cpzEW08 was verified by restriction 
analysis. An apramycin resistance cassette (aac(3)IV) was amplified from plasmid 
pIJ774 (Gust et al., 2003) by PCR with primers containing an AflII site (underlined) 
KOcpzDI_fw GTGGAAGCAGAAGGAAGATGATGAGTCGTGGAGTCCATGCTTAAG 
ATTCCGGGGATCCGTCGACC and KOcpzDI_rv GCTCGGATCGTCACCGCGCT 
GTCCACGAGGGAGGCGTCACTTAAGTGTAGGCTGGAGCTGCTTC for the 
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inactivation of cpzDI or KOcpzDV_fw GCATCCGCAAGGAAGGTCTTCCT 
CGTGAAACGCCATGAGCTTAAGATTCCGGGGATCCGTCGACC and KOcpzDV_rv 
CGCCGGCCGCCCCCGGGCGGTGGCCGGCGCCGTCGTTCACTTAAGTGTAGGC
TGGAGCTGCTTC for the inactivation of cpzDV. Italic letters represent 39 nt 
homologous extensions to sequences up- and downstream of the target genes for 
Red/ET-mediated recombination. Resulting cosmids cpzEW09 (ΔcpzDI::aac(3)IV) 
and cpzEW11 (ΔcpzDV::aac(3)IV) were confirmed by restriction analysis. Excision of 
the cassette was performed by in vitro application of the Cre-recombinase (New 
England Biolabs, Frankfurt am Main, Germany) according to the manufacturer’s 
instructions, taking advantage of the loxP recognition sites flanking the apramycin 
resistance cassette. The obtained cosmids cpzEW10 (ΔcpzDI) and cpzEW12 
(ΔcpzDV) were screened for their apramycin sensitivity and verified by restriction 
analysis. Cosmids cpzEW10 and cpzEW12 were introduced into S. coelicolor M512 
by triparental intergeneric conjugation. Kanamycin resistance exconjugants were 
selected and designated as S. coelicolor M512/cpzEW10-(1-3) (ΔcpzDI) and S. 
coelicolor M512/cpzEW12-(1-3) (ΔcpzDV). 
10. Analysis and isolation of secondary metabolites 
10.1. LC-MS analysis 
Methods for LC-MS analysis were developed in cooperation with Stefanie 
Siebenberg and Bernd Kammerer. The analysis was routinely carried out by Stefanie 
Siebenberg. 
Analysis of caprazamycin and liposidomycin derivatives 
Streptomyces sp. MK730-62F2, Streptomyces SN1061-M, S. coelicolor M512 or 
derivatives thereof were cultured in production medium as described in section 
II.6.2.2. Partial purification of caprazamycins was achieved by extraction of the 
culture supernatant (adjusted to pH 4) with an equal volume of n-butanol. The 
organic phase was evaporated and extracts were resolved in 500 µL methanol. LC-
ESI-MS analysis was performed on a Surveyor HPLC system equipped with a 
Reprosil-Pur Basic C18 (5 µm, 250x2 mm) column (Dr. Maisch, Ammerbuch, 
Germany) coupled to a Thermo Finnigan TSQ Quantum triple quadrupole mass 
spectrometer (heated capillary temperature 320°C; sheath gas nitrogen, collision gas 
argon). Analysis of extracts from the co-expression of pRHAM experiments was 
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performed with a linear gradient from 2% to 40% acetonitrile in aqueous formic acid 
(0.1%) over 5 min followed by a linear gradient from 40% to 100% acetonitrile in 
aqueous formic acid (0.1%) over 20 min. Otherwise, a linear gradient from 2% to 
40% acetonitrile in aqueous formic acid (0.1%) over 4 min was used followed by a 
linear gradient from 40% to 100% acetonitrile in aqueous formic acid (0.1%) over 31 
min. The flow rate was 0.2 l min-1 and detection at 262 nm. Positive electrospray 
ionisation ((+)-ESI) was performed with electrospray voltage of 3.8 kV and collision 
induced dissociation (CID) spectra were recorded with collision energy of 35 eV. The 
respective parameters in negative mode ((-)-ESI) were 4.0 kV and 25 eV. 
Analysis of phenolic compounds 
In order to analyze product formation in the assays with Cpz4, pNS, MUS and phenol 
a similar set up was used as described above. Conditions for sample separation 
were changed to a linear gradient from 2 to 100% acetonitrile in aqueous formic acid 
(0.1%) over 20 min.  
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III. RESULTS 
1. Identification of the caprazamycin biosynthetic gene cluster 
1.1. Generation and screening of a cosmid library 
The unusual structure of caprazamycins and the lack of information about the 
biosynthetic origin made it difficult to select genetic probes for the identification of the 
gene cluster. However, the formation of the permethylated L-rhamnose moiety is 
known from other antibiotics like elloramycin (Patallo et al., 2001) and spinosyn 
(Waldron et al., 2001). Oligonucleotides deduced from a multiple sequence alignment 
based on the elloramycin methyltransferase elmM1 led to the amplification of a partial 
sequence of cpz28 with high similarity to sugar O-methyltransferases. Primer walking 
revealed two adjacent genes cpz29 and cpz30 to be homologous to other O-
methyltransferases suggesting the presence of the caprazamycin gene cluster. To 
our knowledge, this demonstrates for the first time the successful application of 
degenerated primers for O-methyltransferases for probe development. Commonly, 
methyltransferases are considered to be too diverse on nucleotide sequence level 
and too widely distributed in bacterial metabolism to be useful in the identification of a 
specific gene cluster. 
Perfect matching primers were applied to a genomic library of Streptomyces sp. 
MK730-62F2 constructed in a SuperCos1 vector. Eight positive cosmids out of 3000 
could be identified and proven to contain overlapping DNA by restriction mapping. 
Cosmid 31C2 was finally selected for further investigations. 
1.2. Deletion of the genes cpz28-30 
In order to confirm that the identified putative O-methyltransferase genes cpz28, 
cpz29 and cpz30 on cosmid 31C2 indeed direct the biosynthesis of caprazamycins, a 
gene disruption experiment was performed. To avoid possible cross-
complementation all three genes were deleted at once. Therefore, a chromosomal 
6.9 kb fragment was replaced with an apramycin-resistance cassette from pIJ773 by 
the use of Red/ET-mediated recombination (Gust et al., 2003). The cassette was 
flanked by compatible restrictions sites which allowed subsequent removal of the 
cassette generating cosmid cpzLK04. After transformation of the cosmid into 
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Streptomyces sp. MK730-62F2 double-crossover mutants were selected and positive 
candidates were verified by PCR. Three independent mutants were obtained and 
named Streptomyces sp. MK730-62F2 Δcpz28-30 (1), (2) and (3). 
We applied positive ESI-CID mass spectrometry coupled to reverse phase HPLC for 
the analysis of caprazamycin formation in the cultivation broth of the mutants and the 
wildtype strain.  
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Figure III.1.1 Analysis n-butanolic culture extracts from (A) wildtype Streptomyces sp. MK730-62F2 
and (C) Streptomyces sp. MK730-62F2Δcpz28-30 by LC-ESI-MS. Production ion chromatograms are 
obtained from mass scans in positive mode with m/z 1119 [M+H]+ (CPZ E/F), m/z 1133 [M+H]+ (CPZ 
C/D/G) and m/z 1147 [M+H]+ (CPZ A/B). Mass spectrometric fragmentation pattern in the CID 
experiment is shown for CPZ C/D/G (B) from (A).The suggested fragmentation schemes is depicted 
for CPZ D. 
 
In the wildtype strain the known caprazamycins A-G (Figure I.2.3), whose different 
fatty acid side chains result in three different masses, were detected readily as 
depicted in the selected ion monitoring (SIM) chromatograms of Figure III.1.1A (m/z 
1119 [M+H]+ for CPZ E and F at Rt = 21.3 min, m/z 1133 [M+H]+ for CPZ C, D and G 
at Rt = 22.4 min and m/z 1147 [M+H]+ for CPZ A and B at Rt = 24.4 min). 
Characteristic MS/MS fragmentation patterns were observed by collision-induced 
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dissociation of the methylated rhamnosyl-group, aminoribose, uracil and fatty acid 
group. Similar fragmentations have been reported for liposidomycins in FAB-MS 
(Ubukata et al., 1992). For all caprazamycins, product ions of m/z 189, m/z 320, m/z 
427 and m/z 558 could be found correlating with the deacyl-components (Figure 
III.1.1B). For the parent ion m/z 1133 [M+H]+ fragments of m/z 1002, m/z 945, m/z 
814, m/z 701 and m/z 569 were detected. Corresponding fragments with a mass shift 
of −14 Da and +14 Da were observed for the parent ions m/z 1119 [M+H]+ and m/z 
1147 [M+H]+ respectively. Additional evidence was obtained by product ion scans in 
negative mode using the same extracts. While the presence of the caprazamycins in 
the culture broth of the wildtype strain could be confirmed unequivocally, they were 
absent in cultures of all three independent isolates of the mutant S. sp. MK730-62F2 
Δcpz28-30 (Figure III.1.1C). However, product ion scans for non-glycosylated 
caprazamycin derivatives (m/z 931 [M+H]+, m/z 945 [M+H]+, m/z 959 [M+H]+) 
resulted in prominent mass peaks in extracts from Streptomyces sp. MK730-62F2 
Δcpz28-30. This shows that the generated mutant strains are only affected in the 
biosynthesis of the deoxysugar moiety, as desired. Overall, our data proves the 
involvement of the O-methyltransferase genes in caprazamycin biosynthesis and 
strongly indicates that the genes identified on cosmid 31C2 indeed represent the 
caprazamycin biosynthetic gene cluster. In addition, a reliable method for the 
detection of caprazamycins in bacterial culture extracts could be established. The 
LC-ESI-MS/MS mass spectra provided substantial information on the structural 
characteristics of these unusual compounds. Subsequently, cosmid 31C2 was send 
for complete shot-gun sequencing (nucleotide sequence of the gene cluster has been 
deposited at GenBank, accession number FJ490409). 
1.3. Sequence analysis of the caprazamycin gene cluster 
A contiguous 42.3 kb region could be assembled with an average GC content of 
70.2%, a typical value for Streptomyces DNA. In silico sequence analysis guided by 
BLAST homology searches (Altschul et al., 1997), conserved protein domain 
searches (Marchler-Bauer et al., 2007) and the GC frame plot method (Bibb et al., 
1984) revealed 34 candidate genes. A total of 23 open reading frames, designated 
cpz9-31, were assigned to the caprazamycin gene cluster putatively encoding for 
biosynthesis, resistance, transport and regulatory functions (Figure III.1.2). Table 
II.1.1 summarizes the orthologs and proposed functions of the annotated genes. 
Notably, most of the putative gene products did not show homology to proteins found 
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previously in other secondary metabolite gene clusters, which reflects the unusual 
structure of the caprazamycins.  
 
Figure III.1.2 Organisation of the caprazamycin gene cluster. The putative assignment of the genes to 
different steps in the biosynthesis is indicated. Bars above the cluster mark the gene deletions 
performed in this study. (-) indicates that the deletion of the respective region led to an abolishment of 
caprazamycin production. (+) indicates that caprazamycin production was not influenced. 
 
As proposed, the caprazamycin gene cluster would start with cpz9 which encodes for 
a putative regulator of the AraC family. Most members of this family are positive 
transcriptional activators containing a helix-turn-helix motif. They are known from 
sugar degradation and other pathways but are rarely found in gene clusters of 
secondary metabolism (Gallegos et al., 1997). As an example, the AraC-like 
regulator TxtR from S. scabies activates thaxtomin biosynthesis and recognizes 
cellobiose as a ligand (Joshi et al., 2007). The predicted gene product of cpz22 
shows homology to ABC-transporters. Similar proteins can be found in many 
antibiotic gene clusters and are usually involved in self-resistance and export 
(Rodriguez et al., 1993). Cpz12 and cpz27 are two putative sugar kinase genes 
similar to tunicamycin resistance proteins e. g. TmrD from Deinococcus radiodurans 
which structure has been reported recently (Kapp et al., 2008). The 2’-, 3’- and 5’-
hydroxy groups of the uridine have been suggested as potential targets for 
phosphorylation by TmrD, resulting in the inactivation of the nucleoside antibiotic 
tunicamycin. 
Cpz10 shows only low similarity to proteins from the database but exhibits a 
conserved protein domain for aspartyl/asparaginyl β-hydroxylases from the Fe(II)/2-
oxoglutarate dependent oxygenase family (Stenflo et al., 1989). Cpz11 and Cpz26 
have weak homology to putative methyltransferases including possible 
phosphatidylethanolamine N-methyltransferases.  
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Table II.1.1 Deduced functions of genes in the caprazamycin gene cluster 
 
Gene 
 
AA 
 
Protein homolog 
 
Identity/ 
similarity*
 
Proposed function 
     
cpz1 477** SchA30, Streptomyces sp. SCC 2136 84/90 feruloyl-CoA synthase 
cpz2 151 SSEG_02365, S. sviceus ATCC 29083 90/95 acyl dehydratase 
cpz3 278 SchA31, Streptomyces sp. SCC 2136 76/84 transcriptional regulator 
cpz4 513 SACE_7046, Saccharopolyspora erythraea 44/58 hypothetical protein 
cpz5 419 hmgs, Streptomyces sp. CL190 70/79 HMG-CoA synthase 
cpz6 349 SaRppA, S. antibioticus 30/46 type III pks 
cpz7 260 SACE_3529, Saccharopolyspora erythraea 57/65 PAPS 3’phosphatase 
cpz8 212 SACE_5947, Saccharopolyspora erythraea 43/60 hypothetical protein 
cpz9 348 SSEG_03332, S. sviceus ATCC 29083 27/41 transcriptional regulator 
cpz10 182 RSK20926_04892, Roseobacter sp. 25/40 β-hydroxylase 
cpz11 210 SCO_1731, S. coelicolor A3(2) 29/40 methyltransferase 
cpz12 189 SSEG_10045, S. sviceus ATCC 29083 23/34 kinase 
cpz13 441 SACE_4299, Saccharopolyspora erythraea 16/30 aminotransferase 
cpz14 424 Orf-4, S. atroolivaceus 36/53 hydroxymethyltransferase 
cpz15 274 Xccb100_2413, Xanthomonas campestris 26/40 dioxygenase 
cpz16 233 Smed_4814, Sinorhizobium medicea 20/30 nucleotidyltransferase 
cpz17 377 AprG2, S. tenebrarius 19/30 glycosyltransferase 
cpz18 424 CetH, Actinomyces sp. LU 9419 34/49 aminotransferase 
cpz19 460 GK_2312, Geobacillus kaustophilus 39/54 pyrimidine phosphorylase 
cpz20 354 TMCL4, Streptomyces sp. CK 4412 44/58 acyl-CoA synthase 
cpz21 500 TMCL1, Streptomyces sp. CK 4412 35/46 carboxyesterase 
cpz22 1238 SAV_5299, S. avermitilis MA 4680 36/53 ABC transporter 
cpz23 344 AviX9, S. viridochromogenes 31/46 lipase 
cpz24 598 Cja_1569, Cellvibrio japonicus 26/40 hypothetical protein 
cpz25 341 SAV_2980, S. avermitilis MA 4680 45/63 dehydrogenase 
cpz26 417 SSDG_05270, S. pristinaespiralis ATCC 25486 15/24 methyltransferase 
cpz27 192 SSEG_10045, S. sviceus ATCC 29083 39/54 kinase 
cpz28 396 spnK, Saccharopolyspora spinosa 50/66 O-methyltransferase 
cpz29 265 elmM3, S. olivaceus 46/60 O-methyltransferase 
cpz30 419 elmM1, S. olivaceus 43/53 O-methyltransferase 
cpz31 396 elmGT, S. olivaceus 40/53 deoxysugar transferase 
cpz32 543 Tfu_2432, Thermobifida fusca 22/28 nucleotidyltransferase 
cpz33 556 SchA32, Streptomyces sp. SCC 2136 81/88 hypothetical protein 
cpz34 544 SchA33, Streptomyces sp. SCC 2136 85/93 metallophosphoesterase 
 
*     Overall homology [%] 
**   Gene lacks an appropriate stop codon and is considered to be incomplete on cosmid 31C2 
cpz  Bold genes proposed to be essential for caprazamycin production  
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The predicted proteins contain conserved SAM-binding domains (cd02440). 
Interestingly, both genes are translationally coupled to possible resistance genes 
cpz12 and cpz27 by overlap of start and stop codon. Cpz14 is predicted to encode a 
serine hydroxymethyltransferase known to generate glycine from serine. Like other 
PLP-dependent enzymes, they have been shown to catalyze a great diversity of 
different reactions (Ogawa et al., 2000). Upstream and translationally coupled to 
cpz14 is cpz13 with weak homology to aminocyclopropan-carboxylate synthases and 
aminotransferases. 
Several genes seem to be co-transcribed in a cpz15-23 sub-cluster. The first, cpz15, 
displays domain homology on a protein level with clavaminate synthases and other 
α-ketoglutarate dependent dioxygenases. They are known to catalyze various 
oxidation reactions including β-hydroxylation, desaturation and oxidative ring closure 
(Townsend, 2002). A putative nucleotidyltransferase is encoded by cpz16 while 
Cpz17 shows similarity to the glycosyltransferase AprG2 from S. tenebrarius. The 
deduced product of cpz18 seems to belong to the class-III aminotransferases and 
bears 38% homology to CetH from the cetoniacytone gene cluster (Wu et al., 2009). 
Cpz19 resembles pyrimidine-nucleoside phosphorylases which catalyze the 
formation of β-ribose-1-phosphate and a pyrimidine from either uridine or thymidine. 
The genes cpz20 and cpz21 encode proteins similar to a putative acyl-CoA synthase 
(TMCL4) and a carboxyesterase (TMCL1) from the tautomycetin gene cluster (Choi 
et al., 2007). Another possible esterase is Cpz23. It displays similarity to AviX9, a 
protein with unknown function from the avilamycin gene cluster from S. 
viridochromogenes (Weitnauer et al., 2001). The deduced gene product of cpz25 is a 
putative zinc-dependent alcohol dehydrogenase. 
Cpz28, cpz29, cpz30 and cpz31 apparently constitute an operon for the attachment 
and the methylation of a deoxysugar. They show strong similarity to O-
methyltransferases and glycosyltransferases from known antibiotic gene clusters in 
particular to proteins participating in the formation of elloramycin (Blanco et al., 2001; 
Patallo et al., 2001) and spinosyn (Waldron et al., 2000). Both these compounds 
contain the same permethylated L-rhamnose moiety as found in the caprazamycins. 
In elloramycin biosynthesis, the L-rhamnose is transferred to the aglycone utilizing 
the dTDP-activated deoxysugar substrate and is subsequently methylated in three 
successive steps. Interestingly, we could not identify genes for the dTDP-L-rhamnose 
biosynthesis on the cosmid. This was initially surprising, because all genes for the 
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production of a bacterial secondary metabolite are usually clustered. However, 
neither the gene cluster of elloramycin (Ramos et al., 2008) nor of spinosyn (Madduri 
et al., 2001), steffimycin (Gullon et al., 2006) or arranciamycin (Luzhetskyy et al., 
2007) contain genes for dTDP-L-rhamnose formation. We therefore suggested the 
genes for the caprazamycins deoxysugar biosynthesis to be located elsewhere on 
the genome of the natural producer. 
1.4. Heterologous expression of the caprazamycin gene cluster 
In order to investigate whether the genes found on cosmid 31C2 were sufficient for 
the biosynthesis of caprazamycins we intended to express the cosmid 
heterologously. For this purpose, the beta-lactamase (bla) gene on the backbone of 
31C2 was replaced with an integration cassette of pIJ787 (Eustaquio et al., 2005; 
Gust et al., 2004) containing the attP attachment site and the integrase gene (int) of 
phage ΦC31, a tetracycline resistance gene (tet) and an origin of transfer (oriT) using 
Red/ET-mediated recombination. The generated cosmid cpzLK09 was introduced 
into S. coelicolor M512 by PEG-mediated protoplast transformation (Kieser et al., 
2000) and three kanamycin resistance clones were selected, referred to as S. 
coelicolor M512/cpzLK09 (1), (2) and (3). Extracts of cultures of the wildtype and the 
mutant strains were applied to LC-ESI-MS.  
In HPLC-UV-chromatograms peaks appeared with S. coelicolor M512/cpzLK09 at Rt. 
18.1 min, Rt. 19.3 min and Rt. 20.8 min which were not found in extracts of S. 
coelicolor M512 without the cluster (Figure III.1.3A and B). While the masses for the 
caprazamycins could not be detected, prominent mass peaks for the caprazamycin 
aglycones were observed in S. coelicolor M512/cpzLK09 (SIM chromatograms in 
Figure III.1.3B; for the CPZ E and F aglycones m/z 931 [M+H]+ at Rt = 18.3 min, for 
CPZ C, D and G aglycones m/z 945 [M+H]+ at Rt = 19.5 min and for CPZ A and B 
aglycones m/z 959 [M+H]+ at Rt = 21.0 min). Displaying the more hydrophilic 
character of the free carboxylic acid group, the aglycones elute three minutes earlier 
from the reversed phase HPLC column than the corresponding intact caprazamycins 
(compare Figure III.1.1). Positive ESI-CID fragmentation of the new compounds was 
identical to caprazamycins except for the absence of the L-rhamnose moiety. 
Fragments of m/z 814, m/z 701 and m/z 569 were obtained from the parent ion m/z 
945 [M+H]+ (Figure III.1.3C). Analogous fragments with a mass shift of −14 Da and 
+14 Da resulted from m/z 931 [M+H]+ and m/z 959 [M+H]+ representing the 
caprazamycin derivatives with fatty acids of different chain length.  
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Figure III.1.3 Analysis of n-butanolic culture extracts from (A) S. coelicolor M512 and (B) S. coelicolor M512/cpzLK09 containing the caprazamycin gene cluster. 
UV-chromatograms are depicted. Production ion chromatograms are obtained from mass scans in positive mode with m/z 931 [M+H]+ (CPZ E/F aglycone), m/z 
945 [M+H]+ (CPZ C/D/G aglycone) and m/z 959 [M+H]+ (CPZ A/B aglycone). Mass spectrometric fragmentation pattern in the CID experiment is shown for CPZ 
C/D/G aglycone (C) from (B).The suggested fragmentation scheme is depicted for CPZ D aglycone.  
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Molecular ions of m/z 558, m/z 427 and m/z 315, assigned to components of the 
caprazol structure, were found in all three spectra. S. coelicolor M512 without the 
gene cluster did not produce any of these new substances (Figure III.1.3A). The 
analytical data strongly implicates the production of non-glycosylated caprazamycins 
which are similar to the type-(III) liposidomycins (Figure I.2.3) isolated previously 
(Kimura et al., 1998b). These compounds have been reported to show excellent 
activity against Mycobacteria. Thus, culture extracts from the heterologous producer 
were applied to an agar diffusion assay against M. phlei. An inhibition zone of similar 
size could be observed with extracts from the wildtype and the mutant strains, 
whereas extracts from S. coelicolor M512 without the gene cluster showed no 
bioactivity in this assay (Figure III.2.1D). 
The production of the non-glycosylated caprazamycin derivatives correlates with the 
absence of genes for the dTDP-L-rhamnose biosynthesis on the cosmid. Apparently, 
S. coelicolor M512 is unable to provide the dTDP-L-rhamnose in compensation as 
the corresponding enzymes are not encoded on the genome.  
Both, analytical and biological data verify that the genes identified on cosmid 31C2 
indeed represent the caprazamycin biosynthetic gene cluster 
1.5. Determination of the boundaries of the gene cluster 
A set of gene disruption experiments was carried out to determine the cluster 
boundaries. Sequence analysis of overlapping cosmids suggested the caprazamycin 
gene cluster to be inserted into a highly conserved genomic region. cpz1 and cpz3 at 
the one end of the cluster and cpz33 and cpz34 at the other are almost identical with 
a continuous part of sequence from Streptomyces. sp. SCC 2136 (Basnet et al., 
2006). Primer walking and terminal sequencing of overlapping cosmids showed that 
this similarity extends further upstream of cpz1. 
While cpz4 encodes for a hypothetical protein with unknown function, cpz5 showed 
homology to 3-hydroxy-methylglutaryl (HMG)-CoA synthases. HMG-CoA synthases 
catalyze the aldol-addition of acetyl-CoA onto acetoacetyl-CoA and usually 
participate in the mevalonate pathway (Dairi, 2005). A biosynthetic route to the 
uncommon 3-MG moiety was proposed involving a HMG-CoA synthase, a 
dehydratase and a hydrogenase. No function in caprazamycin formation could be 
assigned to a putative type III PKS encoded by cpz6 and the possibly co-transcribed 
genes cpz7 and cpz8. 
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In order to validate the left border of the cluster cpz1, cpz2, cpz3 and cpz4 were 
deleted in cpzLK09 to generate cosmid cpzWP05 and cpz5 was additionally deleted 
to generate cpzWP06. By inactivation of the suggested biosynthetic pathway to 3-MG 
in cpzWP06 we hoped to produce compounds similar to the highly bioactive type-(IV) 
liposidomycins (Figure I.2.3). Cpz6 was inactivated in addition to cpz1-cpz5 in cosmid 
cpzWP07. At the right end of the cluster cpz33 and cpz34 encoding for a hypothetical 
protein and a metallophosphoesterase were deleted in cosmid cpzWP01. A possible 
nucleotidyltransferases encoded by cpz32 was additionally deleted in cosmid 
cpzWP02. 
After introducing the modified cosmids into S. coelicolor M512, positive candidates 
were selected by their kanamycin resistance and verified by PCR. Cultivation and 
analysis by LC-ESI-MS revealed production of caprazamycin aglycones in all 
mutants. In addition, bioassays of the culture extracts against M. phlei did not show 
any difference in inhibitory activity compared to S. coelicolor M512/cpzLK09 
containing the intact gene cluster. In case of Δcpz4, Δcpz5 and Δcpz32 
complementation by host genes seems unlikely as the S. coelicolor genome contains 
no homologs. Therefore we concluded cpz1-6 and cpz32-34 to be non-essential in 
caprazamycin biosynthesis. Given that cpz6 is most likely co-transcribed with its 
downstream positioned genes, a functional knock-out of cpz7 and cpz8 can be 
assumed in cosmid cpzWP07. Consequently, the biosynthetic gene cluster for 
caprazamycins is predicted to span from cpz9 to cpz31 (Figure III.1.2). 
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2. Gene deletion experiments on the caprazamycin gene cluster 
Since the putative HMG-CoA synthase Cpz5 seems not to be required for 
caprazamycin formation and the corresponding mutant S. coelicolor M512/cpzWP06 
did not accumulate the desired β-hydroxyacyl-caprazols, we searched for possible 
acyltransferases within the gene cluster. Two acyl moieties, the 3-methylglutarate (3-
MG) and the β-hydroxy fatty acids have to be attached during caprazamycin 
biosynthesis and the two putative hydrolases Cpz21 and Cpz23 could be considered 
for these transfer reactions. Cpz21 is predicted to contain a typical α/β-hydrolase 
fold, the catalytical triade Ser208-Glu326-His409 and a GxSxG-motif (Holmquist, 
2000). The overall homology of Cpz21 is strongest with TMCL1 from Streptomyces 
sp. CK4412 (Choi et al., 2007). TMCL1, also named TmcC, is assigned to the 
esterification of a dialkylmaleic anhydride moiety to the linear polyketide during 
tautomycetin formation. 
The amino acid sequence deduced from cpz23 shows highest overall homology to 
several hypothetical proteins from Streptomycetes including AviX9 of the avilamycin 
gene cluster from S. viridochromogenes (Weitnauer et al., 2001). According to the 
conserved protein domain search the C-terminus of Cpz23 is similar to SGNH-
hydrolases, a diverse family of lipases and carboxyesterases (Akoh et al., 2004). 
2.1. Deletion of the putative acyltransferase genes cpz21 and cpz23 
This part of the thesis was carried out in collaboration with Diploma student Liane 
Lutsch. Both genes were individually deleted from cosmid cpzLK09 using Red/ET-
mediated recombination. To create in-frame deletions, the disruption cassette from 
pIJ773 was subsequently removed by the use of FLP-recombinase (Cherepanov & 
Wackernagel, 1995) generating cosmid cpzLL06 (Δcpz21) and cpzLL07 (Δcpz23). 
After introduction of the cosmids in S. coelicolor M512 kanamycin resistant mutants 
were cultivated and extracts were analyzed by LC-ESI-MS. Production of the 
caprazamycin aglycones was abolished in S. coelicolor M512/cpzLL06 and S. 
coelicolor M512/cpzLL07. This proves that both, Cpz21 and Cpz23 play an essential 
role in caprazamycin biosynthesis. Metabolites were only identified in extracts of S. 
coelicolor M512/cpzLL06 (Δcpz21) with m/z 803 [M+H]+ at Rt = 16.1 min, m/z 817 
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[M+H]+ at Rt = 17.2 min and m/z 831 [M+H]+ at Rt = 18.6 min by LC-ESI-MS mass 
scan in positive mode (UV- and product ion chromatograms in Figure III.2.1A and B). 
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Figure III.2.1 Analysis of n-butanolic culture extracts from S. coelicolor M512/cpzLL06 containing the 
caprazamycin gene cluster by LC-ESI-MS (see also diploma thesis of Liane Lutsch). UV-
chromatogram is depicted (A). (B) Production ion chromatograms are obtained from mass scans in 
positive mode with m/z 803 [M+H]+ (hydroxyacyl-caprazols E/F), m/z 817 [M+H]+ (hydroxyacyl-
caprazols C/D/G) and m/z 831 [M+H]+ (hydroxyacyl-caprazols A/B). Mass spectrometric fragmentation 
pattern in the CID experiment is shown for hydroxyacyl-caprazols C/D/G (C) from (B).The suggested 
fragmentation schemes is depicted for hydroxyacyl-caprazol D. (D) Bioactivity of culture extracts. 
Butanolic culture extracts from Streptomyces sp. MK730-62F2, S. coelicolor M512/cpzLK09, S. 
coelicolor M512/cpzLL06 and S. coelicolor M512 (in this order from left to right) were applied to an 
agar diffusion assay against M. phlei. 
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Collision-induced fragmentation corresponds to the caprazamycin aglycones by 
sequential loss of the aminoribose (-131 Da), the uracil (-111 Da) and the ribose (-
132 Da) but m/z-values of product ions indicate the absence of the 3-methylglutarate 
(129 Da) (Figure III.2.1C). Overall, fragments matched exactly the predicted 
characteristics of β-hydroxyacyl-caprazols, structurally minimized liponucleosides 
antibiotics. In a bioassay against M. phlei (Figure III.2.1D) extracts of a S. coelicolor 
M512/cpzLK09 and S. coelicolor M512/cpzLL06 (Δcpz21) cultivation broths showed 
both similar inhibiting activities, whereas no growth inhibition could be observed with 
S. coelicolor M512 extracts. Co-expression of intact copies of the deleted genes 
under the constitutive ermE* promoter in the respective mutants restored the 
production of caprazamycin aglycones. 
Although similar to the type-(IV) liposidomycins (Figure I.2.3) the β-hydroxyacyl-
caprazols are expected to be slightly more hydrophilic due to the additional OH-group 
at the 3a-C-position. Thus, they represent interesting novel compounds for further 
investigations e.g. in structure/activity relationships. Moreover, the data indicated that 
Cpz21 is most likely involved in the attachment of the 3-MG moiety. Beside Cpz21 
two other enzymes with homology to para-nitrobenzyl esterases are known from 
bacterial secondary metabolism. Both these enzymes, TmcC and TtmK from the 
tautomycin gene cluster (Li et al., 2008) were proposed to catalyze the attachment of 
an acyl group. However, inactivation of the corresponding genes in the gene clusters 
did not lead to the identification of an accumulated intermediate. Therefore the data 
presented here provides first functional evidence that these family of enzymes indeed 
act as acyltransferases. 
2.2. Deletion of the genes cpz20 and cpz25  
OH
HS-CoA
3-methylglutaconic acid
Cpz20 Cpz25
Cpz21
Figure III.2.2 Proposed reactions for activation and attachment of the methylglutaryl moiety 
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The assignment of Cpz21 as the methylglutaryl transferase in caprazamycin 
biosynthesis leads to the question of the biosynthetic origin of the 3-MG motif. From 
the previous results an involvement of the HMG-CoA synthase Cpz5 could be 
excluded. As an alternative we postulated a biosynthetic pathway via 3-
methylglutaconate an intermediate in the leucine/isovaleriate catabolism. The 
leucine/isovaleriate utilization pathway was extensively investigated in Pseudomonas 
and has been shown to comprise the proteins LiuA, LiuB, LiuC, LiuD and LiuE 
(Forster-Fromme et al., 2006; Forster-Fromme & Jendrossek, 2008; Hoschle et al., 
2005). By BLAST searches we found homologs of the liu genes in the genome of S. 
coelicolor A3(2) to be clustered together (sco2776-sco2779). Therefore we 
speculated that a similar pathway as in Pseudomonas exists in S. coelicolor and may 
provide methylglutaconate as a precursor for caprazamycin biosynthesis. The 
following reaction sequence for the generation of the 3-MG moiety would require a 
hydrogenase and possibly an acyl-CoA transferase (Figure III.2.2). Two such 
enzymes are encoded close to cpz21, which are Cpz20 and Cpz25. Cpz20 contains 
an AMP-binding domain and shows highest homology to TmcF (44%/58% 
identity/similarity) from the tautomycetin gene cluster (Choi et al., 2007). The putative 
dehydrogenase Cpz25 is similar to MupE, a postulated crotonyl reductase involved in 
mupirocin biosynthesis in Pseudomonas fluorescens (El-Sayed et al., 2003; 
Hothersall et al., 2007). Cpz25 was initially assigned to the to first distinctive reaction 
step in a hypothetical biosynthetic pathway to the caprazamycins, the oxidation of 
uridine to uridine 5’-aldehyde. Though, Cpz25 seemed the only reasonable candidate 
for the postulated hydrogenation of 3-methylglutaconate.  
Both genes were individually deleted from cosmid cpzLK09 using Red/ET-mediated 
recombination. To create in-frame deletions, the disruption cassette from pIJ773 was 
subsequently removed by the use of FLP-recombinase (Cherepanov & Wackernagel, 
1995) generating cosmid cpzWP22 (Δcpz20) and cpzWP25 (Δcpz25). After 
introduction of the cosmids in S. coelicolor M512 kanamycin resistant mutants were 
cultivated and extracts were analyzed by LC-ESI-MS. Production of the 
caprazamycin aglycones was abolished in S. coelicolor M512/cpzWP22 and S. 
coelicolor M512/cpzWP25. However, the hydroxyacyl-caprazols could still be 
detected by LC-ESI-MS mass scans (Figure III.2.3). Similar to the Δcpz21 mutant S. 
coelicolor M512/cpzLL06, extracts of S. coelicolor M512/cpzWP22 and S. coelicolor 
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M512/cpzWP25 still showed bioactivity in an agar diffusion assay against 
Mycobacterium phlei (Figure III.2.3). These results strongly indicate, that both Cpz20 
and Cpz25, participate in the formation and/or attachment of the methylglutaryl 
moiety of caprazamycins. Moreover, our data supports the postulated biosynthetic 
pathway to the 3-MG motif, though biochemical investigations e.g. in vitro studies 
have to verify our conclusions. 
 
2.3. Deletion of the putative methyltransferase genes cpz11 and cpz26 
This part of the thesis was carried out in collaboration with Diploma student Liane 
Lutsch. In the diazepanone ring, both nitrogens are methylated. Five putative 
methyltransferases are encoded by the caprazamycin gene cluster, which are Cpz11, 
Cpz26, Cpz28, Cpz29 and Cpz30. Cpz28, Cpz29 and Cpz30 exhibit high sequence 
homology to rhamnosyl-O-methyltransferases from other antibiotic gene clusters. 
Therefore, the N-methylation reactions are likely to be catalyzed by Cpz11 and/or 
Cpz26. Notably, Cpz11 shows sequence similarity (55%) to one of the few 
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Figure III.2.3 Analysis of n-butanolic culture extracts from (A) S. coelicolor M512/cpzWP22 (Δcpz20) 
and (B)  S. coelicolor M512/cpzWP25 (Δcpz25) by LC-ESI-MS. Production ion chromatograms are 
obtained from mass scans in positive mode with m/z 803 [M+H]+ (hydroxyacyl-caprazols E/F), m/z 
817 [M+H]+ (hydroxyacyl-caprazols C/D/G) and m/z 831 [M+H]+ (hydroxyacyl-caprazols A/B). 
Butanolic culture extracts were applied to agar diffusion assays against M. phlei. 
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characterized N-methyltransferases AtM1 from the gene cluster of AT2433 (Gao et 
al., 2006). 
Both genes were individually deleted from cosmid cpzLK09 using Red/ET-mediated 
recombination. To create in-frame deletions, the disruption cassette from pIJ773 was 
subsequently removed by the use of FLP-recombinase (Cherepanov & Wackernagel, 
1995) generating cosmid cpzLL05 (Δcpz11) and cpzLL08 (Δcpz26). After introduction 
of the cosmids in S. coelicolor M512 kanamycin resistant mutants were cultivated 
and extracts were analyzed by LC-MS/MS. Production of the caprazamycin 
aglycones was abolished in S. coelicolor M512/cpzLL05 and S. coelicolor 
M512/cpzLL08. This proves that both, Cpz11 and Cpz26 play an essential role in 
caprazamycin biosynthesis. However, accumulated metabolites could not be 
identified in the mutant strains. LC-ESI-MS mass scans for various possible 
intermediates did not result in the detection of a certain compound, neither in the 
Δcpz11 nor in the Δcpz26 mutant. Co-expression of an intact copy of cpz11 under 
the constitutive ermE* promoter in the Δcpz11 mutant restored the production of 
caprazamycin aglycones. A corresponding complementation plasmid with cpz26 
could not be generated.  
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3. Investigation of the sugartransfer reaction in caprazamycin 
biosynthesis 
Above I described the cloning and heterologous expression of cosmid cpzLK09 
containing the first identified gene cluster of a translocase I inhibitor, the 
caprazamycins. The caprazamycins are glycosylated with a 2,3,4-O-methyl-L-
rhamnose and therefore belong to the large number of bioactive compounds 
containing 6-deoxyhexoses. Usually, these moieties contribute significantly to the 
compounds properties influencing e.g. molecule/target interactions, cell import and 
export, pharmacokinetics and solubility (Williams et al., 2008). The biosynthesis of 
deoxysugars has been studied in detail and generally starts from NDP-activated 
hexoses via 4-keto-6-deoxy intermediates (Liu & Thorson, 1994). However, genes for 
the formation of the dTDP-L-rhamnose could not be identified on cosmid 31C2 and 
therefore only caprazamycin aglycones were produced by the heterologous host S. 
coelicolor M512/cpzLK09. Since potential genes for O-methylation (cpz28 – cpz30) 
and a glycosyltransferase (cpz31) are encoded in the caprazamycin gene cluster, we 
speculated that only four genes are missing for successful heterologous production of 
intact caprazamycins.  
3.1. Co-expression of plasmid pRHAM and the caprazamycin gene 
cluster 
The production of the non-glycosylated caprazamycin derivatives correlates with the 
absence of putative genes for the deoxysugar formation within the gene cluster. In 
order to investigate if all other genes, required for the biosynthesis of the intact 
caprazamycins, are functionally expressed on cpzLK09, we introduced plasmid 
pRHAM (Rodriguez et al., 2000) into the heterologous host S. coelicolor 
M512/cpzLK09. pRHAM contains all genes required for L-rhamnose biosynthesis 
from S. antibioticus; oleS, encoding a dTDP-glucose synthase, oleE, a dTDP-glucose 
4,6-dehydratase, oleL, a dTDP-deoxyglucose 3,5-epimerases and oleU, a 4-
ketoreductase. Three individual clones termed as S. coelicolor 
M512/cpzLK09/pRHAM were selected by their thiostrepton resistance and cultivated 
in production media. Analysis of the culture extracts by LC-ESI-MS revealed that in 
comparison to S. coelicolor M512/cpzLK09 which only produced the caprazamycin 
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aglycones, all mutant strains now accumulated additional metabolites (Figure III.3.1). 
These new compounds correspond to the caprazamycins E/F (at Rt. 20.0 min), 
caprazamycins C/D/G (at Rt. 20.9 min) and caprazamycins A/B (at Rt. 22.3 min) as 
found by ESI-MS product ion scans. MS2 spectra from collision-induced dissociation 
(CID) experiments matched exactly the characteristic fragmentation profiles of the 
intact caprazamycins. This verified that the enzymes for methylation and attachment 
of the L-rhamnose moiety have to be encoded on the gene cluster. A set of genes 
cpz28-31 encoding for three hypothetical sugar O-methyltransferases and a putative 
rhamnosyltransferase are the most likely candidates for these reactions. 
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Figure III.3.1 HPLC chromatograms 
of n-butanolic extracts from A S. 
coelicolor M512 B S. coelicolor 
M512 containing the caprazamycin 
gene cluster cpzLK09 and C S. 
coelicolor M512/cpzLK09 containing 
pRHAM co-expressing the 
biosynthetic genes for dTDP-L-
rhamnose. 
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3.2. Expression and purification of Cpz31 
Cpz31 shows high sequence homology to known rhamnosyltransferases from other 
antibiotic gene clusters, e.g. ElmGT (38% identity/50% similarity) from S. olivaceus 
(Blanco et al., 2001). In order to investigate the role of Cpz31 in caprazamycin 
biosynthesis, plasmid pLK02 containing cpz31 was overexpressed in E. coli and the 
resulting protein purified for in vitro studies. His8-Cpz31 consists of 420 amino acids 
with a calculated molecular mass of 44.7 kDa. Expression of a corresponding protein 
could be observed after induction with IPTG. Solubility of the enzyme was low and 
the yield could not be improved using different culture temperatures or IPTG 
concentrations for expression. However, His8-Cpz31 was partially purified by Ni-NTA 
chromatography resulting in 0.85 mg of protein from 1 litre culture.  
3.3. Reaction of Cpz31 with dTDP-L-rhamnose and caprazamycin 
aglycones 
A butanolic extract from a S. coelicolor M512/cpzLK09 culture containing 
caprazamycin aglycones was incubated with His8-Cpz31 in the presence of dTDP-L-
rhamnose. After 2 h, caprazamycin aglycones could not be observed in the assay 
anymore but instead three new peaks appeared in the LC-chromatograms (Figure 
III.3.2B; at Rt. 17.2 min, Rt. 18.2 min and Rt. 19.7 min) indicating product formation. 
Precursor ions for the rhamnosylated caprazamycins E/F with m/z 1076.6 [M+H]+, 
C/D/G with m/z 1090.6 [M+H]+ and A/B with m/z 1104.6 [M+H]+ were readily detected 
by ESI-MS product ion scans at Rt. 17.4 min, Rt. 18.5 min and Rt. 19.9 min, 
respectively (Figure III.3.2C). The MS2 spectrum obtained from the precursor ion with 
m/z 1090.6 [M+H]+ (Figure III.3.2D) was identical to the predicted fragmentation of 
the rhamnosylated caprazamycins C/D/G (Figure III.3.2A). Characteristic ions with 
m/z 1091, m/z 960 and m/z 848 display the presence of the rhamnosyl moiety. 
Similar spectra were produced by the precursor ions with m/z 1076.6 [M+H]+ and m/z 
1104.6 [M+H]+ representing the rhamnosylated caprazamycins with different fatty 
acid chain length. These compounds were not detectable in assays without Cpz31 or 
dTDP-L-rhamnose. Therefore, we conclude that Cpz31 glycosylates the 
caprazamycin aglycones using dTDP-L-rhamnose as a substrate (Figure III.3.2A)
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Figure III.3.2 Glycosylation of caprazamycins by Cpz31. A Reaction scheme of Cpz31 with dTDP-L-rhamnose and caprazamycin D aglycone as 
substrates. The suggested fragmentation of the reaction product 2c,3c,4c-desmethyl-caprazamycin D is depicted. B Overlay of HPLC 
chromatograms (262 nm) from activity assays with Cpz31 (black line) and without protein (dashed line). The observed shift in retention time by the 
complete conversion of caprazamycin aglycones to the rhamnosylated product is indicated by bold arrows. C LC-ESI-MS product ion scans in 
positive mode for desmethyl-caprazamycins E/F with m/z 1076.6 [M+H]+, for desmethyl-caprazamycins C/D/G with m/z 1090.6 [M+H]+ and for 
desmethyl-caprazamycins A/B with m/z 1104.6 [M+H]+ in the activity assay with Cpz31. D Mass spectrometric fragmentation pattern in the CID 
experiment is shown for 2c,3c,4c-desmethyl-caprazamycin C/D/G. 
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3.4. Introduction of the caprazamycin gene cluster into different 
Streptomyces host strains 
Rhamnosyltransferases have been frequently exploited for the structural 
diversification of glycosylated antibiotics (Blanco et al., 2001; Gaisser et al., 2009; 
Luzhetskyy et al., 2007; Olano et al., 2008) as they often exhibit high flexibility 
towards the donor substrate. In order to generate caprazamycin derivatives with 
altered sugar moieties the cosmid cpzLK09 was introduced into S. fradiae A0 which 
produce the deoxysugars D-olivose and L-rhodinose and into Streptomyces sp. 
TÜ6071ΔplaA6 producing L-amicetose. Transfer of the cosmid DNA into the host 
strains was conducted by intergeneric triparental conjugation. Three individual clones 
each were selected by their kanamycin resistance and termed as S. fradiae 
A0/cpzLK09-(1-3) and Streptomyces sp. TÜ6071ΔplaA6/cpzLK09-(1-3), respectively. 
However, cultivation and analysis of culture extracts from the mutant strains did not 
lead to the identification of new caprazamycin derivatives. Since the caprazamycin 
aglycones were readily detected in the culture extracts, it can be speculated that 
Cpz31 is more specific for dTDP-L-rhamnose than related glycosyltransferases e.g. 
ElmGT from S. olivaceus (Blanco et al., 2001) or StfG from S. steffisburgensis (Olano 
et al., 2008). 
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4. Identification of the gene cluster for dTDP-L-rhamnose 
biosynthesis 
In bacteria, genes directing the biosynthesis of a certain secondary metabolite are 
generally clustered together. However, cosmid 31C2 containing the caprazamycin 
gene cluster missed the genes for the biosynthesis of the deoxysugar moiety. The 
absence of gene for the biosynthesis of dTDP-L-rhamnose within the corresponding 
gene cluster has previously been reported for aranciamycin (Luzhetskyy et al., 2007), 
steffimycin (Gullon et al., 2006), spinosyn (Waldron et al., 2001) and elloramycin 
(Decker et al., 1995). The formation of L-rhamnose involves four enzymes a dTDP-D-
glucose synthase, a dTDP-D-glucose 4,6-dehydratase, a dTDP-3,5-deoxyglucose 
epimerase and a 4-ketoreductase. Since these genes are required for caprazamycin 
biosynthesis, they have to be located elsewhere on the chromosome of the original 
producer strain Streptomyces sp. MK730-62F2.  
4.1. Cloning and sequencing of a dTDP-L-rhamnose biosynthetic gene 
cluster 
cpzDI cpzDIIIorf9
cpzDII
cpzDV
cpzDVIcpzDIV
orf10cpzDVII
Δ Δ Δ
+ ─ +
 
Figure III.4.1 Organization of the L-rhamnose gene cluster cpzDI to cpzDVII on cosmid 4H11. 
Black arrows indicate genes proposed to be essential in dTDP-L-rhamnose biosynthesis. Grey 
arrows indicate genes with unknown function. Squared brackets above the cluster mark the gene 
deletions performed in this study. (-) indicates that the deletion of the respective region led to an 
abolishment of caprazamycin production. (+) indicates that caprazamycin production was not 
influenced. 
 
Using degenerated primers for the amplification of NDP-glucose 4,6-dehydratases 
(Decker et al., 1996), we obtained a 500 bp partial sequence of cpzDIII from genomic 
DNA of the caprazamycin producer. This fragment was cloned and sequenced. 
Annotation revealed high homology to dTDP-glucose 4,6-dehydratases on protein 
level.  
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Table III.4.1 Deduced functions of genes within the L-rhamnose subcluster 
 
Gene 
 
AA 
 
Protein homolog (Accession number) 
 
Homology* 
 
Proposed function 
     
orf9 140 SvirD4_010100037399,  
S. viridochromogenes DSM 40736  
87/93 oxidoreductase 
cpzDI 58 SAMR0798,  
S. ambofaciens ATCC 23877) 
64/75 unknown 
cpzDII 356 MtmD, S. argillaceus  76/86 dTDP-glucose 
synthase 
cpzDIII 327 NanG2, S. nanchangensis  77/83 dTDP-glucose 
dehydratase 
cpzDIV 296 OleU, S. antibioticus  63/71 4-ketoreductase 
cpzDV 268 SvirD4_010100037424, 
S. viridochromogenes DSM 40736  
96/99 unknown 
cpzDVI 202 StrM, S. glaucescens  65/77 sugar 3,5-epimerase 
cpzDVII 647 SghaA1_010100002568, 
S. ghanaensis ATCC 14672  
76/82 cell wall biosynthesis 
glycosyltransferase 
orf10 170 SAMR0794,  
S. ambofaciens ATCC 23877  
83/89 phosphoesterase 
 
*Overall homology [%] 
Bold genes represent the proposed L-rhamnose subcluster  
 
Perfect matching primers were constructed to screen the cosmid library of 
Streptomyces sp. MK730-62F2. Sequencing and annotation of a positive cosmid, 
4H11, revealed a stretch of 6.8 kb DNA putatively involved in the biosynthesis of 
dTDP-L-rhamnose (Figure III.4.1; GenBank accession number HM051054). 
According to the gene function predictions (Table III.4.1) cpzDII encodes for a 
putative dTDP-glucose synthase, cpzDIII for a dTDP-glucose 4,6-dehydratase, 
cpzDIV for a 4-ketoreductase and cpzDVI for a dTDP-deoxyglucose 3,5-epimerases. 
The identified gene cluster consists of two putative operons (Figure III.4.1). CpzDII, 
cpzDIII and cpzDIV are translationally coupled to cpzDV as indicated by overlap of 
stop- and start-codons. The deduced gene product of cpzDV shows homology to 
hypothetical proteins from various Streptomyces strains which are annotated as 
methyltransferases. In the opposite direction, cpzDVI, is translationally coupled with 
cpzDVII, encoding for a putative glycosyltransferase. Homologs of CpzDVII have 
been assigned to bacterial cell wall biosynthesis. The putative gene cpzDI, 105 bp 
upstream of cpzDII, encodes for a small protein of 57 amino acids with several 
homologs from Streptomyces genomes.  
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Figure III.4.2 LC-ESI-MS product ion scans for caprazamycins E/F with m/z 1118.6 [M+H]+, for 
caprazamycins C/D/G with m/z 1132.6 [M+H]+ and for caprazamycins A/B with m/z 1146.6 [M+H]+ in 
butanolic extracts of A Streptomyces sp. MK730-62F2 B Streptomyces sp. MK730-62F2 ΔcpzDIII 
and C Streptomyces sp. MK730-62F2 ΔcpzDIII/pRHAM. 
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Many of them, e.g. SvirD4_37404 from S. viridochromogenes DSM40736 and 
SAMR0798 from S. ambofaciens ATCC 23877, are located next to hypothetical NDP-
glucose dehydratase genes. Since orf9, a putative oxidoreductase gene and orf10, a 
possible phosphodiesterase gene, have no apparent role in deoxysugar metabolism, 
we proposed the L-rhamnose biosynthetic gene cluster to span from cpzDI to 
cpzDVII. 
4.2. Inactivation of cpzDIII and complementation with pRHAM 
In order to confirm the involvement of the postulated L-rhamnose biosynthetic gene 
cluster in caprazamycin biosynthesis, the hypothetical dTDP-glucose 4,6-
dehydratase gene cpzDIII was inactivated. The resulting cosmid cpzLK01 was 
introduced into Streptomyces sp. MK730-62F2 by intergeneric conjugation. Four 
double-crossover mutants of Streptomyces sp. MK730-62F2 ΔcpzDIII were finally 
selected and confirmed by PCR. After cultivation, extracts of the mutant strains were 
applied to LC-ESI-MS analysis. In contrast to the wildtype strain, production of intact 
caprazamycins was completely abolished in the mutants (Figure III.4.2). However, 
caprazamycin aglycones could be clearly detected and extracts of the mutants still 
showed bioactivity in an agar diffusion assay against Mycobacterium phlei. In order 
to validate that the disruption of cpzDIII is responsible for the abolishment of the 
caprazamycin production, we complemented the ΔcpzDIII mutant by introducing 
pRHAM. After cultivation, LC-ESI-MS analysis showed that caprazamycin production 
was restored (Figure III.4.2). Analysis of the ΔcpzDIII mutant and the 
complementation confirms that the L-rhamnose biosynthetic gene cluster on cosmid 
4H11 is required for the formation of the L-rhamnose moiety in caprazamycin 
biosynthesis. 
4.3. Assembly of caprazamycin gene cluster 
In order to proof that the identified genes cpzDI-DVII are sufficient for L-rhamnose 
biosynthesis, we assembled the subcluster to cosmid cpzLK09 containing the 
caprazamycin gene cluster (Figure III.4.3). It has been shown that the genes cpz32 – 
cpz34 are not involved in caprazamycin biosynthesis by inactivation experiments. 
Therefore, an apramycin resistance cassette and a spectinomycin/streptomycin 
resistance cassette were used to replace cpz32 – cpz34 by Red/ET-mediated 
recombination generating cosmid cpzEW05.  
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Figure III.4.3 A Strategy for the assembly of the caprazamycin gene cluster and the L-rhamnose 
subcluster. Black arrows indicate genes proposed to be essential in CPZ biosynthesis. aac(3)IV, 
apramycin resistance gene; aad4, spectinomycin/streptomycin resistance gene; hyg, hygromycin 
resistance gene; FRT, FLP recognition site; loxP, Cre recognition site; oriT, origin of transfer. The size 
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of the resistance cassettes and their components are out of scale. B LC-ESI-MS UV-chromatogram 
and product ion scans for caprazamycins E/F with m/z 1118.6 [M+H]+, for caprazamycins C/D/G with 
m/z 1132.6 [M+H]+ and for caprazamycins A/B with m/z 1146.6 [M+H]+ in butanolic extracts of S. 
coelicolor M512/cpzEW07. 
 
Within cosmid 4H11, containing the L-rhamnose gene cluster, a 14 kb stretch of DNA 
upstream of cpzDI was replaced with an apramycin resistance cassette introducing a 
unique NheI restriction site. A 17 kb fragment upstream of cpzDVII was replaced by a 
hygromycin resistance cassette introducing a unique PmeI restriction site. From the 
generated cosmid cpzEW02, a 10 kb PmeI/NheI restriction fragment, containing the 
cpzDI-DVII subcluster, was transferred into Red/ET-proficient E. coli cells harbouring 
cpzEW05. Homologous recombination of the restriction fragment with cosmid 
cpzEW05 was possible between the apramycin resistance gene aac(3)IV (924 bp) 
and 523 bp identical sequences of the hygromycin and the 
spectinomycin/streptomycin resistance cassettes. These sequences include an oriT 
and a FRT site. Red/ET-mediated recombination would lead to an apramycin, 
hygromycin and kanamycin resistant transformant only if homologous recombination 
occurred within these regions.  
The resulting cosmid cpzEW07 was introduced into S. coelicolor M512 by 
intergeneric triparental conjugation. Positive clones were selected by their apramycin, 
hygromycin and kanamycin resistance and termed as S. coelicolor M512/cpzEW07. 
The mutant strain was cultivated and extracts were analysed by LC-ESI-MS. Three 
new peaks appeared in the UV-chromatograms at retention times 20.7 min, 22.1 min 
and 23.8 min (Figure III.4.3B). These peaks were missing in extracts of S. coelicolor 
M512 and S. coelicolor M512/cpzLK09. Corresponding mass peaks were detected by 
product ion scans for the caprazamycins E/F with m/z 1118.8 [M+H]+ (Rt. 20.9 min), 
caprazamycins C/D/G with m/z 1132.8 [M+H]+ (Rt. 22.3 min) and the caprazamycins 
A/B with m/z 1146.8 [M+H]+ (Rt. 24.0 min) (Figure III.4.3B). MS2 fragmentation 
patterns matched exactly the intact caprazamycins. The heterologous production of 
caprazamycins in S. coelicolor M512 containing the assembled gene cluster proofs 
that the cpzDI-DVII subcluster is sufficient for the biosynthesis of dTDP-L-rhamnose. 
4.4. Deletion of cpzDI and cpzDV 
The production of intact caprazamycins by expression of the assembled gene cluster 
now enabled us to investigate on other genes in caprazamycin biosynthesis in a 
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heterologous background. However, to allow further gene deletion experiments, the 
existing apramycin resistance cassette needed to be eliminated from cosmid 
cpzEW07. This was achieved by a SpeI digestion and religation procedure 
generating cosmid cpzEW08. Corresponding SpeI sites were added to the primer 
sequence during the generation of cosmid cpzEW02 and cpzEW05 (see section 
II.9.8).  
Three of the hypothetical genes in the L-rhamnose gene cluster have no obvious role 
in dTDP-L-rhamnose biosynthesis. The potential glycosyltransferase CpzDVII 
contains several conserved domains typical for glycan synthases and is most likely 
involved in cell wall biogenesis. cpzDI is similar to small hypothetical genes often 
located next to genes from deoxysugar metabolism and cpzDV encodes for a 
putative protein with unknown function. The genes cpzDI and cpzDV were 
individually deleted by replacement with an apramycin resistance cassette flanked by 
loxP sites. Subsequently, the resistance cassettes were eliminated in vitro using Cre-
recombinase. The resulting cosmids were termed cpzEW10 (ΔcpzDI) and cpzEW12 
(ΔcpzDV). After introduction of the cosmids into S. coelicolor M512, hygromycin and 
kanamycin resistant exconjugants were selected and designated as S. coelicolor 
M512/cpzEW10 and S. coelicolor M512/cpzEW12. After cultivation, culture extracts 
of the mutants showed no differences in LC-ESI-MS analysis in comparison to S. 
coelicolor M512/cpzEW07 containing the complete L-rhamnose cluster. 
Caprazamycins were accumulated by all of the strains. Therefore we conclude that 
cpzDI and cpzDV have no role in caprazamycin biosynthesis and are probably 
involved in primary metabolism. 
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5. Identification of the liposidomycin biosynthetic gene cluster 
5.1. Cloning and sequencing of the liposidomycins gene cluster 
Due to the structural resemblance between the liposidomycins and caprazamycins 
we assumed similar enzymes to be involved in the formation of both compounds. 
Oligonucleotides deduced from the sequence of the hypothetical N-methyltransferase 
Cpz11 generated a PCR product with sequence homology to cpz11 (81%) and other 
putative SAM-dependent methyltransferase genes. Perfect matching primers were 
applied to a genomic library of Streptomyces sp. SN-1061M constructed in a 
SuperCos1 vector. Two positive cosmids out of 1100 could be identified and proven 
to contain overlapping DNA by restriction mapping. Cosmid 3G5 was finally selected 
for complete shot-gun sequencing. The nucleotide sequence of the gene cluster has 
been deposited in GenBank under accession number GU219978. Sequencing of the 
cosmid clone revealed a 45.8 kb insert with an average GC content of 70.2%, similar 
to other sequences from Streptomyces DNA. In silico analysis using BLAST 
homology searches, conserved protein domain searches and the GC frame plot 
method revealed 39 putative genes. A total of 25 open reading frames, designated 
lipA-lipY, were assigned to the liposidomycin gene cluster presumably encoding for 
biosynthesis, resistance, transport and regulation (Figure III.5.1). Proposed functions 
of the annotated genes and best matches in homology search are shown in Table 
III.5.1.  
5.2. Sequence analysis of the liposidomycins gene cluster 
A comparison of the annotated genes on this cosmid and the caprazamycin 
biosynthetic cluster reveals striking similarities (Figure III.5.1). The genes cpz9 to 
cpz27 have been assigned previously to the formation of the caprazamycin 
aglycones. In the liposidomycin cluster, the genes lipG – lipY show 78% - 86% 
sequence identity to cpz9 – cpz27 on DNA level. All of these genes are transcribed in 
the same direction and several subcluster seem to be translational coupled, indicated 
by overlap of stop and start codons. The only significant difference concerns the 
organization of the genes cpz10-12 and cpz13/14 in two putative operons while their 
homologs lipH-L form a single 4.4 kb subcluster. This indicates that the biosynthesis 
of the non-sulfated, non-glycosylated liponucleoside core structure, the regulation 
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and the resistance mechanism are analog for both compounds (see Discussion 
section). 
 
9   10      12        14        16       18   19         21     22           23    24   25        27        29         31     3211      13         15       17               20                 26        28       30 
11 A     B    C    D  E   F   G    H   I  J    K    L     M N   O   P     Q    R   S        T           U      V    W    X   Y  12
liposidomycin gene cluster (lip)
caprazamycin gene cluster (cpz)
3      4     5       6   7  8
transfer and methylation
of the deoxysugar moiety
biosynthesis of 
the caprazolring
generation and transfer
of the fatty acyl groups
Δcpz1-8 (cpzWP07)
regulation and 
resistance
metabolism and transfer
of the sulfate group
no or unknown
function
Figure III.5.1 Organization of the liposidomycin and the caprazamycin gene cluster. Assignment of 
genes to different steps of their biosynthesis is indicated by different colours. A black bar above genes 
indicate the gene deletion in the mutant strain S. coelicolor M512/cpzWP07. Note that lipA is a 
homolog of cpz5 and lipB a homolog of cpz4. 
 
Genes directing the attachment and methylation of a deoxysugar, similar to the 
cpz28-31 genes at the right end of the caprazamycin cluster, were not identified on 
cosmid 3G5 reflecting the absence of the rhamnosyl moiety in the liposidomycins 
(Figure III.5.1). Instead, downstream of lipY we found an open reading frame orf12 
encoding for a hypothetical protein with no apparent function in liposidomycin 
biosynthesis. The adjacent genes orf13 and orf14 have sequence similarity to protein 
kinases (61%) and DNA helicases (59%) respectively and are most likely involved in 
primary metabolism. Consequently, lipY was defined to be the right border of the 
liposidomycin cluster. On the left end, upstream of the lipG, a set of genes lipA – lipF 
are proposed to play a role in sulfation of the liposidomycins. Similar genes were 
identified adjacent to the caprazamycin gene cluster and have been shown not to be 
involved in caprazamycin formation by inactivation experiments. lipA is flanked by the 
genes orf1-10 which can not be assigned to the liposidomycin biosynthesis but are 
highly homologous to a contiguous part of sequence from Streptomyces coelicolor 
(SCO2293 – SCO2301). Therefore the biosynthetic gene cluster for liposidomycins is 
predicted to span 29.7 kb from lipA – lipY. 
 RESULTS 
  86 
Table III.5.1 Deduced functions of genes in the liposidomycin gene cluster 
 
Gene 
 
AA 
 
Protein homolog (BLAST) 
 
Identity/ 
Similarity[a] 
 
Proposed function 
orf1[b] 198 SCO2301, Streptomyces coelicolor A3(2) 87/91 NGG1-interacting factor 3 
orf2 197 SCO2300, S. coelicolor A3(2) 85/91 hypothetical protein 
orf3 452 SCO2299, S. coelicolor A3(2) 70/76 RNase H/acid phosphatase 
orf4 223 SCO2298, S. coelicolor A3(2) 80/88 KHG/KDPG aldolase 
orf5 261 SCO2297, S. coelicolor A3(2) 87/92 hypothetical protein 
orf6 478 SAV5880, S. avermitilis MA4680 79/85 ribonuclease R 
orf7 208 SCO2296, S. coelicolor A3(2) 62/70 integral membrane protein 
orf8 250 SCO2295, S. coelicolor A3(2) 66/75 transcriptional regulator 
orf9 275 SCO2294, S. coelicolor A3(2) 81/87 transcriptional regulator 
orf10 310 SCO2293, Streptomyces coelicolor A3(2) 80/87 integral membrane protein 
orf11 173 RHA1_ro01178, Rhodococcus jostii RHA1 31/36 hypothetical protein 
lipA[c] 391 hmgs , S. anulatus 70/79 HMG-CoA synthase 
lipB 413 MkanA1_04597, Mycobacterium kansasii 36/51 sulfotransferase 
lipC 246 Mpop_3269, Methylobacterium populi 23/38 hypothetical protein 
lipD 350 SaRppA, S. antibioticus 30/45 type III pks 
lipE 260 Francci3_1340, Frankia sp. CcI3 56/65 PAPS 3’phosphatase 
lipF 212 gll2605, Gleobacter violaceus PCC7421 41/56 hypothetical protein 
lipG 336 Cpz9, Streptomyces sp. MK730-62F2 65/75 transcriptional regulator 
lipH 173 Cpz10, Streptomyces sp. MK730-62F2 82/88 β-hydroxylase 
lipI 213 Cpz11, Streptomyces sp. MK730-62F2 76/84 methyltransferase 
lipJ 185 Cpz12, Streptomyces sp. MK730-62F2 71/80 kinase 
lipK 443 Cpz13, Streptomyces sp. MK730-62F2 80/86 aminotransferase 
lipL 424 Cpz14, Streptomyces sp. MK730-62F2 87/91 hydroxymethyltransferase 
lipM 276 Cpz15, Streptomyces sp. MK730-62F2 82/90 dioxygenase 
lipN 233 Cpz16, Streptomyces sp. MK730-62F2 81/91 nucleotidyltransferase 
lipO 377 Cpz17, Streptomyces sp. MK730-62F2 81/87 glycosyltransferase 
lipP 424 Cpz18, Streptomyces sp. MK730-62F2 82/88 aminotransferase 
lipQ 457 Cpz19, Streptomyces sp. MK730-62F2 82/88 pyrimidine phosphorylase 
lipR 354 Cpz20, Streptomyces sp. MK730-62F2 88/91 acyl-CoA synthase 
lipS 495 Cpz21, Streptomyces sp. MK730-62F2 83/88 carboxyesterase 
lipT 1237 Cpz22, Streptomyces sp. MK730-62F2 78/85 ABC transporter 
lipU 344 Cpz23, Streptomyces sp. MK730-62F2 83/93 lipase 
lipV 599 Cpz24, Streptomyces sp. MK730-62F2 70/80 hypothetical protein 
lipW 342 Cpz25, Streptomyces sp. MK730-62F2 90/95 dehydrogenase 
lipX 417 Cpz26, Streptomyces sp. MK730-62F2 75/84 methyltransferase 
lipY 185 Cpz27, Streptomyces sp. MK730-62F2 70/79 kinase 
orf12 207 StAA4_29435, Streptomyces sp. AA4 61/71 hypothetical protein 
orf13 399 SSDG_03666, S. pristinaespiralis 25486 45/61 Ser/Thr protein kinase 
orf14 997 FRAAL6332, Frankia alni ACN14a 46/59 DNA/RNA helicase 
[a]  Overall homology [%] 
[b]  Gene lacks an appropriate stop codon and is considered to be uncomplete on cosmid 3G5 
[c]  Bold genes proposed to be essential for liposidomycin production  
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The characteristic feature of the liposidomycins is the sulfate group at the 2’’-OH of 
the aminoribose. The deduced gene product LipE shows high homology to 3’-
phosphoadenosine 5’-phosphosulfate (PAPS) 3’-phosphatases in the database 
(56%/64%; identity/similarity). This family of enzymes is predicted to take part in the 
regulation of the intracellular level of PAPS, which is the most important sulfate donor 
in sulfation reactions. Proteins involved in the metabolism of PAPS are encoded in 
other gene clusters of sulfated natural products, e.g. cylindrospermopsin (Mihali et 
al., 2008) and saxitoxin (Kellmann et al., 2008). Translationally coupled to the lipE 
gene is lipD, a putative type III pks gene, and lipF encoding for a hypothetical protein 
with unknown function. The gene product of lipB is similar to several conserved 
hypothetical proteins from bacteria and fungi with unknown function. 
Notably, a LipB-homolog from Thermobaculum terrenum is annotated as an 
arylsulfotransferase due to the presence of a corresponding conserved domain 
(pfam05935). Therefore, we propose that the region lipA-F, including the genes for a 
PAPS-phosphatase and a potential sulfotransferase is responsible for the supply and 
incorporation of the sulfate group in liposidomycin biosynthesis. Surprisingly, similar 
genes can also be found upstream of cpz9, adjacent to the caprazamycin gene 
cluster (Figure III.5.1). The genes lipD-F show 82%, 80% and 83% sequence identity 
to cpz6-8, respectively. In addition, homology is observable for the putative HMG-
CoA synthases LipA and Cpz5 (81%/89% identity/similarity) and to a lesser extend 
for the hypothetical proteins LipB and Cpz4 (32%/50% identity/similarity). 
5.3. Heterologous expression of the liposidomycin gene cluster 
In order to verify that the identified genes were sufficient for the biosynthesis of 
liposidomycins, we prepared the cosmid 3G5 for heterologous expression. For this 
purpose, the beta-lactamase (bla) gene on the backbone of 3G5 was replaced with 
an integration cassette of pIJ787 containing the attP attachment site and the 
integrase gene (int) of phage ΦC31, a tetracycline resistance gene (tet) and an origin 
of transfer (oriT) using Red/ET-mediated recombination (Gust et al., 2003). The 
generated cosmid lipLK01 was introduced into S. coelicolor M512 by triparental 
intergeneric conjugation and three kanamycin resistance clones were selected. 
Extracts of cultures from S. coelicolor M512 and the mutant strains were applied to 
HPLC and ESI-MS/MS analysis. 
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Figure III.5.2 HPLC chromatograms of n-butanolic extracts from A the liposidomycin (LPM) producer 
strain Streptomyces sp. SN-1061M B S. coelicolor M512 C S. coelicolor M512 containing the LPM 
gene cluster lipLK01 D S. coelicolor M512 containing the caprazamycin gene cluster cpzLK09 E S. 
coelicolor M512 containing the caprazamycin gene cluster cpzWP07, lacking the flanking genes 
cpz1-8 and F the caprazamycin (CPZ) producer Streptomyces sp. MK730-62F2. The different LPMs 
in A, C and D have been assigned by LC-ESI-MS/MS and are indicated by black arrows and bold 
letters. The black arrows in F indicate the identified sulfo-CPZs E/F (1), C/D/G (2) and A/B (3). 
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In UV-chromatograms of S. coelicolor M512/lipLK01 extracts (Figure III.5.2C) four 
prominent peaks at Rt = 22.4 min, Rt = 24.7 min, Rt = 26.8 min and Rt = 30.0 min 
appeared which could not be found in extracts of S. coelicolor M512 without the 
liposidomycin cluster (Figure III.5.2B). Mass peaks for known liposidomycins with 
corresponding retention times were observed in product ion chromatograms; for 
liposidomycin X with m/z 996.5 [M+H]+ at Rt = 22.7 min, for liposidomycin B and C 
with m/z 1010.5 [M+H]+ at Rt = 25.0 min, for liposidomycin H with m/z 1024.5 [M+H]+ 
at Rt = 27.1 min and for liposidomycin L and M with m/z 1038.5 [M+H]+ at Rt = 30.3 
min. Characteristic fragmentation patterns were observed by collision-induced 
dissociation of the sulfate-group, aminoribose, uracil and fatty acid group as 
published for FAB-MS (Ubukata et al., 1992). Similar fragmentations have been 
shown for the caprazamycins in section III.1. For further evidence, extracts of the 
genuine liposidomycin producer Streptomyces sp. SN-1061M were analysed by LC-
ESI-MS/MS. In UV-chromatograms, the wildtype strain produced several peaks 
which represent the liposidomycins Z, A, B, C, G, K, L and M (Figure III.5.2A). 
Product ion scans clearly detected liposidomycins X, B/C, H and L/M and the 
fragmentation patterns matched exactly the liposidomycins found in the heterologous 
producer. In summary, the analytical data proves that S. coelicolor M512 containing 
lipLK01 produces liposidomycins which confirms the identification of the 
liposidomycin gene cluster. 
5.4. Identification of new sulfated caprazamycin derivatives 
Postulating that the genes lipA-F confer to the capability of a sulfotransfer reaction, 
the same should apply to the cpz4-8 genes flanking the caprazamycin cluster. In 
order to verify this assumption, we carefully reinvestigated S. coelicolor M512 
containing the caprazamycin gene cluster and the genuine producer Streptomyces 
sp. MK730-62F2 for the accumulation of sulfated caprazamycin derivatives. And 
indeed, HPLC-chromatograms of extracts from S. coelicolor M512/cpzLK09, showed 
peaks at similar retention times as the liposidomycins at 24.2 min, 26.3 min and 29.3 
min (Figure III.5.2D). The extracts were further analyzed by LC-ESI-MS/MS to 
confirm the identity of the new compounds. Ions with m/z 1010.5 [M+H]+ at Rt = 24.4 
min, m/z 1024.5 [M+H]+ at Rt = 26.5 min and m/z 1038.5 [M+H]+ at Rt = 29.6 min in 
product ion chromatograms matched the liposidomycins B/C, H and L/M. CID 
fragmentation in positive mode was characteristic for the liposidomycins, with the 
initial loss of the sulfate group (80 Da). For precursor ion with m/z 1010.5 [M+H]+ 
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fragments with m/z 931, m/z 800 and m/z 687 were detected which presumably 
derive from acylated fragments (Figure III.5.3A).  
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Figure III.5.3 Mass spectrometric fragmentation pattern for collision-induced dissociation experiments 
in positive and negative mode. A LPM B/C from S. coelicolor M512/cpzLK09 and B sulfo-CPZ E/F 
from Streptomyces sp. MK730-62F2. Suggested fragmentation schemes are depicted for LPM C and 
its glycosylated derivative sulfo-CPZ E. 
 
Molecular ions with m/z 427 and m/z 315 were assigned to components of the 
caprazol structure. The observed CID fragmentation pattern of these new 
compounds matched perfectly to the liposidomycins produced by the heterologous 
host S. coelicolor M512/lipLK01. Using the same extracts, product ion scans in 
negative mode provided additional evidence (Figure III.5.3A). Dissociation of 
precursor ion with m/z 1008.5 [M-H]- (LPM B/C) gave ions with m/z 243 and m/z 371 
which probably represent the acyl part, ions with m/z 556, m/z 592 and m/z 636 for 
the caprazol core structure and with m/z 929, the desulfated (-80 Da) compound. The 
identification of liposidomycins in the culture broth of a strain expressing the 
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caprazamycin gene cluster shows, that enzymes for a sulfation reaction have to be 
encoded on both cosmids, cpzLK09 and lipLK01. We analyzed another mutant strain, 
S. coelicolor M512/cpzWP07, which contains an intact gene cluster for the production 
of the caprazamycin aglycones but additionally possesses a functional knock-out of 
the genes cpz1-8 . Peaks for liposidomycins could be found neither in HPLC (Figure 
III.5.2E) nor in LC-ESI-MS analysis. This proves that the homologous genetic regions 
lipA-F and cpz4-8 are involved in an enzymatic mechanism for the sulfation of 
liponucleoside antibiotics. 
Our findings prompted us to search for sulfated caprazamycin derivatives in the 
wildtype strain Streptomyces sp. MK730-62F2. Product ion scans revealed prominent 
mass peaks with m/z 1198.5 [M+H]+ (Rt. 29.4 min; CPZ E/F + 80 Da), m/z 1212.5 
[M+H]+ (Rt. 31.6 min; CPZ C/D/G + 80 Da) and m/z 1226.5 [M+H]+ (34.7 min; CPZ 
A/B + 80 Da) in extracts from the caprazamycin producer strain. Analogous peaks 
were found with m/z 1196.5 [M-H]-, m/z 1210.5 [M-H]- and m/z 1224.5 [M-H]- in 
negative mode. Positive CID of the new substances was similar to the caprazamycin 
as shown in section III.1. Precursor ion m/z 1198.5 [M+H]+ produced fragments with 
m/z 189, m/z 320, m/z 427, m/z 558, m/z 687, m/z 800, m/z 931, m/z 1011 and m/z 
1119 (Figure III.5.3B) displaying the loss of the rhamnosyl-moiety, the aminoribose, 
the uracil, the lipid components and a sulfate group. In negative mode (Figure 
III.5.3B), fragmentation of precursor ion with m/z 1196.5 [M-H]- resulted in ions with 
m/z 333 and m/z 559 which possibly represent the glycosylated acyl part of the 
substance, in fragment ions with m/z 592 and m/z 636, the sulfated caprazol core 
structure and with m/z 1117, the desulfated (-80 Da) compound. Though the position 
of the sulfate group is still unclear, a comparison of the ions m/z 363, m/z 592 and 
m/z 636 indicate that the sulfate is bound to the aminoribosyl moiety similar to the 
liposidomycins. The prominent fragment m/z 363 matches well with a caprazol 
substructure (592 Da) lacking the sulfated aminoribose. Therefore we propose that 
the substances identified in the extract of the caprazamycin producer Streptomyces 
sp. MK730-62F2 (Figure III.5.F) are indeed sulfated caprazamycins, which so far 
have not been described. 
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6. Characterization of Cpz4 as a novel arylsulfate 
sulfotransferase 
This part of the thesis was carried out in collaboration with Diploma student Kornelia 
Eitel. Sulfation describes the transfer of a sulfate group onto an acceptor molecule. 
The responsible enzymes, the sulfotransferases, participate in different processes 
such as intracellular signaling, extracellular interaction and detoxification of 
xenobiotics (Chapman et al., 2004). Sulfotransferases have been extensively studied 
in humans and other mammals and are usually classified in the membrane 
associated and the cytosolic type. In contrast, little is known about bacterial 
sulfotransferases. Recent reports suggested their function as important modulators of 
e.g. plant host interaction in Sinorhizobium meliloti (Cronan & Keating, 2004) and 
virulence in Mycobacterium tuberculosis (Goren et al., 1974). Several sulfated 
bioactive compounds were isolated from microorganisms over the last decades, 
including the micafungin precursor FK463, (Iwamoto et al., 1994), the cyanobacterial 
toxin cylindrospermopsin (Harada et al., 1994) and the liponucleoside antibiotic 
liposidomycins (Isono et al., 1985). Though, in bacterial secondary metabolism only 
few sulfotransferases have been studied in vitro. StaL, involved in the biosynthesis of 
the glycopeptide A47934, catalyzes the transfer of a sulfate group from 3’-
phosphoadenosin 5’-phosphosulfate (PAPS) onto the acceptor substrate (Lamb et 
al., 2006; Shi et al., 2007). Another PAPS-dependent sulfotransfer reaction has been 
investigated in curacin biosynthesis (Gu et al., 2009). 
The vast majority of known sulfotransferases from eukaryotes and prokaryotes uses 
PAPS as the sulfate donor substrate. However, a small class of microbial 
sulfotransferases is PAPS-independent and transfers a sulfate group from an 
aromatic donor to an aromatic acceptor molecule. These enzymes were termed 
arylsulfate sulfotransferases (ASSTs). The reaction of ASSTs proceeds by a ping 
pong bi-bi mechanism with a covalent modification of the enzyme by the sulfation of 
an active site histidine (Malojcic et al., 2008). In vitro studies of eight arylsulfate 
sulfotransferases (ASSTs) have been published from bacteria (Baek et al., 1996; 
Kang et al., 2001a; Kang et al., 2001b; Kim et al., 2007; Konishi-Imamura et al., 
1994; Kwon et al., 1999; Kwon et al., 2001; Malojcic et al., 2008), but for all of them 
their precise physiological role is yet unknown. 
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6.1. Analysis of the Δcpz1-3 and the Δcpz1-4 deletion mutants 
In the last section I showed that the heterologous host strain S. coelicolor M512 
harbouring the entire caprazamycin gene cluster not only produces the caprazamycin 
aglycones but also sulfated derivatives thereof i.e. the liposidomycins. In our search 
for the gene, which might be responsible for the sulfation reaction, we focused on 
cpz4 (GenBank accession number GU323955) located 4.2 kb upstream of the gene 
cluster. Cpz4 exhibits significant sequence homology to a large number of 
hypothetical proteins from bacteria and fungi. A conserved protein domain 
(Pfam05935) was found, characteristic for the arylsulfate sulfotransferases (ASSTs) 
(Baek et al., 1996). Overall, the known ASSTs show only low sequence similarity to 
Cpz4 e.g. 26% in the case of the ASST from E.coli CFT073 (Malojcic et al., 2008). In 
order to investigate the role of cpz4 we compared the previously generated deletion 
mutant S. coelicolor M512/cpzWP05 (Δcpz1-4) with mutant S. coelicolor 
M512/cpzWP04 (Δcpz1-3). Culture extracts of both mutants were applied to LC-ESI-
MS/MS and analyzed for the presence of liposidomycins. As expected, the 
caprazamycin aglycones were accumulated by both mutants (Figure III.6.1). 
However, the sulfated liposidomycins (LPM E/F with m/z 1010.5 [M+H]+ at Rt. 24.4 
min, LPM C/D/G with m/z 1024.5 [M+H]+ at Rt. 26.5 min, LPM A/B with m/z 1038.5 
[M+H]+ at Rt. 29.6 min) could only be identified in the mutant containing an intact 
copy of the cpz4 gene as demonstrated by HPLC-UV and HPLC-MS analysis (Figure 
III.6.1). This result proves that Cpz4 is essential for the sulfation of caprazamycin 
aglycones. 
A homolog of Cpz4 was also found in the liposidomycin gene cluster of Streptomyces 
sp. SN-1061M. lpmB is located at one end of the cluster and its gene product shows 
32% identity and 50% similarity to the central 300 amino acids of Cpz4. Notably, 
LpmB (412 aa) lacks 101 amino acids which form the C-terminus of Cpz4 (513 aa). It 
appears likely that lpmB has a similar function as Cpz4 in liposidomycin biosynthesis 
though a conserved protein domain such as Pfam05935 could not been identified. 
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Figure III.6.1 HPLC-UV and HPLC-MS analysis of n-butanolic extracts from a cpz4 mutant strain. A 
UV-chromatogram of an extract from S. coelicolor M512/cpzWP04 containing a derivative of cosmid 
cpzLK09 in which the genes cpz1-cpz3 are deleted and B the respective product ion chromatograms. 
C UV-chromatogram of an extract from S. coelicolor M512/cpzWP05 containing a derivative of cosmid 
cpzLK09 in which the genes cpz1-cpz4 are deleted and D the respective product ion chromatograms. 
UV-absorption was monitored at 262 nm. Product ion chromatograms were obtained from (+)-ESI-MS 
mass scans for CPZ E/F aglycones with m/z 930.5 [M+H]+, CPZ C/D/G aglycones with m/z 944.5 
[M+H]+, CPZ A/B aglycones with m/z 958.5 [M+H]+ and for their corresponding sulfated derivatives 
LPM E/F with m/z 1010.5 [M+H]+, LPM C/D/G with m/z 1024.5 [M+H]+, LPM A/B with m/z 1038.5 
[M+H]+. LPM (liposidomycins); CPZ (caprazamycin). 
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6.2. Expression and purification of Cpz4 
For the biochemical investigation of the potential sulfotransferases, cpz4 and lpmB 
were cloned into a vector for the expression as N-terminal His-tagged proteins and 
introduced into E. coli Rosetta2™ (DE3)pLys. Induction with IPTG led to the 
production of a protein with ~57.7 kDa matching the calculated molecular mass of 
His8-Cpz4 (57.626 kDa). However, LpmB could not be obtained as a soluble protein. 
Hence, we proceeded with Cpz4 alone. Ni2+ affinity chromatography and subsequent 
gel chromatography resulted in 25 mg of protein from 2 L of culture, showing 
approximately 95% purity in SDS-PAGE. This protein was used for further 
biochemical studies.  
6.3. Analysis of Cpz4 as an arylsulfate sulfotransferase 
 
Figure III.6.2 LC-ESI-MS/MS analysis of sulfotransferase assays with Cpz4 using phenol as sulfate 
acceptor and either pNS (p-nitrophenol sulfate) or MUS (methylumbelliferone sulfate) as sulfate donor 
substrates (see also diploma thesis of Kornelia Eitel). A TIC (total ion current)-chromatograms. B MS2 
spectrum of the enzymatic reaction product phenolsulfate with m/z 173 [M-H]- at Rt. 18.4 min from the 
assay with Cpz4, phenol and pNS. 
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Identification of a conserved protein domain typical for ASSTs suggested that Cpz4 
may catalyze a PAPS-independent sulfation reaction. Accordingly, Cpz4 was 
incubated with either p-nitrophenol sulfate (pNS) or methylumbelliferone sulfate 
(MUS) as sulfate donor substrates and phenol as an acceptor substrate. Product 
formation was monitored by LC-ESI-MS/MS analysis. In the total ion current (TIC) 
chromatograms a peak appeared at ~18.3 min both in assays with pNS and in 
assays with MUS as donor substrate (Figure III.6.2A). The formation of this product 
was dependent on the presence of active Cpz4. The mass spectrometric data of the 
new compound (Figure III.6.2B) corresponded to the expected product phenolsulfate 
with m/z 173 [M-H]- and MS2 fragments with m/z 93 (phenol) and m/z 80 (sulfate). 
These experiments showed that Cpz4 can act as an arylsulfate sulfotransferase. 
6.4. Biochemical properties of Cpz4 
The biochemical properties of Cpz4 were determined with pNS as the sulfate donor 
and phenol as the acceptor substrate. Reaction velocities were photometrically 
measured at 405 nm, the absorption maximum for the product p-nitrophenol (pN). 
The aryl sulfotransfer reaction was strictly dependent on the presence of active Cpz4 
and pNS. However, a low formation of pN was detected in assays without phenol, 
indicating a certain sulfatase activity of Cpz4. Therefore, hydrolysis of pNS was 
monitored in parallel assays without phenol and the amount subtracted from the 
initial results for all subsequent experiments. The reaction (as described in section 
II.7.4) showed a linear dependency on the amount of Cpz4 (up to 250 nM) and the 
incubation time (up to 90 min). In the absence of NaCl pH values ≤7.0 resulted in 
precipitation of the protein in the assay. Inclusion of 1 M NaCl prevented precipitation 
and allowed to assay the protein in a range from pH 4.0 to pH 11.0. Maximal activity 
was observed at pH 6.7 with half-maximal values at pH 5.0 and pH 7.6. Low 
concentrations of Mg2+ (1 mM, 5 mM, 10 mM) had no significant effect on the 
reaction velocity. The presence of 20 mM Mg2+ or 2 mM Ni2+ in the assay led to 
precipitation of the protein. Notably, addition of 0.1 mM EDTA increased product 
formation of Cpz4 by 2.5-fold and was therefore routinely included in the assay.  
6.5. Influence of inhibitors on Cpz4 activity 
While PAPS-dependent sulfotransferases follow a sequential mechanism, the ASSTs 
e.g. from Eubacterium A-44 (Kim & Kobashi, 1991) and from E. coli CFT073 
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(Malojcic et al., 2008) have been shown to react by a ping-pong bi-bi mechanism with 
sulfation of an active site residue of the enzyme. Until recently it had been assumed 
that the sulfate is transferred first to a histidine residue and subsequently to a 
tyrosine residue (Chapman et al., 2004). However, (Malojcic et al., 2008) could only 
show the formation of a sulfohistidine in the E. coli ASST. Specific inhibitors were 
added to assays containing Cpz4, pNS and phenol. In the presence of 1 mM PMSF, 
which targets nucleophilic hydroxy groups, the turnover of pNS by Cpz4 was not 
affected. In contrast, addition of 3 mM of diethylpyrocarbonate (DEPC), which 
specifically modifies histidine side chains (Sambrook & Russell, 2001), led to a ~90% 
decrease of the activity. These findings indicate that one or more histidine residues 
are essentially involved in the catalysis of the reaction.  
6.6. Site-directed mutagenesis 
A multiple sequence alignment of characterized and putative ASSTs including Cpz4 
revealed three highly conserved histidine residues i.e. His180, His253 and His308. 
The corresponding histidine residues in the ASST from E. coli CFT073 were reported 
to be essential for the catalysis of the sulfotransfer reaction (Malojcic et al., 2008). In 
this enzyme, the sulfate group is covalently bound to His436 and further stabilized by 
His252 and His356. Consequently, each of these histidines was replaced with 
leucine in Cpz4 by site-directed mutagenesis. Heterologous production of the mutant 
enzymes as His-tagged proteins and subsequent purification led to 17.4 mg 
(His180Leu), 1 mg (His253Leu) and 6.2 mg (His308Leu) of soluble protein from 1 L 
cultures. Activities of all three mutant enzymes against pNS and phenol were 
reduced to ≤5% in comparison to the wildtype enzyme. On the basis of these findings 
and the results obtained from the addition of specific inhibitors, we would assume a 
catalytic role of the histidines in Cpz4 similar to the ASST from E. coli CFT073.  
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6.7. Kinetic analysis of Cpz4 
Figure III.6.3 Kinetic analysis of the Cpz4-catalyzed sulfate transfer reaction from the aromatic donor 
substrates pNS and MUS to phenol (see also diploma thesis of Kornelia Eitel). A Double reciprocal 
plot of reaction velocities, obtained with pNS and phenol, over pNS concentration (27 µM, 54 µM, 108 
µM, 189 µM, 270 µM pNS). Partial regression of velocities from data sets with fixed initial 
concentrations of phenol (13 mM (Δ), 26 mM (), 39 mM (O) and 52 mM (▼)) shows parallel lines 
indicating a ping pong kinetic. B Double reciprocal plot of reaction velocities, obtained with pNS and 
phenol, over phenol concentration (13 mM, 26 mM, 39 mM, 52 mM, 75 mM, 100 mM and 160 mM 
phenol). Partial regression of velocities from data sets with fixed initial concentrations of pNS (27 µM 
(■), 54 µM (Δ), 108 µM (), 189 µM (O), 270 µM (▼)) shows parallel lines up to a phenol 
concentration of ~50 mM. C Initial velocities with pNS at initial fixed concentrations of 27 µM (Δ), 54 
µM (), 108 µM (▲), 189 µM (O), 270 µM (■) over phenol (0 mM, 6.5 mM, 13 mM, 26 mM, 39 mM, 52 
mM, 75 mM, 100 mM and 130 mM). This data set was globally fitted (see section II.7.4) to obtain the 
depicted kinetic parameters for Cpz4 with pNS and phenol as substrates. D Initial velocities with MUS 
at initial fixed concentrations of 25 µM (), 50 µM (Δ),75 µM (●), 100 µM (), 150 µM (■), 200 µM (▲), 
250 µM (Δ), 300 µM (O), 350 µM (—), 450 µM (▼) and 550 µM () over phenol (12.5 mM, 20 mM, 36 
mM, 60 mM, 70 mM, 100 mM, 130 mM and 160 mM). This data set was globally fitted (see section 
II.7.4) to obtain the depicted kinetic parameters for Cpz4 with MUS and phenol as substrates. Spotted 
lines in C and D indicate linear dependency of the reaction velocities and phenol concentration on low 
phenol concentrations. 
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Applying a constant concentration of phenol (75 mM) and varying concentrations of 
pNS, a plot of product formation over substrate concentration gave a hyperbolic 
curve, as expected for Michaelis-Menten kinetics. Using different concentrations of 
phenol with 25µM of PNS, the reaction velocities increased up to a phenol 
concentration of 75 mM and thereafter declined, indicating substrate inhibition. In 
order to investigate the reaction mechanism, Cpz4 was incubated with different fixed 
concentrations of phenol (13 mM, 26 mM, 39 mM and 52 mM) and various 
concentrations of pNS. Double reciprocal plots of initial velocities over pNS 
concentrations resulted in a series of parallel lines (Figure III.6.3A), characteristic for 
ping-pong kinetics (Cleland, 1963). Increasing concentrations of phenol lead to a 
proportional increase of Vmax and Km. When the intercepts of the lines (1/Vmax) were 
plotted against the corresponding phenol concentrations (1/cphenol), a linear relation 
was observed (Figure III.6.4A).  
 
20 40 60 80
2 e8
4 e8
MUS25µM
MUS50µM
MUS75µM
MUS150µM
MUS450µM
6 e8
1/cPhenol [M-1]
1/
v
[M
-1
s]
20 40 60 80
4 e7
8 e7
1.2 e8
1.6 e8
2.0 e8
1/
V m
ax
[M
-1
s]
1/cphenol [M-1]
A B
1/
v
[M
-1
s]
1/
v
[M
-1
s]
1/
V m
ax
[M
-1
s]
1/
V m
ax
[M
-1
s]
1/
V m
ax
[M
-1
s]
Figure III.6.4 Kinetic analysis of the Cpz4-catalyzed sulfate transfer reaction from aromatic donor 
substrates pNS and MUS to phenol (see also diploma thesis of Kornelia Eitel). A Double reciprocal 
plot of maximal reaction velocities with pNS and phenol (obtained from Figure 4) over initial fixed 
phenol concentration (13 mM, 26 mM, 39 mM, 52 mM). B Double reciprocal plot of reaction velocities 
with MUS and phenol over phenol concentration (12.5 mM, 20 mM, 36 mM, 60 mM, 70 mM, 100 mM, 
130 mM and 160 mM). Partial regression of velocities from data sets with fixed initial concentrations of 
MUS (25 – 450 µM) shows parallel lines up to a phenol concentration of ~40 mM. 
 
A similar set of assays using different fixed pNS concentration (27 µM, 54 µM, 108 
µM, 189 µM, 270 µM) and various phenol concentrations was performed. Again, the 
double reciprocal plot shows a series of parallel lines but only up to a phenol 
concentration of ~50 mM (Figure III.6.3B). At higher phenol concentrations the curves 
rise asymptotic towards the y axis, a manifestation of substrate inhibition by phenol 
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(Goldstein, 1944). Another series of assays with various concentrations of both 
substrates phenol and pNS was performed to determine the kinetic constants of the 
reaction. A global fit of the data plotted in Figure III.6.3C (as described in section 
II.7.4) resulted in the following parameters: Vmax 19.8 nM s-1, Km,pNS 48.1 µM, Km,phenol 
25.9 mM and Ki,phenol 46.1 mM. kcat was determined as 0.14 s-1.  
A similar approach was initiated using MUS as the sulfate donor substrate. 
Conversion of MUS was determined by measuring fluorescence at 460 nm and an 
excitation wavelength of 360 nm. The reaction showed linear dependence on the 
amount of active Cpz4 (up to 200 nM) and the incubation time (up to 25 min). The 
reaction was dependent on the presence of MUS and phenol. No sulfatase activity 
could be observed in a control without phenol. A dataset was generated applying 
various phenol concentrations (12.5 mM - 160 mM) against constant initial MUS 
concentrations in a range from 25 µM to 550 µM (Figure III.6.3D). Double reciprocal 
plotting of the reaction velocities over substrate concentration confirmed the ping 
pong bi-bi kinetics with substrate inhibition of phenol as observed with pNS as the 
sulfate donor (Figure III.6.4B).  
Kinetic parameters were calculated as Vmax 15.3 nM s-1, Km,MUS 34.5 µM, Km,phenol 
29.7 mM and Ki,phenol 41.7 mM. kcat was determined as 0.15 s-1. 
The Km values for pNS (48.1 µM) and MUS (34.5 µM) are similar to the Km for MUS 
published for the ASST from E. coli CFT073 i.e. 44.5 µM (Malojcic et al., 2008). 
However, catalytic efficiency for phenol (kcat/Km) is low at 5.5 M s-1 and 5.1 M s-1 as 
may be expected for an artificial substrate. 
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6.8. Sulfation of caprazamycin derivatives extracted from bacterial 
cultures 
 
Figure III.6.5 HPLC-UV and HPLC-MS analysis of Cpz4-catalyzed sulfation using different 
liponucleoside derivatives, isolated from cultures of mutant strains, as acceptor substrates (see also 
diploma thesis of Kornelia Eitel). A Formation of liposidomycins from partially purified caprazamycin 
aglycones as substrates and pNS as sulfate donor in HPLC-UV chromatograms and B product ion 
chromatograms. (-)-ESI-MS mass scans for the substrates caprazamycin E/F aglycones with m/z 
928.5 [M-H]-, caprazamycin (CPZ) C/D/G aglycones with m/z 942.5 [M-H]-, caprazamycin A/B 
aglycones with m/z 956.5 [M-H]- and for the products liposidomycins (LPMs) E/F with m/z 1008.5 [M-
H]-, liposidomycins C/D/G with m/z 1022.5 [M-H]-, liposidomycins A/B with m/z 1036.5 [M-H]- are 
depicted. Signal intensity was adjusted to 1.6 108 for all experiments. C Formation of sulfo-
caprazamycins from partially purified caprazamycins as substrates and pNS as sulfate donor in 
HPLC-UV chromatograms and D product ion chromatograms. (-)-ESI-MS mass scans for the 
substrates caprazamycins (CPZs) E/F with m/z 1116.5 [M-H]-, caprazamycins C/D/G with m/z 1130.5 
[M-H]-, caprazamycins A/B with m/z 1144.5 [M-H]- and for the products sulfo-caprazamycins E/F with 
m/z 1196.5 [M-H]-, sulfo-caprazamycins C/D/G with m/z 1210.5 [M-H]-and sulfo-caprazamycins A/B 
with m/z 1224.5 [M-H]- are depicted. Signal intensity was adjusted to 3 107 for all experiments. 
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In order to investigate the role of Cpz4 in the sulfation of liponucleosides, 
caprazamycin aglycones were partially purified and tested as possible substrates. 
Extracts from S. coelicolor M512/cpzWP05 which does not produce the sulfated 
liposidomycins were incubated with Cpz4 and pNS. In a second experiment, pNS 
was replaced by PAPS to test the sulfate donor specificity of Cpz4. The conversion of 
the caprazamycin aglcones was observed with pNS in HPLC-UV chromatograms 
resulting in product peaks at Rt. 23.9 min, 25.9 min and 28.8 min (Figure III.6.5A). 
The new compounds were determined as liposidomycins (LPM E/F with m/z 1008.5 
[M-H]- at Rt. 24.2 min, LPM C/D/G with m/z 1022.5 [M-H]- at Rt. 26.1 min, LPM A/B 
with m/z 1036.5 [M-H]- at Rt. 29.1 min) by LC-ESI-MS analysis (Figure III.6.5B). MS2 
fragmentation patterns matched exactly the liposidomycins from the original producer 
Streptomyces sp. SN-1061M. In the structure of liposidomycins the sulfate group is 
attached to the aminoribosyl moiety. Our results indicate a similar position in the 
Cpz4 product molecule. No liposidomycins could be identified in HPLC-UV 
chromatograms of assays containing PAPS as the donor substrate. However, traces 
of liposidomycins could be detected by ESI-MS product ion scans in control assays 
with Cpz4 lacking pNS or PAPS but not in assays without Cpz4. A similar 
phenomenon has been observed by Malojcic et al. (Malojcic et al., 2008) for the 
ASST from E. coli CFT073 and may indicate a covalently bound sulfate in the Cpz4 
active site.  
Thus, we conclude that Cpz4 is responsible for a PAPS-independent sulfate transfer 
reaction in liponucleoside biosynthesis. In contrast to the previously reported ASST 
reactions Cpz4 uses a glycosidic instead of an aromatic acceptor substrate. 
Additionally, we tested whether Cpz4 sulfates intact caprazamycins and hydroxyacyl-
caprazols. These compounds were extracted from S. coelicolor M512/cpzEW07 and 
S. coelicolor M512/cpzLL06, partially purified and assayed with pNS and Cpz4. Note 
that in both extracts some sulfated derivatives are already present. However, after 
incubation with Cpz4 a substantial increase of the sulfo-caprazamycins at Rt. 28.5 
min, 30.8 min and 34.1 min was observed in HPLC-UV chromatograms (Figure 
III.6.5C). The identity of the products was confirmed by ESI-MS mass scans for sulfo-
caprazamycins E/F with m/z 1196.5 [M-H]- (Rt. 28.7 min), C/D/G with m/z 1210.5 [M-
H]- (Rt. 31.1 min) and A/B with m/z 1224.5 [M-H]- (Rt. 34.3 min). 
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Figure III.6.6 Cpz4-catalyzed sulfation of hydroxyacyl caprazols from culture extracts with pNS as 
sulfate donor analysed by LC-ESI-MS (see also diploma thesis of Kornelia Eitel). A HPLC-UV 
chromatograms before and after the formation of hydroxyacyl sulfo-caprazols from partially purified 
hydroxyacyl caprazols (Fig. 1, 4) as substrates and pNS as sulfate donor. B Respective product ion 
chromatograms obtained from (-)-ESI-MS mass scans for the substrates hydroxyacyl caprazols E/F 
with m/z 800.5 [M-H]-and hydroxyacyl caprazols C/D/G with m/z 814.5 [M-H]-. Product formation was 
determined by mass scans for hydroxyacyl sulfo-caprazols E/F with m/z 880.5 [M-H]- and hydroxyacyl 
sulfo-caprazols C/D/G with m/z 894.5 [M-H]-. Signal intensity was adjusted to 3 107 for all experiments. 
 
Similarly, product formation was found for Cpz4 and the hydroxyacyl-caprazols as 
substrates (Figure III.6.6). These findings suggest that Cpz4 is promiscuous in regard 
to the liponucleoside acceptor substrate.  
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6.9. Activity of Cpz4 with synthetic liponucleoside precursor 
Figure III.6.7 Activity of Cpz4 with synthetic liponucleoside precursor and phenol as sulfate acceptor 
substrates (see also diploma thesis of Kornelia Eitel). A Conversion of pNS [%] with the different 
substrates (1 - 6 and phenol) is noted above the respective bars. Concentrations of pNS and acceptor 
substrates were 500 µM and 200µM respectively. B MS2 spectrum of the product 1a (m/z 878.4 [M-
H]-, Rt. 26.2 min) formed by Cpz4 from compound 1 and pNS. The proposed fragmentation scheme 
for 1a is depicted. C MS2 spectrum of the product 2a (m/z 694.4 [M-H]-, Rt. 35.1 min) formed by Cpz4 
from compound 2 and pNS. The proposed fragmentation scheme for 2a is depicted. 
 
Several structural precursor of liponucleosides (Figure III.6.7A) were synthesized as 
described in (Kaysser et al., 2010). They were investigated as substrates for Cpz4 
and compared to phenol in a photometric assay. All acceptor substrates were used in 
a concentration of 0.2 mM. Conversion (%) of pNS (300 µM) was very low for 
compounds 4 (0.28%), 5 (0.16%), 6 (0.10%) and phenol (0.15%) (Figure III.6.7A). A 
higher turnover of 0.59% was observed with caprazol (compound 3) a putative 
intermediate in liponucleoside biosynthesis. Notably the acylated compounds 2 and 
1, were sulfated by Cpz4 with 10-fold (1.82%) and 100-fold (23.2%) higher 
conversion rates than phenol. This clearly suggests that Cpz4 is a specific 
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sulfotransferase for the biosynthesis of sulfated liponucleosides. It requires both, the 
fatty acyl and the uridyl moiety of the liponucleoside for an efficient structural 
recognition of the substrate.  
Product formation was verified by LC-ESI-MS/MS analysis in negative mode. Mass 
peaks for the sulfated products 1a and 2a were found with m/z 878.4 [M-H]- at Rt. 
26.2 min and m/z 694.4 [M-H]- at Rt. 35.2 min, respectively. Ions with m/z 848, m/z 
622, m/z 578 and m/z 466 in the 1a MS2-spectrum (Figure III.6.7B) match the 
expected fragments containing a sulfated aminoribose. The ion with m/z 349 may 
derive from an uridyl-diazepanone substructure. The lack of an ion with m/z 429, 
corresponding to a sulfated analog of the m/z 349 fragment, suggests that the 
sulfation of compound 1 takes place at the aminoribosyl group similar to the sulfation 
of liposidomycins. MS2 fragmentation pattern of product 2a (Figure III.6.7C) displays 
an analogous situation.  
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IV. DISCUSSION 
The caprazamycins and liposidomycins are potent anti-mycobacterial liponucleoside 
antibiotics and belong to the translocase I inhibitor family. Their complex structure is 
derived from 5’-(β-O-aminoribosyl)-glycyluridine and comprises a unique N-methyl-
diazepanone ring. The biosynthesis of these unusual compounds was unknown at 
the beginning of this study. 
My thesis describes the identification and analysis of the caprazamycin biosynthetic 
gene cluster from Streptomyces sp. MK730-62F2. Heterologous expression led to 
the production of non-glycosylated bioactive caprazamycin derivatives and a set of 
gene deletions established the borders of the cluster. Inactivation of cpz20, cpz21 
and cpz25 resulted in the accumulation of novel simplified liponucleoside antibiotics 
which lack the 3-methylglutaryl moiety. Heterologous co-expression of the gene 
cluster with pRHAM, led to the production of intact caprazamycins. In vitro studies 
showed that Cpz31 is responsible for the attachment of the L-rhamnose to the 
caprazamycin aglycones. An L-rhamnose gene cluster was identified elsewhere on 
the Streptomyces sp. MK730-62F2 genome. This subcluster was assembled to the 
caprazamycin gene cluster using Red/ET-mediated recombination. Heterologous 
expression of the resulting cosmid led to the production of caprazamycins. From the 
genetic information obtained from the caprazamycin gene cluster, the liposidomycin 
biosynthetic gene cluster could be identified in Streptomyces sp. SN-1061M. A 
heterologous host accumulated the liposidomycins. Comparison of the liposidomycin 
gene cluster and the caprazamycin gene cluster finally led to the identification of 
novel sulfated caprazamycin derivatives. Cpz4 from Streptomyces sp. MK730-62F2 
was shown to be an arylsulfate sulfotransferase responsible for the formation of the 
sulfated liponucleoside antibiotics by in vivo and in vitro experiments. The enzyme 
was biochemically characterized using p-nitrophenol sulfate, methylumbelliferone 
sulfate and phenol as substrates. Biogenic and synthetic nucleosidic compounds 
were readily sulfated by Cpz4. Overall, the in vivo, in vitro and in silico analysis of the 
caprazamycin and the liposidomycins biosynthetic gene clusters provides first 
insights into the formation of the liposidomycin-type liponucleoside antibiotics and 
sets basis for detailed investigations of the biosynthetic pathway. 
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1. Identification of the gene cluster for dTDP-L-rhamnose 
biosynthesis 
Based on the identification of the L-rhamnose biosynthetic genes in this study, we 
propose two gene clusters, the caprazamycin and the L-rhamnose subcluster to 
participate in caprazamycin biosynthesis. Co-expression of pRHAM, containing all 
genes required for the biosynthesis of dTDP-L-rhamnose, led to the accumulation of 
intact caprazamycins in a heterologous producer strain harbouring cosmid cpzLK09. 
This clearly demonstrates that only the genes for the formation of dTDP-L-rhamnose 
are missing in the heterologous caprazamycin producer. Thus, the genes directing 
the attachment and methylation of the L-rhamnosyl moiety have to be encoded on 
cosmid cpzLK09. Three putative methyltransferases, Cpz28, Cpz29 and Cpz30 show 
highest sequence homology to known rhamnose O-methyltransferases from 
elloramycin (Patallo et al., 2001) and spinosyn biosynthesis (Waldron et al., 2000). 
Most likely, these proteins have a similar function in caprazamycin formation. 
Screening of a cosmid library of the caprazamycin producer Streptomyces sp. 
MK730F-62F2 led to the identification of cpzDII, cpzDIII, cpzDIV and cpzDVI 
elsewhere on the genome. The deduced gene products match the required enzymes 
for the biosynthesis of dTDP-L-rhamnose. Involvement in caprazamycin biosynthesis 
was demonstrated by inactivation of cpzDIII resulting in the accumulation of 
caprazamycin aglycones. In contrast, inactivation of the collocated genes cpzDI and 
cpzDV had no influence on caprazamycin formation. Based on the presented results, 
we propose the biosynthetic pathway for the latter steps in caprazamycin 
biosynthesis as follows: generation of the deoxysugar would start with the activation 
of glucose-1-phosphate by the addition of deoxythymidyldiphosphate (dTDP) 
catalyzed by the putative NDP-glucose synthase CpzDII. Subsequently, the glucose 
dehydratase CpzDIII would dehydrate dTDP-glucose to dTDP-4-keto-6-
deoxyglucose. This product would serve as a substrate for the sugar 3,5-epimerase 
CpzDVI resulting in dTDP-4-keto-L-rhamnose which is further reduced to dTDP-L-
rhamnose by the 4-ketoreductase CpzDIV. Cpz31 would than attach the L-rhamnose 
to the caprazamycin aglycones generating 2c,3c,4c,-demethyl caprazamycins. 
Sequential methylation of the deoxysugar moiety by the putative O-
methyltransferases Cpz28, Cpz29 and Cpz30 would finally lead to the 
caprazamycins. 
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Usually, genes involved in the formation of a bacterial secondary metabolite are 
clustered together. However, biosynthetic gene clusters of rhamnosylated 
compounds often lack the genes for L-rhamnose formation (Decker et al., 1995; 
Gullon et al., 2006; Luzhetskyy et al., 2007; Waldron et al., 2000). In the case of 
elloramycin (Ramos et al., 2008) and spinosyn (Madduri et al., 2001) these genes 
were identified elsewhere in the genome. Inactivation experiments in 
Saccharopolyspora spinosa suggested that the gtt, gdh, epi and kre genes provide 
the rhamnosyl moiety for both, spinosyn and cell wall biosynthesis. The presence of 
cpzDVII, a putative cell-wall biosynthesis glycosyltransferase gene may indicate a 
similar role for the L-rhamnose cluster in Streptomyces sp. MK730F-62F2. L-
rhamnose seems not to be essential for the strain as inactivation of the glucose 
dehydratase gene cpzDIII did result in a viable corresponding mutant.  
In order to allow investigation of the entire biosynthetic pathway of caprazamycins, 
we assembled the L-rhamnose and caprazamycin gene cluster on cosmid cpzLK09, 
using a new strategy based on Red/ET-mediated recombination. This technology, 
designated as recombineering, was initially established for DNA manipulations in E. 
coli (Datsenko & Wanner, 2000; Zhang et al., 1998; Zhang et al., 2000) and has been 
adapted to Streptomyces (Gust et al., 2003). It was successfully applied for functional 
studies and engineering of antibiotic biosynthetic machineries (Gust et al., 2003) e.g. 
heterologous expression (Eustaquio et al., 2005) and combinatorial biosynthesis 
(Eustaquio et al., 2003). More recently, recombineering was used for the 
reconstitution of large biosynthetic gene clusters from overlapping inserts (Binz et al., 
2008; Hu et al., 2008; Wolpert et al., 2008). This “stitching” overcomes the problem, 
that genomic library clones rarely contain an entire gene cluster due to limitations of 
the average insert sizes. While “stitching” relies on the presence of overlapping, 
identical DNA sequences in both clones, we now show for the first time that 
assembling is possible without the need of overlapping DNA regions. For the 
presented strategy, Red/ET-mediated recombination is restricted to sequences in 
form of resistance cassettes. These cassettes were introduced into the L-rhamnose 
donor cosmid and the recipient cosmid harbouring the caprazamycin gene cluster. 
Final assembly was achieved by Red/ET-mediated recombination between a 
restriction fragment from the donor cosmid with the recipient cosmid. FRT and loxP 
recognition sites and SpeI restriction sites were introduced for the latter excision of 
the resistance cassettes. The in vivo usage of Cre- (Fedoryshyn et al., 2008b) and 
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the Flp-recombinase (Fedoryshyn et al., 2008a) has now been successfully 
established in Streptomyces and allows the rapid generation of unmarked deletions. 
However, if Cre- or Flp-recombinase is used, a “scar” sequence comprising a loxP or 
an FRT site is maintained which can cause undesirable recombination events in 
further recombineering experiments. Therefore, elimination of the apramycin 
resistance cassettes was performed with SpeI digestion and religation of the cosmid-
DNA. In this study, cpzDI and cpzDV were successfully deleted on the assembled 
cosmid and the corresponding mutants analysed.  
Since manipulation of natural producer strains can be difficult and time-consuming, 
heterologous expression of entire biosynthetic gene clusters in more amenable and 
fully sequenced host strains is desirable. In addition, formation of a natural 
compound often relies on the supply of specific precursors provided by genes 
encoded outside the gene cluster, e.g. deoxysugars (Ramos et al., 2008), isoprenoid 
derived moieties (Haagen et al., 2006) or other small subunits (Ostash et al., 2007; 
Yu et al., 2002). Therefore, the new assembling approach described in this study 
may help to establish heterologous expression and genetic engineering of scattered 
gene clusters.  
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2. Investigations on the role of the glycosyltransferase Cpz31 
Translationally coupled to the genes cpz28-cpz30 is the putative glycosyltransferase 
gene cpz31. An in vitro assay with His8-Cpz31 using dTDP-L-rhamnose and 
caprazamycin aglycones as substrates showed a complete conversion of the 
aglycones after two hours incubation time. The products were unambiguously 
identified as 2c,3c,4c-desmethyl caprazamycins by LC-ESI-MS/MS analysis. This 
result implies that attachment of the deoxysugar occurs prior to its sequential 
methylation. A similar order of sugartransfer and subsequent tailoring reactions was 
found in the biosynthesis of other glycosylated compounds such as tylosin (Bate & 
Cundliffe, 1999), oleandomycin (Rodriguez et al., 2001), mycinamycin (Inouye et al., 
1994) and chromomycin (Menendez et al., 2004). Cpz31, together with most 
glycosyltransferases involved in natural product biosynthesis, belongs to the GT-1 
family of glycosyltransferases as classified by the CAZy system (Coutinho et al., 
2003). Cpz31 exhibit significantly higher homology to e.g. the 4,6-dideoxy-4-
hydroxylamino-a-D-glucosyltransferase CalG3  (36%/50%) from Micromonospora 
echinospora (Zhang et al., 2008) than to the rhamnosyltransferases AraGT 
(29%/38%) from S. echinatus (Luzhetskyy et al., 2007) and SpnG (29%/39%) from 
Saccharopolyspora spinosa (Chen et al., 2009). Luzhetskyy et al. (Luzhetskyy et al., 
2005) proposed that similarity based relationships of glycosyltransferases is better 
understood in consideration of the aglycone substrate then of the sugar donor. In this 
aspect, Cpz31 is distinctive from other known glycosyltransferases involved in natural 
product biosynthesis. The rhamnosyl moiety of caprazamycins is linked to the 
methylglutaryl moiety by an ester bond and not by a glycosidic bond. While acylated 
deoxyhexoses are common in plants, they are rare in bacterial secondary 
metabolism. So far, only the phenazine derivatives aestivophoenins (Kunigami et al., 
1998) and phenazoviridins (Kato et al., 1993) and the rhamnopyranosides (Hu et al., 
2000) have been reported. Thus, Cpz31 may serve as a new enzymatic tool for the 
modification of bioactive compounds.  
Rhamnosyltransferases have been frequently exploited for the structural 
diversification of glycosylated antibiotics (Blanco et al., 2001; Gaisser et al., 2009; 
Luzhetskyy et al., 2007; Olano et al., 2008) as they often exhibit high flexibility 
towards the donor substrate. Though, heterologous expression of cosmid cpzLK09 in 
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S. fradiae A0 which produce the deoxysugars D-olivose and L-rhodinose and 
Streptomyces sp. TÜ6071ΔplaA6 producing L-amicetose did not lead to the 
identification of new caprazamycin derivatives. Since the caprazamycin aglycones 
were readily detected in the culture extracts, it can be speculated that Cpz31 is more 
specific for dTDP-L-rhamnose than related glycosyltransferases e.g. ElmGT from S. 
olivaceus (Blanco et al., 2001) or StfG from S. steffisburgensis (Olano et al., 2008). 
Further investigations will have to proof this assumption.  
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3. Characterization of Cpz4 as an arylsulfate sulfotransferase in 
liponucleoside biosynthesis 
In this study we show, for the first time, the physiological function of an arylsulfate 
sulfotransferase type enzyme. Gene deletion experiments proved the requirement of 
cpz4 for the biosynthesis of sulfated liponucleoside antibiotics, since in the absence 
of cpz4 the liposidomycins were not produced. Purified Cpz4 protein accepted 
different liponucleoside derivatives and synthetic caprazamycin precursor as 
substrates for a sulfotransfer reaction. Therefore, we conclude that Cpz4 is the 
sulfotransferase responsible for the biosynthesis of sulfated caprazamycins in 
Streptomyces sp. MK730-62F2. We isolated the hydroxyacyl-caprazols, the 
caprazamycin aglycones and the intact caprazamycins from suitable engineered 
producer strains. All of them were sulfated by Cpz4. In this case, conversion rates 
could not be quantified as the substrates represent mixtures rather than pure 
compounds. Structural analogs of putative intermediates of the caprazamycin 
biosynthetic pathway were synthesized and investigated as substrates of the 
enzyme. Clearly the fatty acyl-containing caprazol derivative (1, Figure III.6.7) was 
sulfated with much higher reaction velocity than non-acylated analogs or phenol. 
Compound 2 (Figure III.6.7) lacking the uridyl moiety was converted 13 times slower 
than 1 (Figure III.6.7). These findings allow us to hypothesize at which stage of the 
caprazamycin biosynthetic pathway the sulfation may occur. We would propose that 
after cyclization of the diazepanone ring and attachment of a hydroxy-fatty acid side 
chain all subsequent intermediates represent genuine substrates for Cpz4. This 
could imply that the sulfated liponucleosides are either dead-end products which are 
not further processed. Alternatively, the enzymes catalyzing the subsequent 
reactions in caprazamycin biosynthesis would be flexible towards a sulfated 
substrate. Recently, we observed that the rhamnosyltransferase Cpz31 from the 
caprazamycin gene cluster is able to glycosylate not only the caprazamycin 
aglycones but also the liposidomycins (data not shown). Therefore, we would favour 
the latter hypothesis. However, the physiological or ecological function of the sulfated 
liponucleosides is still unknown (Malojcic et al., 2008). 
Cpz4 represents one of the few biochemically characterized sulfotransferases from 
bacterial secondary metabolism. However, in sharp contrast to StaL from S. 
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toyocaensis  (Lamb et al., 2006), CurM-ST from the curacin gene cluster (Gu et al., 
2009) and to most other known sulfotransferases (Chapman et al., 2004), Cpz4 does 
not utilize PAPS as preferred sulfate donor. Instead, it efficiently uses aromatic 
sulfate donor substrates such as pNS or MUS resembling the ASSTs isolated from 
other bacteria and fungi. A genuine sulfate donor of the ASST-type sulfotransferases 
remains to be identified. Kinetic investigations showed that the reaction catalyzed by 
Cpz4 follows a ping pong bi-bi mechanism as has been reported for previously 
investigated ASSTs (Burns et al., 1977; Kim & Kobashi, 1991; Kwon et al., 2001; 
Malojcic et al., 2008). X-ray structural analysis and biochemical characterization of 
the ASST from E. coli CFT073 indicated the transient sulfation of an active site 
histidine residue (Malojcic et al., 2008). The results obtained for Cpz4 by site-directed 
mutagenesis and by use of inhibitors may suggest a similar role for one of the 
conserved histidine residues in Cpz4. 
For none of the ASSTs reported so far, the genuine substrates are known. They have 
been biochemically investigated using phenol or other synthetic aromatic compounds 
as acceptor molecules. Cpz4 now represents the first ASST-type enzyme shown to 
preferentially sulfate the hydroxy group of the sugar moiety of a glycosidic substrate 
rather than a phenolic hydroxy group. Recently another ASST-type sulfotransferase 
involved in A-90289 biosynthesis has been identified (Funabashi et al., 2010).  
Notably, a BLAST search identifies numerous genes with significant sequence 
homology to Cpz4 in bacterial and fungal genomes. Almost all of them are annotated 
as hypothetical proteins and it remains to be shown whether they are structural 
genes for sulfotransferases. A sequence homology based clustering analysis 
(Frickey & Lupas, 2004) of Cpz4, functionally characterized ASSTs and homologs 
thereof separates two major clusters (Figure IV.3). One of them comprises the E. coli 
ASST (Malojcic et al., 2008) and all of the other five previously characterized 
sulfotransferases (Baek et al., 1996; Kang et al., 2001a; Kang et al., 2001b; Kim et 
al., 2007; Kwon et al., 1999). Within this group, the ASSTs from enterobacteria form 
a well-defined subcluster, while the enzyme from Eubacterium A-44 (Kim et al., 2007) 
and putative ASSTs from other firmicutes form another subcluster. A second, clearly 
separated cluster comprises Cpz4, LpmB as well as further hypothetical proteins 
mainly from actinobacteria and fungi. The biochemical and physiological investigation 
of these potential ASSTs represents an exiting challenge for future research. 
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Cpz4
LpmB Streptomyces avermitilis
Saccharopolyspora erythraea
Mycobacterium kansasii
Aspergillus niger
Aspergillus oryzae
Burkholderia vietnamensis
Aspergillus flavus
Microsporum canis
Pichia pastoris
Citrobacter freundii
Escherichia coli
Eubacterium A44
Clostridium perfringens
Salmonella typhimirium
Cluster 2
Klebsiella K36
Enterobacter amnigenus
Pseudomonas putida
Lactobacillus plantarum
protein
BLAST hit connection between proteins with P-value 1 x e-18 – 1 x e-89
BLAST hit connection between proteins with P-value = 1 x e-90
Cluster 1
Figure IV.3 Cluster analysis of ASST-type sulfotransferases and homologous hypothetical proteins. 
Protein sequences were obtained from PSI-BLAST searches using Cpz4 (accession GU323955), 
LpmB (accession GU219978), the ASST from Eubacterium A44 (accession ABG76784) and the ASST 
from Escherichia coli CFT073 (accession NP_755656). All data bank entries with at least 25% identity 
to the respective query protein sequence were included. If the database contained entries from 
different strains of the same bacterial species, only the entry with the highest sequence identity was 
included. Alignment and clustering of the resulting 93 sequences was performed with the help of the 
CLANS (Frickey & Lupas, 2004) online tool (http://toolkit.tuebingen.mpg.de/clans#). Pairwise 
sequence similarities were calculated using BLASTP and the BLOSUM80 matrix. The proteins were 
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clustered by their pairwise P-values (up to 1 x e-3). Attraction and repulsion was set at 10 and the 
attraction exponent at 1. In the figure, selected proteins are labelled by their origin, including the 
functional investigated ASST-type sulfotransferases (bold). 
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4. A model for the biosynthesis of liponucleoside antibiotics 
Sequence analysis of the caprazamycin and liposidomycin gene clusters combined 
with the analytical data from heterologous expression, gene inactivation experiments 
and in vitro studies may allow a first proposal of the biosynthetic pathway (Figure 
IV.4.1) to the liponucleoside antibiotics although many of the suggested reactions 
remain speculative at present. Below, the postulated biosynthesis is described for the 
caprazamycins, though the liposidomycins would be generated analogously, except 
for the formation of the permethylated L-rhamnose moiety. 
A key question in the biosynthesis of caprazamycins and translocase I inhibitors of 
the same class is the origin of the glycyluridine (Figure IV.4.1, 1). Metabolic labelling 
studies have shown that uridine is incorporated directly into related uridyl antibiotics 
such as tunicamycins (Tsvetanova et al., 2002). A pathway to the tunicamycins has 
been proposed to start with the oxidation of uridine to form uridine-5’-aldehyde (Price 
& Tsvetanova, 2007). We suggest a similar reaction for caprazamycin biosynthesis, 
which may be catalyzed by the putative oxygenase Cpz15. The resulting product 
could undergo a subsequent aldol addition with a PLP-glycine adduct to generate (1). 
This mechanism would be very similar to that of the well studied serine 
hydroxymethyltransferases, which are known to produce β-hydroxy-α-amino acids 
from glycine and various aldehydes (Makart et al., 2007). Cpz14, with significant 
sequence similarity to serine hydroxymethyltransferases, is an obvious candidate for 
the catalysis of this reaction. The next step would be the transfer of a 3-amino-3-
carboxypropyl group to the 5’’’-amino group of (1) to form (2). A corresponding 
reaction occurs in the nocardicin biosynthesis (Gunsior et al., 2004). In this pathway, 
the gene product Nat utilizes S-adenosyl methionine (SAM) to transfer the 3-amino-
3-carboxypropyl moiety to a nucleophilic acceptor (Reeve et al., 1998). Nat shows 
conserved domains of SAM-dependent methyltransferases, which are also found in 
Cpz11 and Cpz26. Hence, both genes may be candidates for a 3-amino-3-
carboxypropyl transfer in caprazamycin biosynthesis, although we consider them 
rather to be involved in the two N-methylation steps discussed below. Notably, 
Cpz13, a putative PLP-dependent enzyme of the aspartate aminotransferase family 
(Pfam00155), exhibits homology to known aminocyclopropane carboxylic acid (ACC) 
synthases from plants.  
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Figure IV.4.1 A model for the biosynthetic pathway of the liposidomycins (7) and caprazamycins (8). 
Isolated metabolites, caprazamycin aglycones (6), hydroxyacyl-caprazols (4) sulfo-hydroxyacyl-
caprazols (5) and sulfo-caprazamycins (9) are indicated as well as the putative intermediates 
glycyluridine (1), 5’’’-N-(3-amino-3-carboxypropyl)-uridine (2) and 6-N-(β-hydroxy-3-amino-3-
carboxypropyl)-uridine (3). Structurally related nucleoside antibiotics the tunicamycins, the 
muraymycins and FR900493 are included. PLP is pyridoxalphosphate. 
 
As the formation of ACC from SAM resembles the postulated reaction for the 
attachment of the 3-amino-3-carboxypropyl moiety in caprazamycin biosynthesis we 
would favour Cpz13 as a candidate for the catalysis of this step to generate (2). We 
further speculate that (2) could be a common intermediate in the caprazamycin (8), 
liposidomycin (7), FR900493 and the muraymycin biosynthesis. β-hydroxylation of 
the 3-amino-3-carboxypropyl group of (2) would lead to (3) and could be catalyzed by 
either Cpz10 or Cpz15. Both proteins show homology to oxygenases. 
Subsequent biosynthetic steps, including formation and transfer of the aminoribose, 
cyclization and N-methylation of the diazepanone ring and attachment of the fatty 
acid would finally lead to the hydroxyacyl-caprazols (Figure IV.4.1, 4). Compounds of 
this structure were accumulated in the Δcpz21 mutant strain and are probable 
intermediates of the caprazamycin pathway. Reasonable candidate genes for these 
biosynthetic steps can be found in the cluster. However, the sequence of these 
reactions, described in the following paragraphs, is speculative at present. 
Cyclization of (3) by amide bond formation between the carboxyl group and the 
secondary amino group would immediately result in the characteristic diazepanone 
ring. For this reaction, a previous activation of the carboxyl group e.g. in form of an 
acyl adenylate, a coenzyme A ester or an acyl phosphate would be required. The 
putative kinases Cpz12 and Cpz27 may be involved in this reaction. 
Interestingly, a contiguous set of genes, cpz16-19, was found in the caprazamycin 
cluster which can be assigned to all steps required for the generation and attachment 
of the aminoribosyl moiety. This reaction sequence may start from a second 
molecule of uridine-5’-aldehyde, derived from uridine by a Cpz15 mediated oxidation 
as described above. Subsequently, the 5-aldehyde group could undergo an 
aminotransfer reaction, yielding a 5-aminated nucleoside possibly catalyzed by the 
hypothetical aminotransferase Cpz18. CetH, an ortholog of Cpz18, has recently been 
assigned to the aminotransfer reaction in biosynthesis of the aminocyclitol 
cetoniacytone (Wu et al., 2009). 5-Amino-ribose-1-phosphate and uracil would be 
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generated from the aminated nucleoside by Cpz19, a putative pyrimidine-nucleoside 
phosphorylase. A similar reaction has been shown in flourothreonine biosynthesis 
where a 1-phospho-ribosyl derivative is formed under catalysis of the pyrimidine 
phosphorylase FlB (Huang et al., 2006). Subsequently, the potential 
nucleotidyltransferase Cpz16 may convert the 5-amino-ribose-1-phosphate to dNDP-
5-aminoribose. Then, the putative glycosyltransferase Cpz17 could transfer the 
aminoribose moiety forming a glycosidic bond. 
Generally, ribosyl moieties are attached by phosphoribosyltransferases (Sinha & 
Smith, 2001) using 5-phosphribosyl-1-diphosphate as a donor to generate a 5’-
phosphoribosylated product. Then, the 5’-phospho group is removed by a 
phosphatase. Similar reactions have recently been shown to lead to the ribosyl 
moiety in butirosin biosynthesis involving BtrL and BtrP (Kudo et al., 2007). However, 
no orthologoues to BtrL and BtrP were found in the caprazamycin gene cluster, 
making the pathway described above a more likely alternative. 
The fatty acid moieties of liposidomycins and caprazamycins are probably derived 
from primary metabolism, as feeding studies with labelled palmitic acid in S. 
griseosporeus showed the direct incorporation into liposidomycins (Kagami et al., 
2003). Hydroxylation of the fatty acids could either occur within primary metabolism 
or by the oxygenases Cpz10 or Cpz15. Cpz23 may be involved in the attachment of 
the hydroxy-fatty acids, due to its homology to lipases. 
In the diazepanone ring, both nitrogens are methylated. The N-methylation reactions 
are likely to be catalyzed by Cpz11 and/or Cpz26. Notably, Cpz11 exhibits sequence 
similarity (55%) to one of the few characterized N-methyltransferases AtM1 from the 
gene cluster of AT2433 (Gao et al., 2006). Gene deletion experiments showed cpz11 
and cpz26 to be essential in caprazamycin biosynthesis. However, a possible 
intermediate of the biosynthetic pathway could not be identified. 
First insights could be obtained concerning the biosynthetic origin of the 3-MG 
moiety. By our inactivation experiments we could exclude an involvement of the 
putative HMG-CoA synthase Cpz5. As indicated by functional investigations in this 
study we would assign the catalysis of the transfer of the methylglutarate to Cpz21. 
The substrate of Cpz21 is probably provided in form of a coenzyme A ester. The 
deletion of cpz20 and cpz25 resulted in a similar phenotype, which is the 
accumulation of the hydroxyacyl-caprazols. Therefore, we would speculate that 3-
MG-CoA is generated from 3-methylglutaconate by hydrogenation and CoA-
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activation catalyzed by the putative alcohol dehydrogenase Cpz25 and the 
hypothetical acyl-CoA synthase Cpz20, respectively.  
Cpz21 generates the caprazamycin aglycones (6) which are similar to the type-(III) 
liposidomycins (Figure I.2.3). Based on the sequence homology to Cpz4, LpmB is 
assigned to catalyze the subsequent and final step in liposidomycin biosynthesis, the 
transfer of the sulfate group from a sulfated aromatic donor. In contrast the formation 
of the caprazamycin would proceed with the reactions which finally lead to the 
permethylated L-rhamnose moiety. 
Analogous to the biosynthesis of elloramycin (Ramos et al., 2008), the L-rhamnosyl 
group of the caprazamycins is synthesized from enzymes encoded on another 
cluster on the genome of Streptomyces sp. MK730-62F2. cpzDII, cpzDIII, cpzDIV 
and cpzDVI have been shown to be sufficient and essential for the provision of the 
deoxysugar in caprazamycin formation. These genes encode for the required dTDP-
glucose synthase, dehydratase, epimerase and 4-ketoreductase to generate dTDP-
L-rhamnose as discussed in section IV.1. Subsequently, the rhamnosyltransferase 
Cpz31 catalyzes the attachment of the deoxysugar to the caprazamycin aglycone as 
demonstrated by in vitro studies. Sequential methylation of the deoxysugar moiety is 
likely catalyzed by the hypothetical sugar O-methyltransferases Cpz28, Cpz29 and 
Cpz30.  
As shown in this study and discussed in section IV.3, Cpz4 produces the sulfated 
liponucleoside derivatives (5), (7) and (9) from (4), (6) and (8) and a so far 
unidentified aromatic sulfate donor. 
The identification and analysis of the caprazamycin and liposidomycin gene clusters 
provide the first molecular basis for the proposal of a translocase I inhibitor 
biosynthetic pathway. Since the formation of intermediate (2) can be speculated to be 
similar for other structurally related compounds, this work may help in the 
development of probes for the discovery of gene clusters of other uridyl-antibiotics. 
As proposed, several biosynthetic steps to the caprazamycins and liposidomycins 
seem to be distinctive and unique in bacterial secondary metabolism. Apparently they 
represent intriguing subjects for further functional investigations. 
A detailed understanding of the caprazamycin and liposidomycin biosynthetic 
pathways combined with the successful establishment of a heterologous expression 
system sets the basis for genetic and metabolic engineering towards the production 
of new liponucleoside antibiotics with improved properties. 
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